var title_f10_23_10608="Patient positioning for thyroid and parathyroid surgery";
var content_f10_23_10608=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F67508&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F67508&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 544px\">",
"   <div class=\"ttl\">",
"    Patient positioning for thyroid and parathyroid surgery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 524px; height: 327px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    For thyroid and parathyroid surgery, the patient is positioned supine in the semi-Fowler, or beach chair position, with the neck in extension. A roll can be placed transversely under the scapulae to facilitate exposure of the anterior neck and great care is taken to assure there is no neck hyperextension.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_23_10608=[""].join("\n");
var outline_f10_23_10608=null;
var title_f10_23_10609="ECG third degree AV block";
var content_f10_23_10609=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63951&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63951&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Third degree AV block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 107px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_23_10609=[""].join("\n");
var outline_f10_23_10609=null;
var title_f10_23_10610="Montgomery-Asperg Depression Rating Scale - page 3";
var content_f10_23_10610=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F81162&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F81162&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 619px\">",
"   <div class=\"ttl\">",
"    Montgomery-Asperg Depression Rating Scale, page 3",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 599px; height: 589px; background-image: url(data:image/gif;base64,R0lGODlhVwJNAsQAAP///wAAAJmZmSIiImZmZt3d3YiIiERERLu7uzMzMxEREe7u7szMzHd3d1VVVaqqqsDAwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAABXAk0CAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2t7i5uru8vb6/dgcHNwQEPMUmAwYxBgFRzUYMAwHGMgEIONckCNpK3NgvAwKEDAcBAQrLKA7n5wwP5w0iCgELItwBwyIN7QEDDwCatTOwwN0IgecMJOh3Dl4AgAzOjdvHMIC8AuzimSjYLwHHdgkA8OsHcKE6F/jQ/01kIu5GSwDIdsScMVOPg2ozutnQuaJAgAI5BAyg4RMogJeCpgGcttIEvJAAHGqjZw9mO6P85DWDytEeRwYkuo54OoJAgJDs9IU9V3WB0oD5SnwdMXcEPwclTMLgJqJZ1SVIabysiYMwDMN3EjSNwZNG4xRFgw6dEfno4j/0lk0Dd4JsVHRnAVCdB1pdVrjVxNYVIVaEZwAL6JlVYHRtvb7URiwESNcga98U8ZLQ+4IvgMgMFloEIEDBQgXYhEYkkFzjAnNn7Y1MAHYA9mEIDSAjkGDaAKAFlKcjEZ68eaDXzx34Cxu7R6Ei8JOnl6CAzwDjVLecSOco1s4B+CnT1/9QAspTwnYMcAMQPAg09xw28eVjjzjs4MccPQqM454/8H0HQIMlpHeOMQhx5pM0Q0EIAALT0INAZJE1hw42MtIIGmfH/eQTdstgdw2KLw4wQIbzEehPRO2QUNSQCZVgJI0mnqicgyMIaMxLLXH40xgCBOBAZip4Bo8DJo1Wpjj+UNTOS6oBBxtbY4V2UDtc2lYVOyeZddKd/TTwkUYjtWMPcSg5A9NQsWFTAHTN8ThUc8tEehx0BkB6QAEG6NPAMN4t4NNSE43H3VHyCCNCAoNaJgJ53bWqDqzseVqAh/r1B0AC1Yij6aQIdAqUAwjEhF+nrxIE3aZAhroPeNCF+KH/pQAccKtmB4CFH41APaDAArSymu0w6Q377AiuTjpOYEESYI+0Is23XkE3jlnUNwEZQO+osWXK05TLlWnqmOrmK2+220YEVAMCeCilkAXfNkJlpZ6aMAk3nYgXmO92WwYBCsA2gAJgoaCmmREpMJo5zmpzWmwBgFVnzX7mCZVucZ7QGqBlBTDoaqsRKBzPsd7TDpAp+ZqSRB4W5eHTAHJTjD1GxgmyrDAZExMy3WhbwmDVgN0PTjNSszCvQyk7mThUCyB2WdXghy83C8RNQtaTmeVg1D8x9OVEyzJUwNfG6KT3CN008PFilfFtHADX4PgTvSJI7ijlQBKMHsVAxV2Z/+CxHUAdc5NN7J++Y17cOsiL96UAAeps/VJKQGrBTclW9VnCynglerDgBDq40Dg3p/ybxZ/tHBwKrTWD0262KV/0XXkJvZczZWKDNwkeRrTA1MyzVkzNB/hue6pel504OHOPQPasifPm8/kMsN11X1DBXX78+0Md/ZDxvROkzwT8qNtkxPeQsRFuKAopAeI4N4ICmqBxj0tR6w5Ywc1VjnWgUku2+jS5gYEuSKsLXflGZ7+DkMwAEnNdClGoOhHArnwlYAABDrCk9ZUBSiURWmt05hoz2ZAtzZhMmUp2mknhLHk5K6LzjAY9PJmsgVuRC3CuZ8ThaK84jjIAymJjjP8FIKs5sxqGh8gIG2TRDjYKeIAYvTU4G44DV/ubYALkIY1Y4XGCB/BIv0jwxtg8QFwFuE7b8LIAPAprdm0s1nkAgKxR5Wcyu8MQJM0YLZQxh0XVWgYaYTKMQM5LMw9MW4BCAkh0eWSTyNrbMBhgLXhVZo6fLMg4ulcQgPCjAPzyFy4FIC8AMceEMywKvuBYRmRFTpD+EoADsNYAcdEHhZarzZ3AATI2cnJv48DbHj/0rsuAQQDqEVj5MuKONRWxHtM4CT0EkKizAAQhQmQIrPqhjtc8z2dWPA470bY86+nTSe0IYj+ueYLJNQBlCFDOp3R0FqBILKLy2dU0umgWdKD/0o7HFNp43Hci8ygIfAmZYAHsAyShnEM432kbPeICUozm41gFKgAt8yGxAezMpp+S4DnSIaHPVGimvlppgbDxEg+JcUUBRIaK4gJUbU41WJBrnVU8GtKFYEMg5gCKQJ7V0fWU6SzIzOZWEVDVyij1LAgQUH8aeQ7VqZWQ56DRRFpSVfYMJG1nqaU5gRGGGEaBWE4wpBQMS9jGQoKxTDjrgJhQIIZGNnWOzaxmN8vZznr2s6ANrWhH+waxfVEL0DjBaTMnwhhUpgojlUFqiUFQKMArBoH5xr4eEwZXgQ+zMODtF/hFCQBe4bYpQK4LAKfNEyBmCLFlwnOL0NF+CGWw/y5A7mtfmwLI+kC5KnCbY3JnA+4CwbsvmC4ejGsF8CYDuyxg7grUC4ToLoG+RYife1mgXa2a9wTo5cF+navA8e7gvz4IcAvwiwUxYaSyUfVaeUh0nHTKyjvyuUeNZHaOASjPBBkRZDGa0ZQ52ew74UmQOpgljvaU8TsLyJAgGXeVfFSJch2O0IHA55y8iiDE9hgxgHwqn4wso2lBbp9P4EfQjChAjUM5KbNQRMgJ+woZTLKHiT8kEa6FSZo/0ZG1VKDfLFF5T1A9ikSxCTojNccrYxZBP+DyJAnSDkAoQnJ95BOe3oDFAbOsRzFSgqAeNwYh1fCRjbhsramuZ4KIzv/W0s5slwJ1R6JGxk2d+xEZgXj4Q8ph2o49/eEGi8xYv2of/WCyqgG0Sh+4CtN8NHavI40JYihANbBYjV0C4KVdIWkqBCcT63Kuem6wYtZ1tAk4eRiMkHgxTHNEFBJdS3iv8+EGXp4tv2XE1tc0PMgkLbksYjtLUuuala92jQxkDwrc1qKnl0MGFnBFZVxkPknGHrIxE7zoKOgKkec8Z0NRApd82Koy8p6F2G6fq8JcG07MFhDB6E6b1Sh4UcC2aW9rArrgEZ4YAyLT776IilTZNqLB+NWAS01mt9i6OHnsrLSEa+ElcxNXyCcYto/ekHEIKN3pUJDzkiHmoRnmibD/OX6bL69acFZb2G9FoFakx0XaShxK0QPINW1MqbreVjXeLLm3FUOZ6XljSFPEa7Z2GMPqpQTWXufONXxq1YD6nnvsZnQlrhVj4CcMSEjwOAKn6qMgH46J6MBOQfldxnEPEIYBHCAPi2e9BAi4UgmLZbiehzzzS4vM3vnWdUld7vA1Yy69EK8/QlZj9Ti7+US2PkGew8/nevcgOMSzHry7xui17dRXh6H0VHYtJk7fXwPDgr+p07Aowg/IMLB+SYb9nusv8fpP2AQUsUU3fenOnNkFeHxjWJDmgld+C6NPL2ImIIMXnkgEXaDf3FtWNMLRxksoD/gZwlGM12R4v5F4/4m2Tr5iWkByW7REO6FCVqpGfoalAPnHVro3f0AnfiEngXKWLyp0fxzkeBuIQrCXPy93egPYenRjcgO4BS9hLI30diGRHA+IDLvWR/FnR710TBUyTSMkEvgmbonEbrXVACHRSKXkSr+iDuSzLi3xR8ZgSv1SSHFEAtb0fD9BhLCRAMNAds5XbkH4gKWHQuNkgxbXMySAhUZIfpnETJEEbVkYdtkCTQaAhlqYHmARQeN0cbdjTMmRNuRlfSBlGd4US78BEN1zFMtASxzoOcs0K7nxO/jGLwQAXDExiBHFRwoCbEl4AlRRELyDDGSHgndiiNegSzrIDauUaiW1DFgog/85yEvaYIns4UnEFIYw9yj3Zg+3OIkQCFxkJ4nAdVwrAWTHYR5CuGrS4A8KknwtcVYLwQByBRS7VgLEaBgq4hyulGFnBUOp41MguI1SxVIu1UV0oRzZdI1aeCL0IEKtV404kX2mB0z8oSD2ZUxyoRzvR35qVkESpU0kk2H781YJcCPPoYVm1GHeUyCCdRAzZX68VX811Y9+ZWNMNVPL0H9rlTbNlYV1RWroNyP9iADzeJFrto3UqA8HIBzIsFMIcnkTaQ7RUSDa8FS5kYxKcpHGyCLyoQ0dxVYSiVdcBY805JF0FThilWO9mEPrSGefhghVaALhpwpvpgKEJwMMxgf/O5QI7EVaKVBW5iQNr3BSGiQf97dgtSUIS6aVScOVbNmWbvmWcBmXcjmXdLkKxCUJCkY5aykDk1MDfVmXgHkGeUkGg6kDfzkDhxmYillYwagGhZkDiRkDkbmYlBkDAmIABAMjTDJvalZkVSJjh4JjdWYhPuYk/YEioCklyoFV7FAbpPksWTYjG7VLPfYsHiIjJNASI9GUlzQdsTlW3OOS25FIMEZn9FCZyEkDG5csBLMwmmg7Kbdt9aBsExWM4CZz1TZJDiAu6CZJ9aFN7VJLIsNj2OJuGwcPu/IsLSdA/9Ja4uAwItEUmIKBScgv8JCUqIYs7mafm5Oc/tkCfUlw/40XiMmnfcCkNvYgMXCXlPETN1F3TRgUcYVXgv/hdpMDK8yFH6SXmwIgdKUmMYJDL3yhPwAUovowmf+Zoh1kV61TfCAllCSHP041AMPHoCdxfrDRfBcoEvDnfAzUQhfKjSIgPhrqOxzaFy/kfJSzficanNVXokyqNCo6pdCzHswZeJqYhwtJQUUhhYeEb3R4duypneLSTMmSKVPILrO0pTyWRnF4ShtXJunppstCiwQlDtJETUoKhf4iLmBhFvdGnMN2LJknh35qFaxFpYoqmwkhoFM1DPiQAFtqoOPISOZYkGLqISEGTP1YqSmymoHIYzl1HCzFqMZEUb7iIWUVK//viY/MljoCiQ0dtRCZIx+TsamxulW0+nCL2qt98JgT6qvC2lnAWn3DeqzImqzKuqzM2qzO+qzQGq3SOq3UWq3Weq3Ymq3auq3c2q3e+q3gGgWGNVtJQK5XcA13aQR/aa4yUKwJ1pjhegMVMa/0WlctMFV76W/nYBTCVQOP6a4ocJVV0K9DgKIwsHROALDxqgL9yRgu4AB4ERGllnHoUA0EOwP/Cq9WeZZccLFBYLDhYHxNoLALiwING1wusC5bqa/NABQziZTSoTaSehYjgZLtsEsHdymGhg1zJmYicmcCgCJeQmhTR5qNQVHGFn+tWTNKQkkQBp0AqWgfBBQYRlP/wLln2TGRj1i1+nC1RbuzIFZZKQa2ptkdYOaatYkhxekjp5q25IebJWsNNXCyJ1AZBGCkdXsN4IauMqOz6kArsdEfp9KmhoUf2KmGk2RN5LFw3dkxDBBttWW41jJzJBBv8gCdYOETC2NtnLlvD7Bx+BIZnsufAaEredsds/YQpPu11FYCnNtUk1ttJwdwH6qeWrct5xlmtsuesxu3cusY99o6d7sNSzMx+fINIygxMTE3LaEQUVK4Lld9TmU4iqd2YvRGXBesohiHBEB3NxhuW+dDlrF5ojt3IuoMD4p5fQcy51sChuuS7NJPJYOwGtoPUXYZzAV1m4OhFFq/c+K7/7+bEykLDlUJGTwJk8mbOstbO0GrPSOas0npVFNUvdekQzxELpEbvfpYeOQBf8kXOfLbubkHdOVrR+2bo2bxYRpIQezbpO6rwYYVvsZXpA5kAuFTD8snpc1yw+OjdXgLwC5At0H8sBEbez2hfXwrqxocQMwrAIiEqNCblFWIiloSQJaIIGmzAFyovfBbYXc4eM62pbd0Hi/4K2GctMJyqlM7b08MqF7aG6TIVHN3qIBatF1cul+4ifhppxKaH58Yd3BqVrpLpxDEx0D8AkLcAon8qTfGAmkJF18FswpcDU0saTa2wQKkP0UZEA3JdVXVZyxpx8bKGhlBo4AlqUn7Wv/EGKlb2owyyYGcOasl46kvqX90N6sN+76jPALEuI2tt6p9zGUVRapLZaq0OaqqOlT5esgXNLdUusVu4K4ky8yq5cz/uVGrEgfSrLHUHMDe3M3gPAeLvALjHM7mjAblnALpfM7sLAbrXM3tHM9q8M7N/AIFLM/4DAX0XALrbJL5/M/6bM30t8wAXdBDsM8kQM8ra9AMHQQIzTgwsNANPdE88NByFtEETdEavRMC3QISvdEgLcDA2wKS5bEhfdLkXK8qHSUo3dIu/dIwHdMyPdM0XdM2rQSY45flnFtrvFpI8MhKwNN/eNOZgBA/rFp8wgI5TQMg21/aNGDTTAUDRnX/d1cDCEbUcoDFFBLE2BARLXQCS42YO21O3AXV3AwGUx1uN3DVWE0HVa3O3LRKGuG06JCpkzGcVOa1HfS0a0ZwLTYQYYM2c8a2j2dpAKeN+8qUIxfYNaRM9tHD1RdpEiq6JnIlWZYkMWLYu1kOS7PZbT0HBjDUqhWTicRwnDJudo3HlMSd0LK6J7CMAScAfp204MZda7Qe6Mkes+u5KMRyi6TWVggquiKK/xYYlH0wDwDCzaK583Jy8AkxyHFr8PXZZ/AAl4E7/DxUCWldcyMtJHqj1uvCUsJ4ZDPbXDN2rUU+ujEopLc10Id6OqbFrZVN6as/oOdjxj0mIDM6ZxM5//broTQE4NT9BnPIGHFlpf8zft/dQfRxwrx8gB9FSQ1g3kgBfrmj3s2yN+pDd++9ghauQZ8DHzJ6eStsyzW03y3aQpFjpLyHmVrV4gPeBilpDQnZobCEAEQYY+mISIqk2tt543TcsGO4jIkIHeZNeG/iFPgWp3c3THUkK7uoRGYIxwRyOGj6pYL6iiYuQ/PWiHzq4kbh5Hk6Qss05h8Y42lAPIoMDvAgAFVVlOloyTz0YznVV7iMeSN5FBbJZlS7Szdmj2GhHMZsAsDs3mPikXJmTmAVZhsFU7ZKZzA52fp9y3kVq6+1qtG4Vc47zGgeWlMpBDhaeD/Y6QUtlj+AD/8ci4ikvuqs3uqu/uqwHuuynqw0eTSz7uoOECBpeuuwLpIbyeud/h8ZDezUrYjEDusffew3PZB+qOykznjOHu3SPu3UXu3Wfu3Ynu3aHq4dVRu+pQTfTtJnPQXSEu5c0O3lOOVd+YStRQNnNd0oBehwkROiTe9FwK6OVQADkOoXVO82AJ8uILArkNbvtcuo1e46YNIzAPDill78LgNxlrLwjsj+buBPENWoIKkPn9AVTwMPMO6upwMEX8OYnAVhnfAdPwMfj0Abn4I6UBC/ngIwvwMKz9UXD/KxALECyxMe6SXCvBgeuWMpOCLnQbQy4mA++/N9NvQTNkloJjRGq7b/ZBkWj60/MVsMQOuRVk+2TjZ9EvYeFabMPw/X2zCbWgJVSIt5Zi/0gCVExZn039b06GFhns0uUeKOJGb3+8q04nDXhs21GvYjqfn0wZIlUps7W7aZh69WWya5oSaazrBlRF8iGSa0oLoJFdfyIVhzIjEUjosXlku8MWedElYrAdSetCub4TIuoX9bqmL6R0pOGOduufKdW/+3itHs67n1rYtqlvT65uJbuBL6JssZuYsRxvC4orFLfXL8jLXAzdJx4xL3pi/8BvDcTdFpk8Ruud/Y1JCgELTbqfu5teady3a6AIfcoCtc4KaJ67FkdzUr26azrfv80dZqr1ZhCfP5/5sAAs9QAAQBoCgSsEiKBi5qHOgSMIZCGOiREAQvAM2GEwyGpZMJ1WwCDixWciAkTlmFXxBlVT5Py+EXgESdswGxak1YmJPxuVNcBNwY5/n+fOgR1YTVAcT49HBdKcHIAKykJBjo8PgAKbZBGuy9QKnxqBUMQjUZRhksKBwQMAwVBJD8oTwojLW+AriSzElNVV1ZPTKumMC9IPAalgEHpJSmNCiw1DgHFyLk4t5CS/PJnW1uBwiKkTauZAlMAi6yt7u/w8fLz9MvGqjJwTvf5QEwEBwYAEcAgQQOXvA7ki/FoDFQDjQgc8VAAiUEDQIow4kJOTZervRJEuBBuwUmFP+iSbIJSkI93lS+NDVjXK1yh9AUPMiOGjMUkfwBFGgmp7GeACJtYihmJMKKGx12tHaTCAEF67LBAjSr1gts2HZFfKFMQDVDJgngeKFAZ7JfZI06IzLARRGeza7dymVgbqBuKenspUtzDM9iKf4FNFxvMePGjh+D8fiOpwsCSQ4IWcEgASuKRSvDjFzzRIMaRBSwIpjxygohmwtwJlLx55CGUDL93ZUAjiROPVA9mFVgQUA6tVaABiCceOg5DXYvSEBz1IkEERkMMAC7c8V7Spyh6iHgFWZHOGJ7ThHezKukhKLsJmKgtb+KoqJa95ddgAM4ELvestdwQHCVgle3zKH/Q2onjHWDEOMhQAlw6jEF4WofOcheIwA8h4d0UdQAW4YQ3kBSA690GF0N38Q0CxwpfkgdiLjstgMeDhyTWQALIAeZjz8C+eNt+mSBwD0BDNDZFKc4QMWGWCCZ2kKEyMhANIKwYNWFM0SzxgJNIunCeAFcZZtkY2oS0xYsJLAhEizoxEtxK7FxZJI+SNPcGdGxOV1U2CGZ3ZdOYvFdkQgMwIIQR5I5aJhDIKqocUqhsGYAbZ7GAkdQEQLoANltxqYulSIIZnxDkkrCV3ugFYCWY7F3aQxvBqBTCkdK4QKsYyYQF2yufvirOLH2Spc0r/yqwIcs/sXnK70qO1gTwtaA/0Cv4hTAaA89Btmtt9+CG66445JbrjsFKPCkueuemy6774obF7zz0luvvffimy+QYwYQlr7m8uvvvwO3Iy/BByOcsMILM9ywww9DHLHEE1NcscUXY5yxxhtz3LHHH4Mcssgjk1yyySejnLLGjJKpsssvwxyzzP/eMbPNN+Ocs8701Lyzzz8DHbTJjNoqtNFHI510w1ZepbTTT0MdtbixSF211VdjvcgBLiDgbtZfgx220Sey0LTYZ6Odttprs92222/DHbfcc9Ndt91345233nvz3bfffz/s3rwtl8vnQhqx4929ijOWy1fiPt5Yz0McYBo8kSOXC7fdGh4PqvoyPv9E591+vjat8biCj+Ai76UE4gS/3pjjCEJOu+SWPxa5gbTrvkjpSrQuz+8KB+/t8GfPcok81awecgOSbYlw7I0jazu4vdczuezWp7r7qO0c/wz04I+/8PPghh82bfUwr2wLKJAd2wsCRKOAAAUMEBG62olTNhr1C8EE90CCa64VEfpdSwbxG46cFAOlJJ2DcF64lmlC1S8+uK8UYEqF6BroimsV5H0AMNUCtLUHEmZETniS1OxCYZoVfG8AKozCFB6UpDUgQwi5AEgbUkeF+rAgLBvEXW2YkIBEjQBKa8jGtXrQwlzkUAFwQIUiIlgDO7EiBRE0gAXDQj9XBVAyOcz/Bi8AcaRowI9NrLBCk76ngkRFQ1f8CcAe4seALS5CWGJgI+0Q6KrKnIA40oBDL1hhwU1BZYBftN/NbpCoSznQHe0LYHdMUxpjJNFFDBgJgVzRgwe8AlEkcFFB3IIKF6ALAfSjpFxIgCOqrc88LmhAEj4nQ1zY75S4VKVKGFmQVnKIiLDkX0Tu0YNfCugoDAJJEpJJIBkuwBUkSQH9sDI7VqDqlui6RDXp17RqXpMr+9NlKpN5SXY8ITb5AxADPKmc6hXgiQjKzqSOYwhaFhEP7kqlKJUjxd+B84Lj4ZEhQNmXYKYwi6LT0g10dQApHfSSw6scLoUgQ4X+b5a1PMEw/zlxEAecgAEHkVEpHZFJKdpMmh4SWATVxbyYIANJCAEFe5zyFSuw7BW3WQY6QiKTZmTBIy2x5RVMEEFFMWsXZiSiJ7ARDD9ohRZlgKospOoW2UzBmreASEMlQgiKZHUTYGUBVqLQgK7iYZ1HpSPVtEcpGR1jCnjRhRXkGU8EeSaWtWjJU9aaDlCgaqzMOFC2XsiMmPqCHWWR418QW6AhlKIBB4ndHnZ4Ak9wqEtX3AEgSGoHmtosLQeNx0sbK7CmKAGU8fmKAh6QHkp9ZAWK8SnVYDBN4JkmD0RFgQMaINv56ekyS4Xsbcv6VOFWdUtU9eeWrLDJbQ0Wno5QwDnFcv+F3j7XPHTI7iOcSl3LYcQ8imkrEZ8io7UwgrUPsOtXwoPSpxy0H5T67a2cAlsUcDe6qnrFHR7xH+sqFi6MBUs+d6LAySpvuzsiRXEDc1DECMSzM7Bvzii6AHouzyg+VdBQilJAf3DyIK5IjRTpsxmuWAEVgcTRhpP4yvj0RouGsMxjM9IDKyFAxTfiJR3OACNhwph/JDhuK6NTHUCcQUBGbq4AhFMC/d6Ujq67cbqcjBY6WFm/XpDyCO2r4y8h4DkLUBEeJEiljpRIQyM2gxTtitYnQ++cPaLxU76MIxPbxyNZLmsu9sxh1XzhBldJs4Wm2kzUdLgJgqZcDaxk0QT/V7MENPkBbwzw4yjoaAEd2gwi8YwzYRUNHqWlQ6u0hJAuEQB/+rOKK+onAx1oCsWZoWABfDpCUVkKUzONUo0H0CVAWEsatQ6uh9gU6lzPVbt0QCGaTsgmOMBKTlDG65S88OsVSsE40i6rXEiVBUfQ2lkfAqUbzQSlXLX6j1q9KwlaxTXuWWlYWCxwsLGVqSWiatuEffKlaMHvVwmB3EPgVVoM7YQsHfMEAu8KCD9ikS4loN0nQHayPqQtXCCRQLeB9RIB1z2X6bVhGPYqkEbOGLeai4cQq27iypsCFy0G5fFonsfXhb2Q+fAAkVwY/XY+Pcb0/DEOSLC5XKEu6anx/x1DB0OWiA6PpTeG5jWfOtWrbvWrYz3rWt8617vesWrQ6+cbo+giRlfgwyQKet6RuvG0AA/3mH0x6YNM+sjOrskByiObm0dtvc4usM9remzPWPFE8wKQvmPw77j5Czbpxna4p/CMmftjfif2ck0O8UDqu9/NBXh4Cb7aHjsfOiWTAKdTU/T0YPzLVb8I95DeMZSXffkuT67JnT5InO98zKcw8f4R7oxGacOzh2DBHszbj9RFIglkyI0LdbEQWY0+w2O9mja+wI6RBgAj7ZjC54tlhoV0yBGRVIAtSvhWch0js3yKhE2+oYEvQAYCIsVloIpDkPkHokAXskU9fgT2Pf+DqExLw3EIFbCC91lXGy1SGCnRCWiLCazZCJ1AA7KZpLzA+PmRBmUJ7jAKoswRNlhgQTAfjSDcAfIa7y3GiLnCAe1IjxgUO5jcekRIj+DTKkUBX6yTNjFSiu1TuuwBOXmND4RIDz7UENzBJTHSViRhDUCTSoVfRXkU+a1RRMgIpwDY/NBC+8WEN01FLGHDeixcbgyTEPIYfFHUNiUUErpYhHBUEQqA43FIOlgSEV2USY3SP3nEmpVBEyBeHvSTizCSAJwWQxwEDiJTErFccx2h5pyUSahTRJBdJMhhA6CeCipBXLUAYfXX8OFCq5gZ2LXEHtxBE/ThMvnVHvhVBh7/WPSkgGNd0n84FqxkYROEg5+c2Xs0RAqUgWD5hfvlA2Z5j7IdxVXsgSek4pR0QivGTt/ZBIf0RyqsAg31AsnlVCicgCa2BSG4iGdcYyIowS32GHKNlsNtiV4AVlSUwh+ggipgFCa+A3pZAyca1hA4QMT9FCbcSm6hxEGZ4nVFxDLMlhzQ13cwY4L91+7AkFmR3OuUQW85WBGY2xXuosPl1y92YTAWF4AMmVHE0jEWV0HW0zLCD4IpgTNeVitShVUkpOtMBIWNgTxuYy1YwRe8FjURxa3wRRHQ1nBlYRnoBUzKyDqaUVWYDTwqAaHFAGHNAjZ5Yn5gx6BpSQ3OWHOU/yKDUJkc2RkCwNxWzl+j9WCC/ZkYHAAHncaCMBkZZOWlTaQYbJrGScYX7BmzLMec5AOlyccLdNV6jMf37AFeSsJWusdDgOWjAU8bNgFFORp/+EcDjCXJeRoxVIgh0AZLKABK4dl2yEb2VQSZ+ZSYkdlPXoHmSNmJyQiBRCVjMiRSvgOuLGVe3EKr9AqkRMMRNY39IR8CAoZpmOK1XUi9HcCAkBVwfg8AuiJDnCB73Fap9QAt8uK1VRwuYiH+IAlckty2JZWcNAcu8IKuIWcM2J/yVFZ3cg2tDaYYGOf0mAo2muASWRA+MifJ3dumuKaYlA0UtOCtoJqj8IWBQMuyxP+EuNnhVZUVxyFSE3gKqFwLPrKmxdiexDxog0ro1kUoxFTohGJohmrohnJoh3roh4JoiIroiJJoiZroiaJoiqroirJoi7roi8JojMrojNJojdrojeJojurojvJoj/rojwJpkAqp26hBkRrpkSJpkirpkjJpkzrpk0JplErplFJplVrplWJplmrplnJpl3rpl4IpkkLAkJJpmZrpmaJpmqrpmrJpm7rpm8JpnMrpnNJpndrpneJpnurpnvJpn/rpnwJqoArqoBJqoRrqoSJqoirqokaMmTHGhbqD4sVD3mUPMyje3s0PBgbY0TEa+gRSr7gewIRqO9id6IDqIkBqwjD/gJy84wuA0hRoyatOgf6ASf6wwgPIyVmxDBexiSyUzSZNgYjVagMwANlkgWRlQQKCCZmMiqxOwW6wQDFEQxYZqwPoQpOExYmEhUhRgSUeBVPcmgE4a6/iqjScVTwwivzQi6S2w01d4jy4B7seXvnIQ1IxBiMZD71OHgSOqqh6i+Rl4cUkCgJskuupFsbFACj5Gy8yxZfwahKtKivcwI6AGAuQRBP5BLgmCkk4rBFQrK/alKtUygFs5LdO08RKa1pIwXUogFBgaxqtWmuVpMnylgT1yjQVLAlELLqaxj3ai7zm0Ty9a71OCdD6xNBG6nbWww08no/MnueQhr6ui9G+/0PsuSTGrIC/3Sw7HOy3NpnIHoarYNQ9xIdeRmvFJkAkuArhbO0mIZronC3IzkCtvMPWltnHTusK5IO23lq2XpAUmI3dNsk62C3Z7pw73EEfAFAJlB8+8lGtLe4XlaYBkZH/fNsXON+wmNTabgj9Ze4LPZIN5cYQsVkCSV+0dqdiAOAH7hoaAeMcfFvQ3lUZUSMzeJ8A0dEthGccwJ9RTUFAmJHqkc2djCAB4NHuYEcSeN/nBuAroBCjiMHxbSCn8t+mkKD5bRGsYO4MRd8hXeD9zUvquECvHOU7VQS6SNG4ksQjicONZYEDnOzZAuuY3CPbauzvrgPKvtyl1Gz5Qv8CuE6sGuQA3aLBsLzsAUZEHCnBtWQB4YIrsMJJybach2TjIxYECTzTEQaiFA3iWf0gXrjgAmzC9kbTSKzHm3HbE5pwrLZHTJjTivhSRZBiEhDH96RhWEJKQVlqRvpFu1ZPCGNDEzKuDr2CGLaHqTVEpE1PJZKFBSMSgLxBRDkhHK6hM+0hDtBgEMRwOyCeSFFhRljhHl0VCUuTGXbxQXTwvXzRp4BramVBApCEwooOLS2JPxhrWugvsPJJqACC3Woa+wKC/sptuNYtAMfttN6DrYxHDRww38YRBB+E4NpsGxdrsu6aJzKKaVwjFJxBL4ICOPoVYY2wYa7GYnGkOS7/Qyb05EyMIx0MQxSz4sy+Tie2Mheei3S1UO3KFH6GkkemyVuJAXDAXFJKo5JkAXs2QUt9xSwW1TJNxVZoY/0Nn63ZA2flIhZqLynzVA2pQyV0gb6gAvcM8v4uLNOFGvneLRzo8f/2cRsjp04IsvnObagtsCHjLQ7o7QBa4QUhMA0BwolEMrgO7v9KMDrDg0Qm0U3uVUX0IkwOhUGIpCjnA+a6hSkPI5NVA1LA1HC9rg2cBEZFlkkiRD2+rr3KLmFhQ0vWAmmqcj7sIg3sHkIYpUJX5Mep9EMG5BVQzVbIpDQDV26wA4SdxWjQ5Bhr81s4kFA/ND3Ty8qms6vyL1SX//OqThPgGkCqpRUey2/cfms7kwRV40kgc3XXXpiUEUfJ+vEhq+wFWQlKHWxZs0LWCgFA0ywhZ+w0XTUJwDXPVgJBfRgBHER0NCdrTK5mUsRWMuV7UTSGTOaGoFWDaElf1qXydiaA/gXMSYjMvmJhHueeTbZfDDMobUgu5/Jj8vJwRHYLU0p1pc4oxYVqQkRkPvFFPyY94diWKBkQKGWOTWUQxMRRCFOmtaVPHBAOQ/aK5Yh5bAZ3vBP1isvwivXHjrOvHqum8YJt07E4kMSurnPG8mqwWjcV5G/cLmtaFMCyakc9x+89U+vvjgqt5B5+IUN5SLID42x2k6w81Ezalv8QqpWAZpnjfPJneQobYTnLhewKm4jWd4Kgw+0uNRaHuB1igF4LrRybAcaObPqbdvrFgeMTR6I0gsTnaW+ulNGJP1yJD7jllLwnCRgoFp7ywblKc/qmRjzvsXDNI/3yHGTIJSccUUPBOSSAcV8VcWrLgHNIv7Lp05rLMINLyI3LIsqDA/hvvRgdb1U5uKTqYljJ4RIMleMpk4tLqSFtPeScl3fLI6krPShA096LynGfm4vLlmeP1P5LmzNqnuv5nvN5n/s5xhiMO5TqnxP6uwR6oSP6wBx6ov/p497ukF8K2Wiybr7fGkhuAQVRO0RQfDDv5iow8n6KhF1vEjE6m97/oRAXBAOgQsRJkw32EiB0sBnCAz2p8AOcsK94CZAbURWWuqnrdBZs1FTgFD+6xCtagnmgAzuEQh2PhUV/nKhHRa+raRmo9EMAwrAbQbHjJERLNxfjYyw0u4DFOLS/h7SjaS8immpYe2xVJR0Ydo0gN3APAVTSuimZOK7rwltab1RgqrkDqUaMOFle+6JQuhwgOXH2uBbVZr07HMGNNoJQ5wBYJ1wtur8japdbfMbfnZ1rfMd7/MeDfMiL/MiTfMmb/MmjfMqr/MqzfMu7/Mvj6aAvgqN+R5YH7GNQLczrjbDYvLfpQsXnC+vFOJ1bRNEquc4LjZVO+UFsUqsGrY1I/8XCCP1FE/3AGT3SW40n0oPWs4PXxLQSeNItGMK8aSG0uID+6Zz+7Yb3plNtSrrDDe+qytUXHN/8zf0M7e6+CV/pvk8WqD2aY33OcL08DL4t6AIBFGLQRshBgOc9Fa274NMwtU4NnzEVrvpdrW8casP9CG0WD73OlTELsxtWwKClbvEM40FwBv7RFL4+oI6Is5RcAQheIAdfpV6qIKMb8IY1YyHVUHQ7TqO7ft7HhXsm0CMmdPQrA/7q30zrT4Y8eA2Ug/2M5Yrt58YmpZlefjRQJEZD+D4pXzWrCe3wp3BF+/Lxa1dH48H2M3/QOL87vD9vMf2C3zIqtcCcPb4T1P8AYF41CBjAojyHACDBQhBACwCHCAyoLTiL3CwBErORRAhXbPQLomqCIUAQKPgegEb0oSi8As9BTODF7ggiEvWITqvX7Lb7DY/L5/S6/Y7P6/f8vv8PuMaFNwhXkBAQQGOYBGCQ9BgwwJAmoJCYoFVwgIkAlujgmKj44gIjQ2PDxIAYkLn1o4owkLgYQ5A4uyRLG7AUyamF66rQ9eW10PoZEBro/AwdLT1NXW19XV1op43NBtYNztZwEF5ufo6err7OrsZN937+3T7dm0BJn6+/z9/vTx1PTsB/BAsaPIgwocJ/A+E0XAgxosSJFCtCfOgGo8WNHDt6/AhyWx6NIUv/mjyJMuU+koLoJLClMqbMmTRrvmHpTg4UUjZ7+vwJlCPONDhnBD2KNKlSekPRFIW5NKrUqVT3ND3ytKrWrVy7Yh1Jx6jXsWTL9rwaI6vZtWzbekQLgOTOXG7r2r1bEC5cvHz7+jU3KrDgwYL/Gj6MOLHixYwbO34MObLkyZQry1Q1jSedR2lUPGNAy8iXREucijhVbd4wLeYwW4ORTFKbRoEOkLsJ1XLQSAEazBGsK06BKHPmAfLszIHoIwpKs0FN7RsD4uhcV4NhwEtGINeGs9Yt9QSAB7RvclcinHoc43+QB0rgHMn358unfXugvXr8aTAa1Hd3XjXegbeVeuah/6EKZqqwUgsnuSiIgoO+xDUKEzU4eNssAVwS4DyRXBKDFa5QIiEKCziYwA5HHJKIC7ydJ6EKmOygCgynwGCDA1FYsuF+R/A4IYO9GTPKbUe08IgAPDb3hAKIKAAEkr5oOKGMruxwYiLkDIChG5FM0sV0y4kI5pIotGAlTBpy2GSPLyRAyytSKnkJk1VgUgB2o7gQIy+kATCcg7kReJIBAd5UpIUQOlHEgBY++kUxxiV4wALDPeCEDx16oQIQ5Dly2zhoWOIIMgfMZxugTFoHqIE1iFCjKUbgeAAls2ghBhtMCtADlKp64gV7R8KXwgC4KrCAJUA04AUBxDpB3nwDiP+Q6iEXWhrAGWp0WkWwCsA0nRYNCHDreMja+F+mP5QrhrNaJGAKsewim50WDhSx3HAMOCrEt+NFMZxvUKhIaEoP7GfloeUluAu52vDbsCOtcDHpDQ27V943BmTIhYSyGTBxCgG0QHBa3DUQCqsD5jkKrGfKeosLmPGWyHxoHAAvClaS9s08XZ5C847aeXeKey+xXEtcAULIxsYx+MCAsCMocAABlASdJ8wUKoIxAlif8g3Qgm1iCwwIxAix0Qas7GrBIRngGzxLW6yEe62yBuF0RFCcH8N1F5KxF06LzAMaehM+QgsB4GNyiCnHN6ADrxgVaykxPwqyTs7eu8Koweb/hwbQCVSi3XQsGKG25FoYtXDEawwOtdQxGEDAt5mHrjUaXd9+pBGZi56GWJcr0MwPaRdyNHGOul3SAc3IjSAKCQjcHKMEaBrD9E0KgIUwXOSqaMNTPBG4uZTg4ogClAhAQPdbvFBGCTeTw8CqkBOnPWguW97A6KzIvAQVoIAVSLDFIa6WIgW4YAH36hnoehcDAQKAgKR6ATlO4QQoHMI3+pMBOazFNPIEiFsE+JwacrCDAzRAggRElxp8gAIoIICFoyNAKJJxGtQFaXT1AsC9SJYt8iEAe0zIIMCU1zbmdUQw/2FD60RGDJ314jS5kFECmIQhLsSGC36z0E4QwThj/8ACEbdIhL+y2AVQpIFFI0MPGgaEgEvAaX8wKAAtBgAvSBngEm2MFhoYmIgBAAEBrTiVA9eAmj22qE2uEIZoqKQzOU4LUIV8lCqYpYYvre+BE2zFKxTZRheeEBOQ4KMp+HibRJoyBjpqpJ4CwIkoPUiKf2KbzZSoRPCZZHDXkF0gHDCodUAHl8RExzDsdBIH+EgavgREFvoxzGJKc5rUrKY1r4nNbGpzm9zspje/Cc5ogPJ54SynOROizAnK75zsbCdB4nhLd8pznuYYjmboic98gqN+h9KnP//5DOEBdKAExUMCBlmegip0oW4Yxj0ZCtGISnSiFK2oRS+K0YxqdP+jHO2oRz96zodiY0GhOUeqwGG3PyKCFoMSaRuW5wduddEOJ72DsDiDBl4CYifLbEOqoskHnOqjpnBgVVLs2EQntswPMH1DM92gCuWUw6jdSOkRsjMHqq4xiZ6Dg9RmGget1uGpszOSM3saB1GGY4r5ECtQrphUQSA0jHloqhvIygZVEGutaK2GVUMUVzW4NQZ2JZ1XOQnWovZVJ5zMpFn94IN4zkGtaw3mOQbbEwcoJ7BE4Y4NhCSwSYwMSHQjEwNiBNomtQIIgfkjinYgonsw4UW6G0WKRtAlIa0NiQUQkov2JIpa1LEVRuCSlkIUSLq28rZzyqkZBxFbBqSJUsf/nW3LsgTLkg2nFSKwZWuPgN0UBWZAYNXXAKYFXN7QzgVsLG6XZDCKGD5wHq2kGm61tINRgMm3nelFhCqEhvpecFYwQ1OiAjyjUiQJvK/tmZPo0oZJXqi6ugWDmLBbqa3tl7iWc9YdNdEKf+EAWVNbLEp+x1mnAAEK/PyVJWiwK998ljjjGhAJgFAAKFniTKOTGlZPVIDBiSqxaZhktRJIBALYUqoMIKe+HgWDaq2qUpcKVxWc08M8Ois+3PqUkAeMHi5hiwpdFMtL3kiKaNnSx6YqwDzIS7cVjUy7i4Mynz445TGPSlLzFZyxqkAOM5ctFEwmJ7SOaLMeiupGBc7d/1X/rOW9Phq3bvYWj6GaCipny3ovjoGgQ0doFzS5w7IdgG9OeuYEiQCvKMGPIzszCoWZ0WGBUVJ+cEYA8VHNaneDYnzncUhYkwy++g2frxGANFLQxm623CMZIhgjOyvNcZZswq7pKhYsWC4Ng/OMx5pV3Dj7DTNMRDPeBLBmTqpg2G8mTnmpc7ZYS7sRKKu2xCokrG+IxWnlbgAq0/fs2h4heTbbN5g73Gg1ZLsY0Vz39YwB7MYeQcIQsptx+v1vZ9NAlDBoBOVQkLkz/yRoEgfQEVRQMvawLwGPm13tdqsFlHcV4o093eJUWOQ4B3hyIlj2w3g7QQIcYAAkKB4QMP/T8ZO1HHMvvxkNtB3NbncsbhA0trHJra2tsqYE6V6DzaM2NHfrvNcAIF7jkO4Cei99xnsT44+8YPC4ZD07QBgcA4RO9JMjD+bBo4HTGI3wbTs9BlBv4teD/VSKX0wbF5+7IEEVg7sP/XTbTrqn9zcEEiMFqE48DwkW2MChyTZzONABD7D3+RGE/hjmKhn8pvaAPa4PgJAaOAeN/EEkp+B6QbTCJnS2giDKEAAijzL97KcEFBbu0VLQ8n+wcD4uyP4JWuui30SOsx0YwIB1tsQCxud7Xd4ifg/IFZxrb2PhJ6H4d1anuLn3TPTl2wv9+34CAn3b7fdvBPeXAfAJZkT/BdBU+5cM5LB//xN4osJtxpIMjjZ+sId42iFSiqcEnHZr+Qc3o1OA/icylAd4+TNJSNdGScF5cqU7hVRpT9NKj/dZnuQ964KCEcd/ieA5agQLIjZ2ESRJ3VVJVCICwBAF6hVcsUQ+ijBci1RtQvIKCHYlghc6pFRGG5JDYRYxqrATa4MiATIcdcIdQNh8NPh2arRF52cdjgKEKyZc7MVh9oZG8zeDrvBBWcgiTkIOQqg7/kV24OVJoWBHkuB8llM/sJQGyzUG/7EMoRCBaQETbMU0Pmgcm9AJc9h/QshxonZHIRhAXAVSm2gNItcVOXYoQseJo9gdReJ6UzEXVEdY/wlFiq3oiq8Ii7Eoi7MoTy5VW/1EFJaFSCl2ByWISDVDi8EoEazWBr7IBk3lKMZoOFxFjMLojObQjLtoB8hIHcp4BPjRBtH4jLHoYY3USYngG+G1APxVI1fkCiLyQVEgjq21INxVWwnmLHIUc3hoS9HmabHWjX+GYSVTJDI4XrxlXkSHIae4jR7lLsR3Pb4Cij92KoVmIc7CACSQCZfiHQyZghXoL0WQV6fxCvByaAIIkK6SjKV2ajTgiWIkg+2mCUf0cJ9WkJwINoIkGA4zbBqHHqcgFjbgHQ63AxXzV4DiUFPYBWpjS9TIGoBXbm/HejS3iisJkqyRlC8JUqIjc/9/pDiUIHlEVzmooAQ2dpU+GRCqw5VUuXdFKZLVSGBy5w3akZJh55SOEkRSSYo2xH8GkHoMVATkJx4ot5U5iW5R8GxmAD79kmRoAIKncUMvEYDgp44JRUSAl32OYAvz0D0nEgYkxphP6WkYKApy2VG1U12EpCWVpkZC2Jep8JekyQxvaCE+qDs7+AL/Vix/MoTEMQwBcpuAB4musClHgCHI0Aq1qZmAkoWd6ZkbZY3HqZxdkZzL6ZzPCZ3RKZ3TSZ3VaZ3XiZ3rQDO6mJ3dWRI65Z3hKRPgKZ7lWSijQE7mqZ4hUT/cuZ7vGRECBZ/zGZ+D5Cv0iZ8QISK2mJ/96Z///wmgASqgA0qgBWqgB4qgZlFYmbQXbRAbJbctrDgV5NkHMKWN3AIIA8JT5oChz8AqIrWggYBZciCfXLEMv4GedCVnkmUNWHUYFMoHFgqhfrCfsqUGA4JM2KCNeTCiIQoIIxoHJaoVWGBiKqZ6z3SjmlgN/oEYMLoHMjoNPVQA6ZSkUqCk0bCjeNCjV+oHQAoHQloVJykQ5wEDqeUdtiSO9JVgxiWIdyIJdKVJaRI9OmKWICko2Sha1zOQ29Uiq8VK8EgGivBabmqjawBJrQIaoAN4+ehISWImf7oh5LCPbbIrD6YAzCIJqxNfreKO8xBdaWBaZwpLSSMOj/WNQ+Id/xLCbcBFqcuCJ4BHWsQ2If+oBZqkWnTBX9dYDGX3g6PDprfRjrUQKKTqFMmlYL6QWs6FhHh0XGnKlp8jJmzkL17hA/ZAkCZ4DDf2K6LqlBapMZAmM5r2AFY2LrfYLU4YBLXSa9waMORzrZ3GlcS3W77xCBxZKu8SLyDXZl/GBh85HA+HO5cDkTXgG1tWLMeyAIoWaCZpKH8mBjsmAyyoiqQyHCIQLRoTKmZFrqnZrgPDBvUzAC2gBdoKitz6UovDLdvXQz+UljG2Z2K0k0mASRDrLD4kaoaGsq7gQzImrkWUkUo2JB6LSKFgsCR7n1tFCVyiKgLgrc/aJDSAau55VP9BlAyqmDCd9XY74wsmG7PsBndPVwyLcm3cdhtQE02YUae2tJZYERhAG3ODoG9gu208KauyYahl2TaLmpZiM15xx0RY4yGp5CIhAzH6FhigQwJVQwlcq6S0oyMPoLUcSxxdEm+5oFMCBZk5Mzsho5KwszgyaJNp8BIN4G/1Q2ZV6DDmloch8m9FM5O6E21oR7dtiRXcAaZUUWeQFwe0YWB0ppleiQtgF6/axjSO0HRXVbaLc7ZLkLZAtwaNp7rIEbeEx3Ci8XU49wZEmbd7y72b23dlpZZXNTozNzgtcDie4SgloG+qmEkvx7gsigbjUJVNaVdmpzSXWzZpSX0sd77/fNOUniu8YpSVJWMADjAJmkViTGMDzOa8s/N4f6dD12q/SYAZDhCOX+m0F2e7UpsUqbIAEuYQQMBAWXCX9+IdmRmY6utnzUd7TKB82BtBSVBC6Poomfm+VaB5SykDGAhHcLvCDVh55Dd97FNAf+QvGmRXB/iHgScyAzQ69beBkbl9NCRG5ds+8ccFT+Z9GqM+1DcqpqdCN0xUpbADh2CXCqR6yIZoaTA+MpSy2/dn96LESjZ6CeA+6GN+UUBCJmQMe9k5RzAdo0MezaDA1pZkansEBNh/GITGeAle6nd0IsBPKVx+JDx0bpdHHTQWbJSeGVEk+CCasKSZXniIYkSI/0nogqv6pjTsGl54w3k0c8QZicQhvdpxyjFpg8dksa5yqHbVh3ikNWoFSgvkSXHYCemzSIF7OWi0hRuyYtqhy4bjgmL8WAIwMaiDgiarykT4IUCwXAJ4Rx65gkCARmNIHLYKukuVBv7iBPbmJ4qAyIT1JIv8SCiorEQ4AHy0ar3QDL/pdqAhCSAsjEebDk6aoO8JGu1ApQfN0A3t0A8N0REt0Xbwk3VgjD6Kflw60c9Z0XRw0Vdahhq90cvZ0ZPFWRgd0vA70rLIG+w1qjzxIdyQkg+WBPzFqMHVRgPiLi0dBJWkoXVSpCvNifrSsSvQZTKdwUxSsw45sKaGZvsCmP+3JWdJi2epOS/XKtSjWLnGw1tSZ1hMaQyhC3hbrcaRmQKxuwQiG4Rjk9WyOMFq3K0c89WJGHSTB3hvzafc8daPYsEVOb5tPYttzNVOCX3vgwaVecky6MeUR8aQXJHqI9iRrE5wTcUdCticeIZqOwxkFDxawscas1SAl9nnrD5nWAP63GvDLDK4eNmt7dqvDduxLduzTdu1bdu3jdu5rdu7zdu97du/DdzBLdzDTdzFbdzHjdzJrdzLXUyE4dzPDd3RLd3TTd3Vbd3Xjd3Zrd3bzd3d7d3fDd7hLd7jTd7lbd7nrd0QwNzrzd7t7d7vDd/xLd/zTd/1bd/3jd/5rd//+83f/e3f/w3gAS7gA07gBW7gdTDGdtCcRbhY32DZ0yjShoVTq9EGD94OWhWzuJjgebDg65ClJqUZQnIqbrCf5XoJZ4AI4xoYoVAEvTAJ04GexNe2qAJhPpC7f0QYsXEGOvJ0DiJhjzC+5DG+C1DiImAFcfMIOpDjUxpIDaCidztrlxXUeZXWvMgcRfrhl7O60vjVkRfhe+ClTtU3y4TRfIB2iuUMHa6UBWGHH5wFQt4GOoLkoXDi2ROXKV5GfncbeC7jqyYJKmJPI2jjT45cVMfnPC4ycUwKQE54Otvn3nvks7OahT5xVAtMcYAcj4DV1BDma3DmchBZjKUHp4DR/9HEHthoDZ2OpxNH5l9+B58OVVMuB2quwwWB6OQzvpcgWZcAE3Uu4ygel5egonyOCDRgBb6zIRvyNIlA6Hdi6HGJ6JywBCRAL44O50muBpEuCs+j7dPRxXSAHAOSWpbwJM8sJqkljoRK1celXjYCJ5lKSWZkC+3+7vo4kDdTIZ867l4gqnfqQ2ZkVlZyKi9NA/olXQfGet9give+oun+IzSNYxxmh0hACQ5APyvQXkrQShXyq1pHNM0QLu7+YfEuhU3TMjfN0xMvq/FB7nRhJSki8G0pJiXidrYO05POJmuw8U5ddnfu81Tg7WtA7DwBBeNLC59gIszeBtou44IhAv/CXuleY+06e+vxOxjcPiRBUCRSixwzbLSe4Cszy84KCSUWya9idinS1tSntueLmNYkGa8nOSBf9vXfIKoCswIKmwakHrR/fAtEa4gm5DMMa24WuWeXJmU5KK8kkPejk/gXskkT17Mr6h3kCvhvkrRsnz3BhHRwP9W1Vwm7+vCXhiBCOdMwQSpZXg63ju09z9qgEuO+PvRAr+xqMPQ0UPQiUwxWIKlKLw5Z/+t/+vQ3TgtSH+RUTwp8tPtZ3/rODl6YSqzH9o7eGLkqOQ+RS7ff5s5VXnlpt8E5p+Ud17aq+23Vz+9rnKp6vvdGoLb+dlymLvgSOP4rSrczp/BKB/r/VeAAJjADIOA0QIAAQOMAg3AKw7m2cgwUQXEXQGIsygNAIAiJRZIJcDDUmqzTEEpEHAJW07NpSFgDzZcLViB0mVEAGA1LA7ZddTMun9PrdrojwEQHEicFzp1AgMJKQBDP4QkXIiBDHOOi3klDwAhZl1XBgtXjXOWIJGIeU9XMj8LCoB/AQ19bwMGJayHoiUGACqWlHJmuHYLXoEnwQk0aQ4AqDEBx08JQAMNBaEzWU1bUWVTJyZLTzDaRopyOUnWz8rEYjrnOd5tszZk7jsGAiYHs2TpcGnkcc9DIeApjsBsKFVlqMFBAwIA+BSYQpqAB58S1GSd0mHuRRpsRbkng/8nJFpKIAl3dFp5IxiTYF2ZgHCTY8e1MGjDIJsFkc+cn0KBzSMVQoKDAqlavasDDpaLSlADMEiHCdcCYAHmREjEZNMAYoBkD9HCSRseWqBNEgw3YkWcEKpuTFowdQQsFL1i/0E5DVGUPMC9tFDD4QWSBAwQCCgmRlcYwAMQIHkYGYoAwGiIZeewBKYXHCAYDAC/qfFJJAmMQa5i7/EgAAciSwXAMpKOBnwUJ5MVoIK9eAdyRd6PgHUPnGmYHUrchrYPyD0QG4RyQ1bBFDzmAFnBiXB3AdYsPUmEUq9FGu0CoTB85kiD06MiTamRvP4RTkGGcm4zfQSamQe+BF59vs/8ctcAByRnonzBTCfUghHTgkokxDHARyw6usBKDAXlYUc2EsTySTBe63GPFAAyQaIUKF1oRGx+MwfJVJkvVgBZVas33QBWEADaNFQoABk0XBOblVG95LeAbiqTVARMlhCFw4QFIAdLHDmxMaUWVL7AIRZBMbDaIHp4dIZpU8R1jhQHi2NBjAklsFIgQYTZDJVLs5GAbDrpZkcAvLQFSJZ85cKEAcQ3F0g9yG8EpJ3p5ftkPHAVcaASZTjogzwG6WPpieSf46cVmMdS2Q53GHOEmmgPE5wqqx7Hp5oRVmJApU1wKdpxMMCAASALxKSpLjwlepISux0a4LLPNOvsstNH/SjvtHD5Ru2wBEl17bX3bevstuEFlm49x4Zp7Lrrpqrsuu0BZ264LXaADLx03cKkqvfnqu+aHap23L8ABCzwwwQUbfDDCCSu8MMMNO/wwxBFLPDHFFVt8McYZa7wxxxAjJBQ/05oTA5S8bhuyvrjI8R1TTs4ZaxwsMftuuB/vq/KzaBoBbTCQ3rLrLeVCy3IT88Vgc8QoAyUz0gg3PYdJ2458QsnTUas0wySxRufLoT5rLc3SPq0u1s06sDO7+gi1GIr/Rjh2vXSWDWHYdcxdB9M+O6031OGgLe3U6QB47d0Ia20q15F67SzYDl4LN7qFQ5iA2+mqDVQySTTw99t8/9cxsuTuOv5T6DH/C/m+CIwFyK2AKNBCiESE2GawUsE83h9MbNHMWAG0AFxrQQKNBqKEmIDgvTeqkDkAIhBPSAtRIL+o6lb83seLF2r+Z0HPwLmMQWlUgmUUn/oIC6iB91jCAMVS3XsLOTHjoQKOFd8Nhd/PETtG7vNOiM0Wc6hbpSgAsSnWAm7Qo5d0gTlDwAWZpMKAYHApDRNKkRBq15bn+a4GIULABV9TQLSNL0XACwTbJJIG+slieleZw3jw9ZlVHcZ9T6ge6573Oi10gQjro+CixpeARwyASh5iggLZRII3lLB7FgIVATS4A/MZYTM3XB3q8vUDJnACAarLEP955kTEcAxxBejgxARfIYItKmVPU0xPAXqmlC9oqwEwgEe3WlEIXIwACF/U40CUIAtLsRFWNxgBLszgh8sVSA73iEyXegWHe7hlMj7UinOkEbiRtS+BhygkDuTXhg0WaDHR84MFYYAgmJXDLJ28wQPY2MVj1HENQvLGHnpwAybAqgbxieK/CKACnPiqG3bMIBH7GL953dCYtnRSMnbQAAGcMI7dgAgYKFkcJeTSZaLiwhCS4KYofMdSMpBlCf4Yw1YyAHRGYKQsOhkMFQzCk7wMJTOiiYLznA08wyzjAEZQzh1aUQDo9BzASlaCEGmCCl3Agt9mGIMeNKABhPHjrnT/WSgdXK5qF9FBjdCGxh4QRhkMxYFISJZRA5gDSmBYn1TmEIz7XKRRWkspN5vxw03SKSMl64Eom+IYSaZhpjCS6Q8twgKFQioNOmBDSDlJTUxMgh8W5VJ7sikPNLppOQRw2xMuh8Z3/eAABHhENS9nEKEusYdPisYlToPT8jD1pDBz6BXc6Y1MwCAL3ThVeR5Tv7NqwSHsOQJFFGIeGTAVYXXd0B9UAtEZoqxDKXKAA1LxU5Zu1B7y8OhO8IMHiwIgJbLY3TzGIafNtlQwL53XHAYiDVG+lDQ4/UZKTlACnqLKpysN6h7URtupyLZ7NcgtEpQqgMaaDDzKgKp0FFfa/wfQxCZmeCc+4pFVGIhVGm7KDKDAoV35MCBsbRJSWo1T26CRILo/cYV9iDBXxu5qoZBtAnJ3KzcjUEO8yQXsdH1yXmgSIEGBRKzmFBuqpdYXofviRPzS2UELiVY/9fluDJLhB1eogI2D2IQiKuHG8TziP7SEArGYsxoP8qISDGyBhY5QztTc8sOtNYhrMqMUSEEHCP1BkIK0mZgoJIAIovGBIoYRuFkq18M4+LGxhKOboRpknT0OAnFiUOGVmAfCfGgqYwp8rOWohrOvSYWAjtweKROnkWCQIwFgIA5LPQK11mgBnBX0BQcYgxqiFbEO5IhNGOCGO8Qhc3MEuWdPfP9HOBaS7yVt4AcWeHkYwYAxZLeMACY3Msewschf03PmBaxTAHw+B1PwrIyuWmeHAjLlOTuoH4SRiQv5uJLsdHWrWZ0Gv1y85f86iL4quLFO2KPjn6b4qCYwLxieuAwUiWA+WVSvgze+CCZuecx1TKpYevZQTaLQqvjUSr+sxITqFlvtGXh7OH+ipyRH5aVcyOdf5Z4sDWodwCvV5FgFeNQNXEcMYP3SCJ9CVKtjYUEUlfgkiEGRz7IQQmW15EL9LnexJ6RCVVp8kMsmWkvWVyUbjKWIkJY0Vp+g71uDisWx6Aa6h2XsW/rVBLURuLulYXGYzS6+KDcg1f5E0Ahjz8H/HTv6tBzgzYvlEXNhlFbdWslKpFMdcImrOtaRfhSN2SsWMgRKm64V9YBcPetmj1Dgzq72tbO97W5/O9zjLve5073udr873vOu973zXShyDIrMqDX2nxiN2WMh9rrSzrMs9r3xjs/64Ks1lcBPK/LM6qfit+XUsi+rdI//POg7Zvk4sIHyUB/dtCgn3XBtfuqd51zoYy/7h7UPq8FuQSa2tqcFFu0NtV8UeC40AgESwo624yCm+wUGNT0yhckHui9b8PvTduHDytVh/O53PPc9MS9H60IS5+P8JjzQd0VKI5dqw3v0AWL27n9/u175yVvC6l21Gb46mruCq8DyBzZX/+EOJQgWKBMaNID/2cDGjVJpqFMq9BMDBAoNyF8QPIE5+NQGxRCsRZGiEZK2jAulHBIfLAADyhAwkd8wGVx64J8IdgN8wZ8LvuC3+NZEGYD9wdHqHYtvZYIAWJA8kFORqZoOgkEXFYNdXQZliFdBKU5G2JUofQwQWc8HFopdpVZvXMk+oGCxcdRnDQ8MdqEXLosMlkYNZmHilJ55OENzXQ5ORFFi5N90DEEU2FmGFdhXRN/1UWAgLOF9NeFqueHgAIcckh92kUt7AJYWBt0XJqIiCkVGOFkBrJPuAUcNQGIjOkRkJAYPSgGdtQGNHQYmMkMwaMulBZ8SqJoMYcNi4f/hDrza64xijAXVIHXiJULKOgGHK97XGbCZLDSSIT7Z1plY4S2iMArjZqxbzkViodTAqFzflmBIJhbBw0kFMeBJ6W0ItAFdz9lhErZWH+zQNRKBKE3bnaSfMl6IJH6jIG7EoSTKoPQig3Sjbi3dMM4jPdajwzSSPeajPu5jwfROGfEjQAakQA4kQRakQR4kQiakQi4kQzakQz4kREakRE4kRVakRV4kRmakRm4kR3akR34kSIakSI6k+4mZszzBJOiMuYxeHATjsuAMScZk25mPPLZkJtTks7BEP0VL3bBk30CLT8qkUG5LjRSlUdYIUGCWcxkXHTAetLCE6vEk6ln/DbOY3oME5VBmZbRwYVBwpXaMBE4eDZhpjyFI26UQjzH8gAB039+g4gd137xQUXnkQazk3vrED8dZh/AFX8vdWTb+TMs1UT/kHi0ZT/P8iTFEEbCMjzyMH1tqpVZ6JeH9BOjA1hzUCA3ukAbK2CARVFfAgANCICrSwAF6YAwMlPQdgHG9y2KogW4cRgdKRGgiYeWIkT5NE6OMjqBBxAYVGTL9QE3A0gjOJmQOpWTewXEiDqoQADoAkc8EkCQhGCWowO5khxG6zGg2kw7WQGJZBKVw4hsIkBE8oe9cp+l4J8n8UFkRVm7GgVrllB61BzywQBEaVnFmZXLWQX7+QRI0/11TNlV04lRFbFEYMQAdnqL0JWg6fJ1YTid6TodLCM4qbBAazqGBaaPb5FcSDFh7aoFxwAPunMF8CkAggseB3qdM7udlJuXymAXhAegbRlp41Al/mSKGkqYlSgZTtJqC8gd59EedwAFNcEeOJsYB2Oid7YcyJlkJmFqfoQMYQKJK5QNvboJviugeMBimleKComhMqqgcqChNduVNitIRyGXQocpfLliPNuPImcpZPugxFkuDeENquGkBrGm+KRGH6Fr39ZvJLKPLaQu4JSZ/ZSns4Br6uKSXfiSYtuS+9NccmGSjVqpAPmrR5EsVYFArGZ2lfuoiYip3giqplurRMP+LqJqqqoZkqurWqr6ql7YqCcAqrUKmrD6qf9aqrj7krboLn+4qsPIqqgrF4QSrsSJkrwZFsR4rsw5ksgLFsjartO7js/5EtE4rttJjtd7BtWartyrittJBBDnlt5br7IWruaZrQB4luxalur4rvMarvM4rvdarvd4rvn6LShqEHJFJbc7MVDLE4XGeHYCctPwdi3noT04q7NFNwOZr7IWIZToSK7iCJwBBuOyk/v3Bv+6PW0neHWAewZ5nwLynHSqnRDVL40Cs7B3pjv1EMhiDizkXg1JLVG4sJ7jeWWSXpQgNVc6B6mVeSXTsuphskqJsezCO42Aly9bdyOIXlnX/CifyJS8AkQM9hO0FA8zI5QeZzDswEffEFkDcQHlpHxwwn4OEiPWNH170AQPMjjZI0c8BW5JIUDXpkGLMT5BQX8uxxA9FUcntgDGeo/AQD1nmD2I2beMZgKfGwBqVQCGsUWxCyi8FrVmgDGo+KG3YIDzJlB+yQAaiki0tTqgE2gWmQudGTRQlk6IpaUsEwjRV025mEykZB9miJ+gAlAHSnw0GGgsKg2aK7i2o0psqrt49gNs4pxYkwAP4wUU9AHlOVRkkrZ8hTXfKzOYWG0xNZYXKwHBVxgNIaenaQ438G19ZhJncFmmsJ1p1Vp6q1x0FF7UlFUvoVRGwlhRuYU3p/5lR1azx0p0BTCwdJANzNg8ZrKAMVVdO8cOv4GODJoTm6ok5SGodiJYYfW88FKsqBiIFe036qhYuuScBoJf7vud6aZeG4u5+SQH+vtH7IiIGR0Y0MOX/yp3UQgggBAEu5EaRTgl8XJcvCduOgsfQAQhgeVquxYEd2RxxYLC9TJ0q3uJgvAYRXNjJuccPH8OpVW8QABoOzC6hpcaUaRp6Mpk4OOKf+SKD7C8gCcGvBQGj1nDbhVRQ5EGF5AWe/kofFJwHoR6aYq8Ey42dwKTLGRBWENVUmNXQKg46zlxX8JrPjRtp/OkOYFzwGI8QdtywcRn5XYGbGOMmv2MCFIIoyf9b76hEWMqxPaqJw9xA40qNtnCMA6uyRS6G/yIMpaZLBAmwxPgjDdMyMAezMA8zMRezMR8zMiczxVwjBCqzM7edA8AYxj4zNb/dr+hsNWfz0dlLKmuzN2NMQ7zyN4/zxHQrOZ/zw8RJOogzOrezwVBVN7uzPM8zPdezPd8zPuezPu8zP/fz7Ant0QY0w7KLn6TIWMCeR/1EQkOISyKs4PRCw1JcVRJt3hltYOgNIY+XfsbzSw6PRRMrR39eAQxARNvkr8YNNpOunKbj5/QURd/BIxkwHSx0YNTB+Lits9A0yhBTtMiMVQKwz0bLR99MUCtrSD/eKJd00RCDi6K0Hfj/NNEWjlQ9y+Yswr/S9JNIpjYVQDTntFfuNKY8LCP+y0/P3VA/y1nnS1pz61E3HmZ5HkKwQPktF/ygx4UwUOIWke2BLnmo5TyMMpZA0r2sT88J0RjRZQ0UKhB1bZ8CkAu4Dux8rMZJ5izf4fNxViUXblthUMgA0ZGa7WH2gTEUIxZhgfvMDtsIsW4xnBoQsAt9nRAZSt8akRLdwKWQ5R/7z2WyNvEhBAshWwdlREcI3Art7S7gtB0K5o0kW25j1fSkRnETgjwYtgzQ5fiZD93uFRQ+ZiErtdrtDlzv2hioHijtyT3BTHy0DwIqaHxYSxStog9101SPV4G0j3Fp05VW/9G/yBF8jSDipJEJtKAcNARJE0BvpaJB3dJk+G6AD48wJe0Mhe4owXeT3dIsSaBF7JAATOyDL8Ye4BFpCBkVdGZqriA9KQMIJlIGbSBB8R9A0EGHB++Eb9NxLZNyMXhz0K40ndZ0lwsL3OZ5iHjmSuAjrZKOb1PqqibvgBGCYFK1RK6RNbMYzd0DbBDKKC93Bkn0jOdKSdUYTG/UhJUfNB1PR5VLazeKyCmIFsIZyExHeYFd4dVC6W8dtEkeTCCCV80hPvRVLQpYT8cJ404YJlcSosZXKbEVHgsdnyZpXO8MhFqxuRQMOLpK30iiAxd7McUPeg0L7PlayS+yFAk4sP9vE2gNpdMXTZ2w2myvRdgVQhyOG1jBYBxhDcg5OyPdSYn1A89QC/8BdfXbN2SB8zwBgX7dGezOi893B6v5HoSofius4ASihr45UNR3ngPNnsPEPRDin7PxmitXYxU6eAXKtmsXdM2BqScYqNmcDUp6ckFwqbhndgmXJLHVF7DhjXtWP7DVsp8shzI6d6r7ZhSXqhMLM81AIL76JPOEYBjohRaFZN1deFNhZTzynoxamqU3E4Qz+kLfPHRYdiAaRDBZfSCxnFLSa7aHzJBYkN6iprG8iRksTVkKE7BigrLRgvtiiXmBLkI4jYsSyvumzZPxZmTHJsphz7OByIf4Bhn/KY+ue6Rc20s9/Wa4AqQkvSQV2pSxRhlV5/C9Do4PGgqIMXGYfPQ5KapxSNOPOBH3qFy/MRhofdljxqdlgRT7pprFAJD+h8tWKBnb3cTHAAPXdcAZph4Hi5hcCaKmaRyMsO2Zbx+YALrhSraJSeUUqsq7DSZwwS0o6r0ZG+e37nG4CJd3o4JWG2aDvhccHHGgzLCYKeZT0CgTHReMUahkiodkF5wSQhNPBeSrc2Izd5zWXNQHgrv/8WJt2+4jHBuPSpaJSu4ztelfcgI6fw/aSfRRchOAm2xDX0bMG7zlXJZVvneioySXerLo6edTZC57pPiqndL588C48kdm20sf/93Wyb/+7z//gwAgjmRpnmiqrmzrvnAsz3Rt33iu73zv/8CgcEgsGo/IpHLJHB0OAAKhNBDgqqynrRAo8BABREnaNIHFgkAgLYaRjYaA71yu2+/4vPI9wt78JoA3XF4qAgMyhCJ8L4pBClY0jE2HMJV6mJmam5wqk4I0oH2ROI4plzCOky2mPgtdNatLqC20nbe4ubomBAkDAQleCL9rAAsHagkLDAlqU2S9CsBeWMdqBwskzM4ABc0BUwBYflVxagZk3tziyAFQKFzfBt2whGpqJA0OAAxhAA4NCLUL0+vXAC/qwNFD2GVgGxEN1AxgwKXdPAARgTHgJ0/gPUUCpP8peBjF17QoU8wprHjOWDtlJRwky1ZFZiEAlVgGmHdPzrYADXAq+CampyJzE4US3cW0qVMhvbwkILBAwbwHXQwgOlbAwRQG+6AFAzBVnJUDFxNcFOGV3z4tBSCZnTvXDxm4cgdg4/IA3k4AWAsoImQLsAIAcYIqeEBIVYKNA4LiFTC4Syt+sBpQ/hvYwLsG2KwCQECgcb0udAysLSn1WTgRXCgCxRlggVaXNxEfJDtF70YSOWenWXCpqpi4CEJa6YUT0UI6DRApL/m0uvXrMt4cAjNCLRgp2QwoIHARWrhKWHoqHCGevAh/GPeNizR/0RT4+uiKgg3LbOUChb3CjHj//SxgWiFvkIGfA/9dVtUBBGzkSBUDBTAAdyMcuJBnKGiHCBkIOPTfd1SVgJYIDxwmSnAMAegcGD0JcEkllxDCoTEBMDCjc9j16OOPbxiQAIZkzbOAFDnyQ8ABAxzpmghCzhVAXygwsGSTC9ZFnxV23ddGfuSQUoIji/1X2D8NHKaAA1BoiJJ9ACzYYH8loGMVmQ8cENQIRC703428hBMlGWu+h8B/xiD5mwgnGkYXcIiY+WJtkIpAo3M2viPgjj926ulTBOyzgFpVzZNGAe5VlacVYDgZhahqzXUATKqRcACrtWnBQF5WJBDUdLG+qSuvImCBFUmxCbXAK31FVECK/9nUOVtE8xDyShsJTjGsAMxi1MW1JQjgQDZ6JhuSbQpsJABVopGmISGprRaqMbGCNyVth56GqpGLkaBVAaP2JqalkeoLrTHjGeNAcs5VcjC8/hAgXcPO/fXpxRhjQoA07ogwjBpWHKLGPirNAw3H72BRwEskldzNN+FgAWMCcqWxUzowF7slRjzyJ1Ib5iAD8Dcl9CMGGBLCQoAapIWD8zpBK830CD8Fw8XPi6jRLjEGvAuLOSORsPE1cEadb4siB7BPTDM9OgKLC42KDwLfHOAiwfSqcZRE6lL83moZBy54ErIM7gDgPl72Q+GDN+7440gwHrgCuf2ouA+SQ6755v+cd+7556CHLvropJdu+umop6766qy37vrrsMcu++yYqGQx7bjnrvvuKwDK++/ABy+778IXb/zxoau0NvLMN+984Lsi/vz01FefS6PWZ6/99k0ccHTY3Icv/vg+ZHQ7+einr/767Lfv/vvwxy///PTXb//9+Oev//789994eoijgwsuFwMG/OI1OBCgv+Tgr3ckgk43OBMNtPApCgohDk2xoA2WBsEbaHAE54sTSWSXtheoR3on2M+YOngCAsKgLUwgXiNY6Ibz9MxxKlxB5szQMRTkcBM/lEE/KocE+MwuRQNjgRFfEMSFsMCFL0hAEo8gwwHS8AUe2lwTT7DDMTT/I1qBmGIntviCB9wwCUuMXbBgsMRZiSABUNAL2bTEkXN4ZGp9aEebYHGPpIRkKT9BoEoQgJS+9QOBGZnInLwQkgCM5BIyceRnkrGo+GBGDADRyUUaKZeCWCg3MHLHH/GYkceYxSacHBgZGlkMEvRxI57cDQkSMgVN0sMibGmbFOJQsmyVxCBekEIomXSR26BgJMGyhjtKhp5iSkckqjTJWHa5hlQqxZFiUEktczSAAWgTMfdARy1zxo45JrKS94BCJGFSEzopUxmcIoMy48iqX0hDDD/ZE+teQQyYtOCEC4hMA9jZJmJVoVSjKY1lWKiXbkCiFfOaDnPaAhYq4EoM/9ERCuCGiJHNtAhi2TRAJf6FESjcCDQkSBE4FcMY4dRmGF6AVi8go084CWU5CUDMZ+J4gI3A1DBgfFPNaiq2sJgyMiYq6GauslCmFoCkZenFzt70ppmKIyjmsdRh3JbSw0QJAHDJqR9G6hzv7OZgI4gKb0pSz5gqgDhhy2iGcsSFEs0VMpG4i1LZYaApcVQzldJNa9hRSd3gJp7aapNYuSWaaxnHoSNEHV/oVdNQjjCNu6KczuA0nz65iQRdUkSayMap9iAOCzfa1BkfFCEnHsh3lWgUhyrUMwGpJV21+ZN6UOU0BFKVU7Sli+0geJepJHG0HfOlK7/EoP5UYUICaP+USvnQJTj5MqsIewBaTQAQemxkiWPdShhaNdzcZDFIu60RakTUnxDdQwzVzVKYWFvYS0hXRUkkUTYQK0LQCoBI41WPGE2XJJ26II1xSddm0aQlzy6UiH7IZFYuZGBOKYlJQUWtpnIkQTt1TV+ZqpRsoaCnFABETWxybVZyKrbejsGGeCuxf6HEYi6epxfL0002oaBcEDIXT3i6L1Xpcl0XY1en2CvBK3rCE5KE1z5k+KqNaUxVKeMNM1VZWxjIpGX45tVLEJHPVD0cWCHvx0kc9puCnPxfBoqwVbLTQkBRaIIlBrQB0aHJPHblZbMg1F3fSqM49jwSQgyUXlAALq7/MnzRKEzMBOIiVwO65SyQIkakiBjosuCIGAWvS1pBoZaKCwAGKzCDqpNAaXPwRiCcCMxjxTh1i72xESsfelQ8drGtoLCrzajrreZ6678CNuRgHZoZT6rqFFRNj6+5+cqrDmuRrgyGsJWaI2OAlcnCce1Th2QR2LgXGxTRLTZMW1i8JpZZIg3Wml5i2GURRaoWkyKAMQndL/NzMdhQlSksYGFxorPoEpLjFZzQjWSJI8cuUp+P7UQRHHTywv3UjKEk2m8umzE4LdQ3E1TNC1ETjLOxWQm5AeMdHBSNNvyBtFF3mhs9FsGuROm3KGhtHoAQzzrSSpVIUjhDFed0zF/G/42rYZMeWPuHLl9js64ZJKpG/oo03gEhKD0brGu5VkISfQ5UDKDGOl9PWlFm05crhJVjMZsjzEabm41zHWH6eGCVDgyaJDFta9Pjh97eMSzYrBlHq5sXQkg9MrrA8P5jBQShCAQuRJZwvl2BBBPvKcSzwPKUT0ErGL84Bzahi287Y+ZHT/rSm/70qE+96lfP+ta7/vWwj73sZ0/72tv+9rjPve53z/ve+/73wA++8IdP/OIb//jIT77yl8/85jv/+dCPvvSnPzj1WP/62M++9rfP/e57//vgD7/4x0/+8pv//OhPv/rXz/72u//98I9/9iFA/frb//74z7/+98///jb7//8AGIACOIAEWIAGeIAImIAKuIAM2IAO+IAQGIESOIEUWIEWeIEYmIEauIEc2IEe+IHSFwIAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Montgomery, SA. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_23_10610=[""].join("\n");
var outline_f10_23_10610=null;
var title_f10_23_10611="Malathion: Pediatric drug information";
var content_f10_23_10611=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Malathion: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?12/21/12627?source=see_link\">",
"    see \"Malathion: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?11/5/11348?source=see_link\">",
"    see \"Malathion: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F191126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ovide&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1023236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiparasitic Agent, Topical",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Pediculocide",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Scabicidal Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1023248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/21/12627?source=see_link\">",
"      see \"Malathion: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &ge;2 years and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Head lice:",
"     </b>",
"     Children &ge;6 years and Adolescents: Topical: Apply sufficient amount to cover and thoroughly moisten dry hair and scalp, leave on for 8-12 hours (typically overnight application); may shampoo upon completion; during clinical trials, a maximum dose of 2 fl oz was used.",
"     <b>",
"      Note:",
"     </b>",
"     In a blinded-comparative trial with permethrin; a shorter application time of 20 minutes was shown effective (AAP, 2010; Meinking, 2004). Further treatment is generally not necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Head lice resistant to permethrin/pyrethrins or previously failed courses:",
"     </b>",
"     Children 2-5 years: Limited data available: Topical: Apply sufficient amount to cover and thoroughly moisten dry hair and scalp, leave on for 8-12 hours (typically overnight application); may shampoo upon completion; during clinical trials, a maximum dose of 2 fl oz was used (AAP, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"     <b>",
"      Head lice:",
"     </b>",
"     Topical: Apply sufficient amount to cover and thoroughly moisten dry hair and scalp; shampoo after 8-12 hours. If required, repeat with second application in 7-9 days. Further treatment is generally not necessary.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F191116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical: 0.5% (59 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ovide&reg;: 0.5% (59 mL) [contains isopropyl alcohol 78%]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F191107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1023252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: For external use only; avoid contact with eyes. Apply to dry hair and scalp and rub gently until thoroughly moistened; pay special attention to the back of the head and neck. Allow hair to dry naturally; do not use heat; leave hair uncovered; after 8-12 hours, wash hair with a nonmedicated shampoo; rinse and use a fine-toothed (nit) comb to remove dead lice and eggs. Wash hands immediately after use.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Malathion should be a portion of a whole lice removal program, which should include washing or dry cleaning all clothing, hats, bedding, and towels recently worn or used by the patient and washing combs, brushes, and hair accessories in hot, soapy water.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F15131485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); do not expose to heat and open flames.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1023237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of",
"     <i>",
"      Pediculus capitis",
"     </i>",
"     (head lice and their ova) (FDA approved in ages &ge;6 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F191154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Chemical burns (including second-degree burns), skin/scalp irritation, stinging sensations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Conjunctivitis (following contact with eyes)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1023240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to malathion or any component; use in neonates or infants",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F15131484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For external use only; if contact with eyes occurs, flush immediately with water; wash hands after application.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1023241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Lotion is flammable (78% isopropyl alcohol); do not expose lotion or hair wetted with malathion to open flames or electric heat sources (eg, hair dryer, curling iron, flat iron). Do not smoke while applying lotion or while hair is wet.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Skin irritation may occur; temporarily discontinue use; chemical burns, including second-degree burns, and stinging sensations may occur with use.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Systemic absorption may be increased in infants and neonates due to higher skin surface area to body mass ratio and immature skin barrier; risk for malathion toxicity potentially increased; use is contraindicated in these patients.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6221440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F191113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F191123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F15131486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Malathion is an organophosphate which acts as a pediculicide by inhibiting cholinesterase activity",
"     <i>",
"      in vivo",
"     </i>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1023254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?11/5/11348?source=see_link\">",
"      see \"Malathion: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Lotion should be used in conjunction with overall lice management program. Dry clean or wash all clothing, hats, bedding, and towels in hot water. Wash all personal care items (eg, combs, brushes, hair clips) in hot water. May use a fine-tooth or special nit comb to remove nits and dead lice. May shampoo hair right after treatment. Keep topical liquid away from fire or flame; avoid heat, open flames, lighted cigarettes, or electrical heat sources while product on hair. Inform physician if swelling, rash, or fever develops or if application site irritation occurs.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Frankowski BL and Bocchini JA Jr, &ldquo;American Academy of Pediatrics, Clinical Report: Head Lice,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2010, 126(2):392-403.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/23/10611/abstract-text/20660553/pubmed\" id=\"20660553\" target=\"_blank\">",
"        20660553",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Meinking TL, Vicaria M, Eyerdam DH, et al, \"Efficacy of a Reduced Application Time of Ovide Lotion (0.5% Malathion) Compared to Nix Creme Rinse (1% Permethrin) for the Treatment of Head Lice,\"",
"      <i>",
"       Pediatr Dermatol",
"      </i>",
"      , 2004, 21(6):670-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/23/10611/abstract-text/15575855/pubmed\" id=\"15575855\" target=\"_blank\">",
"        15575855",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 87042 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-EE7AE732F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_23_10611=[""].join("\n");
var outline_f10_23_10611=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191126\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023236\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023248\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191116\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191107\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023252\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15131485\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023237\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191154\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023240\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15131484\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023241\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299642\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6221440\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191113\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191123\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15131486\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023254\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/87042\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/87042|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/21/12627?source=related_link\">",
"      Malathion: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?11/5/11348?source=related_link\">",
"      Malathion: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_23_10612="Condyloma acuminatum papules and plaques in a child";
var content_f10_23_10612=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83498&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83498&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Condyloma acuminatum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Soft papules and plaques are present in the perianal and genital regions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_23_10612=[""].join("\n");
var outline_f10_23_10612=null;
var title_f10_23_10613="ATP III guidelines for treatment of high blood cholesterol";
var content_f10_23_10613=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   ATP III guidelines for treatment of high blood cholesterol",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/23/10613/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/23/10613/contributors\">",
"     Robert S Rosenson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/23/10613/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/23/10613/contributors\">",
"     Mason W Freeman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/23/10613/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/23/10613/contributors\">",
"     David M Rind, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/23/10613/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Third Report of the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III, or ATP III) from the National Cholesterol Education Program (NCEP) has summarized the current recommendations for the management of high serum cholesterol [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10613/abstract/1\">",
"     1",
"    </a>",
"    ]. Guidelines from various organizations differ in their applicability, risk estimates, and recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10613/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ATP III guidelines are based upon epidemiologic observations that showed a graded relationship between the total cholesterol concentration and coronary risk (",
"    <a class=\"graphic graphic_figure graphicRef60146 graphicRef50334 graphicRef78556 \" href=\"UTD.htm?22/37/23120\">",
"     figure 1A-C",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10613/abstract/3\">",
"     3",
"    </a>",
"    ]. They are influenced by the absence (primary prevention) or presence (secondary prevention) of preexisting coronary heart disease (CHD) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10613/abstract/4\">",
"     4",
"    </a>",
"    ]. A meta-analysis of 38 primary and secondary prevention trials found that for every 10 percent reduction in serum cholesterol, coronary heart disease mortality was reduced by 15 percent and total mortality risk by 11 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10613/abstract/5\">",
"     5",
"    </a>",
"    ]. No increase in noncoronary heart disease mortality was seen.",
"   </p>",
"   <p>",
"    This topic presents recommendations from ATP III and the NCEP. UpToDate's recommendations for managing lipid abnormalities in primary and secondary prevention are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/32/14856?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in primary prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IDENTIFICATION OF PATIENTS AT RISK",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     ATP III recommendations for risk assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ATP III recommendations for the treatment of hypercholesterolemia are based upon the LDL-cholesterol (LDL-C) fraction and are influenced by the coexistence of CHD and the number of cardiac risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10613/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]. There are five major steps to determining an individual's risk category, which serves as the basis for the treatment guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10613/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Step 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step in determining patient risk is to obtain a fasting lipid profile; the results are classified as shown in the table (",
"    <a class=\"graphic graphic_table graphicRef70489 \" href=\"UTD.htm?31/39/32379\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Step 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;CHD equivalents, that is, risk factors that place the patient at similar risk for CHD events as a history of CHD itself, are identified [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10613/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diabetes mellitus",
"     </li>",
"     <li>",
"      Symptomatic carotid artery disease",
"     </li>",
"     <li>",
"      Peripheral artery disease",
"     </li>",
"     <li>",
"      Abdominal aortic aneurysm",
"     </li>",
"     <li>",
"      Multiple risk factors that confer a 10-year risk of CHD &gt;20 percent (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Step 4'",
"      </a>",
"      below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to the conditions identified by ATP III as CHD equivalents, we consider chronic renal insufficiency (defined by a plasma creatinine concentration that exceeds 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [133",
"    <span class=\"nowrap\">",
"     &micro;mol/L]",
"    </span>",
"    or an estimated glomerular filtration rate that is less than 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2) to be a CHD equivalent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=see_link&amp;anchor=H3#H3\">",
"     \"Chronic kidney disease and coronary heart disease\", section on 'Chronic kidney disease as an independent risk factor for CHD'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Step 3",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major CHD factors other than LDL are identified:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cigarette smoking",
"     </li>",
"     <li>",
"      Hypertension (BP",
"      <span class=\"nowrap\">",
"       &ge;140/90",
"      </span>",
"      or antihypertensive medication)",
"     </li>",
"     <li>",
"      Low HDL-cholesterol (HDL-C) (&lt;40",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [1.03",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"     </li>",
"     <li>",
"      Family history of premature CHD (in male first degree relatives &lt;55 years, in female first degree relative &lt;65 years)",
"     </li>",
"     <li>",
"      Age (men &ge;45 years, women &ge;55 years)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    HDL-C &ge;60",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.55",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    counts as a \"negative\" risk factor; its presence removes one risk factor from the total count.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Step 4",
"    </span>",
"    &nbsp;&mdash;&nbsp;If two or more risk factors other than LDL (as defined in step 3) are present in a patient without CHD or a CHD equivalent (as defined in step 2), the 10-year risk of CHD is assessed using the ATP III modification of the Framingham risk tables (",
"    <a class=\"graphic graphic_table graphicRef64978 graphicRef76742 \" href=\"UTD.htm?30/1/30751\">",
"     table 2A-B",
"    </a>",
"    ) or, preferably, with an online calculator:",
"    <a class=\"external\" href=\"file://hp2010.nhlbihin.net/atpiii/calculator.asp?usertype=prof\">",
"     hp2010.nhlbihin.net/atpiii/calculator.asp?usertype=prof",
"    </a>",
"    . Risk does not need to be assessed in people without CHD who have 0 to 1 risk factors since individuals in this category have a 10-year risk of CHD that is &lt;10 percent.",
"   </p>",
"   <p>",
"    A validation study found that the Framingham CHD predictor performed well for prediction of CHD events in white men and women and black men and women, but it overestimated risk among Japanese American and Hispanic men and Native American women [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10613/abstract/7\">",
"     7",
"    </a>",
"    ]. Several studies have suggested that the Framingham criteria also overestimate the risk in European and Asian populations [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10613/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. It is not clear in all cases if these differences are real or if they are due to differences in research methods, adjudication procedures, or time intervals studied. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39048?source=see_link\">",
"     \"Estimation of cardiovascular risk in an individual patient without known cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Step 5",
"    </span>",
"    &nbsp;&mdash;&nbsp;The last step in risk assessment is to determine the risk category that establishes the LDL goal, when to initiate therapeutic lifestyle changes, and when to consider drug therapy (",
"    <a class=\"graphic graphic_table graphicRef82504 graphicRef67460 \" href=\"UTD.htm?3/46/3822\">",
"     table 3A-B",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Importance of other risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other risk factors for CHD have been suggested by epidemiologic data, such as obesity, physical inactivity, impaired fasting glucose, markers for inflammation, homocysteine, abnormalities of thrombosis, and endothelial dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=see_link\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\"",
"    </a>",
"    .) However, there has been no evidence from controlled trials that targeting these risk factors improves outcomes. Thus, their presence does not influence current guidelines for cholesterol lowering, although ATP III suggests that these factors can be used to modify clinical judgment in some circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10613/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Number of patients affected",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ATP III guidelines include absolute risk and lower LDL-C levels to assess eligibility for lipid lowering therapy. The impact of these changes on the treatment-eligible population was examined by analyzing data from 13,589 subjects in the NHANES III survey [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10613/abstract/11\">",
"     11",
"    </a>",
"    ]. Overall eligibility for treatment increased by 157 and 122 percent for men and women, respectively, and 131 and 201 percent for those &ge;65 or &lt;45 years of age, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Other methods of risk assessment",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Total-to-HDL-cholesterol ratio",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the protective value of serum HDL-C, it has been suggested that the serum total-to-HDL-C is of greater predictive value than the serum total or LDL-C. Data from the Lipid Research Clinics and the Framingham Heart Study demonstrated the following advantages of the ratio [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10613/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among men, a ratio of 6.4 or more identified a group at 2 to 14 percent greater risk than predicted from serum total or LDL-C",
"     </li>",
"     <li>",
"      Among women, a ratio of 5.6 or more identified a group at 25 to 45 percent greater risk than predicted from serum total or LDL-C",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, serum total or LDL-C did not add independent predictive value to the ratio. Risk tables have been constructed that use both the ratio and presence or absence of other risk factors to predict coronary risk and possible indications for therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10613/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Other ratios",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other lipoprotein ratios have also been proposed, such as the apolipoprotein B to apolipoprotein A ratio, which measures the major proteins in LDL-C and HDL-C respectively, and the LDL particle number to HDL particle number [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10613/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33241?source=see_link\">",
"     \"Screening guidelines for dyslipidemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Non-HDL-cholesterol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-HDL-C is defined as the difference between the total cholesterol and HDL-C. Non-HDL-C includes all cholesterol present in lipoprotein particles that is considered atherogenic, including LDL, lipoprotein(a), intermediate-density lipoprotein, and very-low-density lipoprotein. It has been suggested that the non-HDL-C fraction may be a better tool for risk assessment than LDL-C.",
"   </p>",
"   <p>",
"    This issue was evaluated in the Lipid Research Clinics Program, which included a total of 2406 men and 2056 women ages 40 to 64 years at study entry who were followed for an average of 19 years [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10613/abstract/15\">",
"     15",
"    </a>",
"    ]. The LDL-C fraction was a slightly weaker predictor of cardiovascular death than the non-HDL-C fraction. Differences of 30",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.78",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    in non-HDL-C and LDL-C corresponded to increases in cardiovascular disease mortality of 19 and 15 percent, respectively in men, and 11 and 8 percent, respectively in women.",
"   </p>",
"   <p>",
"    ATP III identifies the non-HDL-C concentration as a secondary target of therapy in people who have high triglycerides (&ge;200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [2.26",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10613/abstract/1\">",
"     1",
"    </a>",
"    ]. The goal for non-HDL-C in this circumstance is a concentration that is 30",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.78",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    higher than that for LDL-C (",
"    <a class=\"graphic graphic_table graphicRef53318 \" href=\"UTD.htm?2/46/2795\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;This topic presents recommendations from ATP III and the NCEP.",
"   </p>",
"   <p>",
"    UpToDate's recommendations for managing lipid abnormalities in primary and secondary prevention are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/32/14856?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in primary prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10613/abstract/1\">",
"      National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10613/abstract/2\">",
"      Broedl UC, Geiss HC, Parhofer KG. Comparison of current guidelines for primary prevention of coronary heart disease: risk assessment and lipid-lowering therapy. J Gen Intern Med 2003; 18:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10613/abstract/3\">",
"      Wallis EJ, Ramsay LE, Ul Haq I, et al. Coronary and cardiovascular risk estimation for primary prevention: validation of a new Sheffield table in the 1995 Scottish health survey population. BMJ 2000; 320:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10613/abstract/4\">",
"      Pekkanen J, Linn S, Heiss G, et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990; 322:1700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10613/abstract/5\">",
"      Gould AL, Rossouw JE, Santanello NC, et al. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation 1998; 97:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10613/abstract/6\">",
"      Ballantyne CM, Grundy SM, Oberman A, et al. Hyperlipidemia: diagnostic and therapeutic perspectives. J Clin Endocrinol Metab 2000; 85:2089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10613/abstract/7\">",
"      D'Agostino RB Sr, Grundy S, Sullivan LM, et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001; 286:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10613/abstract/8\">",
"      Bastuji-Garin S, Deverly A, Moyse D, et al. The Framingham prediction rule is not valid in a European population of treated hypertensive patients. J Hypertens 2002; 20:1973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10613/abstract/9\">",
"      Brindle P, Emberson J, Lampe F, et al. Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. BMJ 2003; 327:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10613/abstract/10\">",
"      Liu J, Hong Y, D'Agostino RB Sr, et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. JAMA 2004; 291:2591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10613/abstract/11\">",
"      Fedder DO, Koro CE, L'Italien GJ. New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy: projected impact on the size, sex, and age distribution of the treatment-eligible population. Circulation 2002; 105:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10613/abstract/12\">",
"      Kinosian B, Glick H, Garland G. Cholesterol and coronary heart disease: predicting risks by levels and ratios. Ann Intern Med 1994; 121:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10613/abstract/13\">",
"      Steyn K, Sliwa K, Hawken S, et al. Risk factors associated with myocardial infarction in Africa: the INTERHEART Africa study. Circulation 2005; 112:3554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10613/abstract/14\">",
"      Otvos JD, Collins D, Freedman DS, et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 2006; 113:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10613/abstract/15\">",
"      Cui Y, Blumenthal RS, Flaws JA, et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 2001; 161:1413.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4551 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-05EE575892-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_23_10613=[""].join("\n");
var outline_f10_23_10613=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IDENTIFICATION OF PATIENTS AT RISK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ATP III recommendations for risk assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Step 1",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Step 2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Step 3",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Step 4",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Step 5",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Importance of other risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Number of patients affected",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other methods of risk assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Total-to-HDL-cholesterol ratio",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Other ratios",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Non-HDL-cholesterol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/4551\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/4551|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/19/317\" title=\"figure 1A\">",
"      Increasing plasma cholesterol and coronary risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/19/34109\" title=\"figure 1B\">",
"      Plasma cholesterol and cardiovascular mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/20/27982\" title=\"figure 1C\">",
"      Cholesterol level and mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/4551|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/39/32379\" title=\"table 1\">",
"      ATPIII classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/61/10206\" title=\"table 2A\">",
"      Framingham ATPIII score men",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/17/8478\" title=\"table 2B\">",
"      Framingham ATPIII score women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/4/11340\" title=\"table 3A\">",
"      ATPIII LDL goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/46/10989\" title=\"table 3B\">",
"      Proposed ATPIII LDL goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/46/2795\" title=\"table 4\">",
"      Non HDL cholesterol goals",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=related_link\">",
"      Chronic kidney disease and coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39048?source=related_link\">",
"      Estimation of cardiovascular risk in an individual patient without known cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=related_link\">",
"      Overview of the risk equivalents and established risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33241?source=related_link\">",
"      Screening guidelines for dyslipidemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/32/14856?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in primary prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in secondary prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_23_10614="Dialysis in diabetic nephropathy";
var content_f10_23_10614=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Dialysis in diabetic nephropathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/23/10614/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/23/10614/contributors\">",
"     Lionel U Mailloux, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/23/10614/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/23/10614/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/23/10614/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/23/10614/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/23/10614/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/23/10614/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the development and progression of diabetic nephropathy may be retarded by normalization of the blood pressure (preferably with an angiotensin converting enzyme inhibitor) and strict control of the plasma glucose concentration, many patients still progress to end-stage renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10614/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Important determinants of progression include the severity of histologic disease and the absolute amount of proteinuria [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10614/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diabetes is the most common cause of new patients requiring renal replacement therapy, accounting for approximately 45 percent of cases in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10614/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Although less frequent in other countries, 34 and 30 percent of incident dialysis patients have diabetes in Germany and Australia, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10614/abstract/7\">",
"     7",
"    </a>",
"    ]. An increasing incidence has also been noted in non-German European countries, as reported from data from 10 registries in Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10614/abstract/8\">",
"     8",
"    </a>",
"    ]. However, the incidence appears to have stabilized in Denmark, which may be due to the widespread implementation of intensive renoprotective measures [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10614/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States and Puerto Rico, although the total number of total number of patients who develop end-stage renal disease due to diabetes continues to increase, the risk of developing end-stage renal disease appears to be decreasing among patients who have diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10614/abstract/6\">",
"     6",
"    </a>",
"    ]. Although the reasons for the decline in risk are not known, improved glycemic and blood pressure control and the use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers may play a role [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10614/abstract/2,6,10\">",
"     2,6,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATIENT SURVIVAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient survival in diabetics on maintenance dialysis is lower than that seen in nondiabetics with end-stage renal failure due to chronic glomerular disease or hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10614/abstract/5,11,12\">",
"     5,11,12",
"    </a>",
"    ]. As noted in the 2009 USRDS database, only approximately 30 percent of patients with diabetes survived five years after initiation of hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10614/abstract/13\">",
"     13",
"    </a>",
"    ]. Survival also varies inversely with age, being best in young patients with good blood pressure control and no clinically evident cardiac disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10614/abstract/5,14\">",
"     5,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, these survival data may be overly optimistic as it is based upon information from the United States Renal Data system, a data base that excludes patients who have died within the first 90 days of the initiation of dialysis. When such individuals are included in mortality studies, the survival rate of diabetics requiring dialysis remains poor, even in dialysis centers located in countries with relatively high survival rates. As an example, among 84 consecutive patients with type 2 diabetes requiring dialysis in a center in France, 27 (32 percent) died at a mean follow-up of 211 days [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10614/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cardiovascular disease is the",
"    <strong>",
"     most",
"    </strong>",
"    common cause of death, accounting for more than one-half of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10614/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. In addition to the presence of significant cardiovascular disease prior to the initiation of dialysis, the tissue deposition of advanced glycosylation end products (AGEs) may also enhance cardiovascular mortality once dialysis is begun. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37082?source=see_link\">",
"     \"Patient survival and maintenance dialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/63/30714?source=see_link\">",
"     \"Overview of diabetic nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The adequacy of dialysis and a decrease in nutritional status may also be contributors to the worse outcome in diabetics. The morbidity associated with insufficient dialysis in diabetics may be mediated through anorexia, leading to decreased caloric and protein intake. The potential importance of malnutrition is suggested by the observation that the increase in mortality (when compared to nondiabetics) largely disappears if reductions in the plasma albumin and creatinine concentrations (that primarily reflect inadequate intake) are taken into account [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10614/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6378?source=see_link\">",
"     \"Kt/V and the adequacy of hemodialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15399?source=see_link\">",
"     \"Assessment of nutritional status in end-stage renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Death by withdrawal from dialysis is also more likely to occur in patients with diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10614/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37082?source=see_link\">",
"     \"Patient survival and maintenance dialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/56/8072?source=see_link\">",
"     \"Withdrawal from and withholding of dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIALYSIS VERSUS RENAL TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the 2009 USRDS report relating to diabetics with end-stage renal disease, adjusted patient survival at five years after kidney transplantation in diabetics ranged from 67 to 77 percent at five years [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10614/abstract/13\">",
"     13",
"    </a>",
"    ]. These less than optimal results, due largely to extrarenal vascular disease, are still markedly better than those seen with either hemodialysis or peritoneal dialysis, which is approximately 30 percent at five years [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10614/abstract/13\">",
"     13",
"    </a>",
"    ]. Transplantation is also associated with a better quality of life and a higher degree of rehabilitation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10614/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Because of these substantial benefits, renal transplantation should be offered to any suitable diabetic patient with end-stage renal disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/39/36472?source=see_link\">",
"     \"Renal transplantation in diabetic nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some of the benefit associated with renal transplantation is clearly related to patient selection. Those patients who receive a transplant are usually younger and less likely to have type 2 diabetes or extrarenal vascular disease. However, the improved outcome with transplantation is seen even if the evaluation of dialyzed patients is limited to relatively healthy subjects who are candidates for transplantation (but not transplanted for some reason). Thus, factors in addition to selection bias must also be important. It is possible, for example, that the restoration of near normal renal function following transplantation retards the progression of microvascular disease by reducing the circulating levels of advanced glycosylation end products (as noted previously) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10614/abstract/24\">",
"     24",
"    </a>",
"    ]. This mechanism of possible benefit has been difficult to prove. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17992?source=see_link\">",
"     \"Patient survival after renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     HEMODIALYSIS VERSUS PERITONEAL DIALYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Choice of a dialysis modality in diabetics is dependent in part upon the following factors which apply to nondiabetics as well.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Comorbid conditions",
"     </li>",
"     <li>",
"      Home situation",
"     </li>",
"     <li>",
"      Independence and motivation of the patient",
"     </li>",
"     <li>",
"      Ability to tolerate volume shifts &mdash; Diabetic patients with autonomic neuropathy are often more likely to have hypotensive episodes during hemodialysis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/32/31240?source=see_link\">",
"       \"Hemodynamic instability during hemodialysis: Overview\"",
"      </a>",
"      .) Fluid removal is more gradual with peritoneal dialysis and therefore hypotension is not a problem unless the patient becomes volume depleted.",
"     </li>",
"     <li>",
"      Status of the vasculature",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      abdomen &mdash; Older patients with type 2 diabetes are more likely to have severe peripheral vascular disease that limits the ability to create and sustain adequate vascular access for hemodialysis. Unfortunately, these are often the same patients who are unable to perform peritoneal dialysis due to concomitant illnesses.",
"     </li>",
"     <li>",
"      Risk and history of infection",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among diabetics with adequate manual dexterity and visual acuity, we continue to recommend peritoneal dialysis as an option for maintenance dialysis. Diabetic patients with unstable cardiac hemodynamics, severe vascular disease,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    advanced neuropathy are most often treated with in-center hemodialysis. Few studies have specifically analyzed the efficacy of peritoneal dialysis in these patients. Very few diabetic patients choose home hemodialysis which is generally associated with the highest survival rates. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19144?source=see_link\">",
"     \"Home hemodialysis\"",
"    </a>",
"    .)' and (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/24/3465?source=see_link\">",
"     \"Outcomes associated with nocturnal hemodialysis\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;If dialysis is required, most studies, after adjustment for comorbid factors, have NOT found a survival difference between hemodialysis and peritoneal dialysis in diabetic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10614/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial reports suggested that peritoneal dialysis was associated with a better outcome [",
"      <a class=\"abstract\" href=\"UTD.htm?10/23/10614/abstract/16,27-31\">",
"       16,27-31",
"      </a>",
"      ]. In the Michigan experience, the risk ratio for mortality for diabetics treated with peritoneal dialysis was 0.40 to 0.70 when compared to diabetics treated with hemodialysis [",
"      <a class=\"abstract\" href=\"UTD.htm?10/23/10614/abstract/27,31\">",
"       27,31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, data from the USRDS case-mix study suggest that mortality may actually be increased in diabetic patients treated with peritoneal dialysis rather than hemodialysis. One report found that the increase in risk was limited to elderly diabetic patients, who may have had more underlying peripheral vascular disease [",
"      <a class=\"abstract\" href=\"UTD.htm?10/23/10614/abstract/32\">",
"       32",
"      </a>",
"      ]. A subsequent study of prevalent patients for three successive years found that patients treated with peritoneal dialysis had a 19 percent higher mortality rate than any form of hemodialysis: this increase in risk was greatest in diabetics of any age and in nondiabetics above age 55 [",
"      <a class=\"abstract\" href=\"UTD.htm?10/23/10614/abstract/33\">",
"       33",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      There are, however, potential problems with these data. They were obtained at a time when the delivery of dialysis was inadequate, the importance of residual renal function was poorly understood, and the importance of comorbid conditions was not taken into account.",
"     </li>",
"     <li>",
"      A subsequent very large study attempted to assess the impact of multiple risk factors, including diabetes, on survival after initiation of either hemodialysis or peritoneal dialysis. Utilizing data from 398,940 patients who initiated dialysis between the years 1995 to 2000, some patient characteristics included the following: 12 percent used PD for initial therapy; 45 percent were diabetic; 51 percent were older than 65 years of age, and 55 percent had at least one comorbidity [",
"      <a class=\"abstract\" href=\"UTD.htm?10/23/10614/abstract/34\">",
"       34",
"      </a>",
"      ]. Mortality risk was significantly higher on hemodialysis than PD among younger diabetics with no comorbidity (1.22, age between 18 and 44 years). By comparison, hemodialysis was associated with a lower mortality risk in older diabetics with either no comorbidity (RR of 0.92 and 0.86 for ages 45 to 64 and greater than 65 years, respectively) or a baseline comorbidity (0.82 and 0.80 for ages 45 to 64 and greater than 65 years, respectively). No difference in survival with either modality was observed among younger diabetic patients with baseline comorbidity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Few diabetic patients perform home hemodialysis, the single modality with the highest patient survival rate [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10614/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19144?source=see_link\">",
"     \"Home hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     INSULIN THERAPY IN PERITONEAL DIALYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance of glycemic control in diabetic patients with end-stage renal disease may be complicated by a variety of factors that either increase or decrease insulin requirements. More insulin may be required because of insulin resistance and the glucose load absorbed from the hypertonic dialysate. A 1.5 percent dialysate solution, for example, has a glucose concentration of 1500",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (83",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    well above that in the plasma. On the other hand, less insulin is often required because of decreased carbohydrate intake (if the patient is inadequately dialyzed) and prolongation of the duration of action of insulin resulting from reduced renal and hepatic clearance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/43/18102?source=see_link\">",
"     \"Carbohydrate and insulin metabolism in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A discussion of the use of various agents to maintain serum glucose levels in peritoneal dialysis patients is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7865?source=see_link\">",
"     \"Management of hyperglycemia in diabetics with end-stage renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIALYSIS DOSE AND ACCESS ISSUES",
"    </span>",
"   </p>",
"   <p>",
"    Dialysis dose and vascular access issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/58/1962?source=see_link\">",
"     \"Adequacy of peritoneal dialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6378?source=see_link\">",
"     \"Kt/V and the adequacy of hemodialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/16/23816?source=see_link\">",
"     \"Arteriovenous fistulas and grafts for chronic hemodialysis access\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diabetes is the most common cause of end-stage renal disease in patients requiring renal replacement therapy, accounting for approximately 45 percent of cases in the United States. Although less frequent in many other countries, diabetes is also a common cause of end-stage renal disease throughout the world. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Survival in diabetic patients on maintenance dialysis is lower than that seen in nondiabetics with end-stage renal failure due to chronic glomerular disease, hypertension, or other causes of end-stage renal disease. Cardiovascular disease is the most common cause of death, accounting for more than one-half of cases. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Patient survival'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Compared with dialysis, kidney transplantation is associated with increased patient survival and a better quality of life. We recommend transplantation rather than dialysis to any diabetic patient with end-stage renal disease who is eligible for a renal allograft, ideally before dialysis is even initiated if possible (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Dialysis versus renal transplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among diabetics with adequate manual dexterity and visual acuity, we continue to offer peritoneal dialysis as an option for maintenance dialysis. Diabetic patients with unstable cardiac hemodynamics, severe vascular disease,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      advanced neuropathy are most often treated with in-center hemodialysis. Few studies have specifically analyzed the efficacy of peritoneal dialysis in these patients. Very few diabetic patients choose home hemodialysis which is generally associated with the relatively highest patient survival rates. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Hemodialysis versus peritoneal dialysis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10614/abstract/1\">",
"      Perneger TV, Brancati FL, Whelton PK, Klag MJ. End-stage renal disease attributable to diabetes mellitus. Ann Intern Med 1994; 121:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10614/abstract/2\">",
"      Finne P, Reunanen A, Stenman S, et al. Incidence of end-stage renal disease in patients with type 1 diabetes. JAMA 2005; 294:1782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10614/abstract/3\">",
"      Rosolowsky ET, Skupien J, Smiles AM, et al. Risk for ESRD in type 1 diabetes remains high despite renoprotection. J Am Soc Nephrol 2011; 22:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10614/abstract/4\">",
"      Ruggenenti P, Gambara V, Perna A, et al. The nephropathy of non-insulin-dependent diabetes: predictors of outcome relative to diverse patterns of renal injury. J Am Soc Nephrol 1998; 9:2336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10614/abstract/5\">",
"      United States Renal Data System. Excerpts from the USRDS 2009 annual data report: Atlas of end-stage renal disease in the United States. Am J Kidney Dis 2010; 55(Suppl 1):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10614/abstract/6\">",
"      Centers for Disease Control and Prevention (CDC). Incidence of end-stage renal disease attributed to diabetes among persons with diagnosed diabetes --- United States and Puerto Rico, 1996-2007. MMWR Morb Mortal Wkly Rep 2010; 59:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10614/abstract/7\">",
"      United States Renal Data System. Excerpts from the USRDS 2006 annual data report: Atlas of end-stage renal disease in the United States. Am J Kidney Dis 2007; 49(Suppl 5):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10614/abstract/8\">",
"      Van Dijk PC, Jager KJ, Stengel B, et al. Renal replacement therapy for diabetic end-stage renal disease: data from 10 registries in Europe (1991-2000). Kidney Int 2005; 67:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10614/abstract/9\">",
"      S&oslash;rensen VR, Hansen PM, Heaf J, Feldt-Rasmussen B. Stabilized incidence of diabetic patients referred for renal replacement therapy in Denmark. Kidney Int 2006; 70:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10614/abstract/10\">",
"      Nishimura R, Dorman JS, Bosnyak Z, et al. Incidence of ESRD and survival after renal replacement therapy in patients with type 1 diabetes: a report from the Allegheny County Registry. Am J Kidney Dis 2003; 42:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10614/abstract/11\">",
"      Wolfe RA, Gaylin DS, Port FK, et al. Using USRDS generated mortality tables to compare local ESRD mortality rates to national rates. Kidney Int 1992; 42:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10614/abstract/12\">",
"      United States Renal Data System. Excerpts from the USRDS 2005 annual data report: Atlas of end-stage renal disease in the United States. Am J Kidney Dis 2006; 47(Suppl 1):S1.",
"     </a>",
"    </li>",
"    <li>",
"     www.usrds.org, accessed May 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10614/abstract/14\">",
"      Locatelli F, Pozzoni P, Del Vecchio L. Renal replacement therapy in patients with diabetes and end-stage renal disease. J Am Soc Nephrol 2004; 15 Suppl 1:S25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10614/abstract/15\">",
"      Chantrel F, Enache I, Bouiller M, et al. Abysmal prognosis of patients with type 2 diabetes entering dialysis. Nephrol Dial Transplant 1999; 14:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10614/abstract/16\">",
"      Tzamaloukas AH, Yuan ZY, Balaskas E, Oreopoulos DG. CAPD in end stage patients with renal disease due to diabetes mellitus--an update. Adv Perit Dial 1992; 8:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10614/abstract/17\">",
"      Brunner FP, Selwood NH. Profile of patients on RRT in Europe and death rates due to major causes of death groups. The EDTA Registration Committee. Kidney Int Suppl 1992; 38:S4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10614/abstract/18\">",
"      Dikow R, Ritz E. Cardiovascular complications in the diabetic patient with renal disease: an update in 2003. Nephrol Dial Transplant 2003; 18:1993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10614/abstract/19\">",
"      Lowrie EG, Lew NL, Huang WH. Race and diabetes as death risk predictors in hemodialysis patients. Kidney Int Suppl 1992; 38:S22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10614/abstract/20\">",
"      Mailloux LU, Bellucci AG, Napolitano B, et al. Death by withdrawal from dialysis: a 20-year clinical experience. J Am Soc Nephrol 1993; 3:1631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10614/abstract/21\">",
"      Nelson CB, Port FK, Wolfe RA, Guire KE. The association of diabetic status, age, and race to withdrawal from dialysis. J Am Soc Nephrol 1994; 4:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10614/abstract/22\">",
"      Grenfell A, Bewick M, Snowden S, et al. Renal replacement for diabetic patients: experience at King's College Hospital 1980-1989. Q J Med 1992; 85:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10614/abstract/23\">",
"      Khauli RB, Steinmuller DR, Novick AC, et al. A critical look at survival of diabetics with end-stage renal disease. Transplantation versus dialysis therapy. Transplantation 1986; 41:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10614/abstract/24\">",
"      Makita Z, Bucala R, Rayfield EJ, et al. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet 1994; 343:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10614/abstract/25\">",
"      Passadakis P, Thodis E, Vargemezis V, Oreopoulos D. Long-term survival with peritoneal dialysis in ESRD due to diabetes. Clin Nephrol 2001; 56:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10614/abstract/26\">",
"      Jaar BG, Coresh J, Plantinga LC, et al. Comparing the risk for death with peritoneal dialysis and hemodialysis in a national cohort of patients with chronic kidney disease. Ann Intern Med 2005; 143:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10614/abstract/27\">",
"      Nelson CB, Port FK, Wolfe RA, Guire KE. Comparison of continuous ambulatory peritoneal dialysis and hemodialysis patient survival with evaluation of trends during the 1980s. J Am Soc Nephrol 1992; 3:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10614/abstract/28\">",
"      O'Donoghue D, Manos J, Pearson R, et al. Continuous ambulatory peritoneal dialysis and renal transplantation: a ten-year experience in a single center. Perit Dial Int 1992; 12:242, 245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10614/abstract/29\">",
"      Dumler F, Schmidt RJ, Cruz C, et al. Single center success with a high risk peritoneal dialysis population. Adv Perit Dial 1992; 8:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10614/abstract/30\">",
"      Mailloux LU, Bellucci AG, Wilkes BM, et al. Mortality in dialysis patients: analysis of the causes of death. Am J Kidney Dis 1991; 18:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10614/abstract/31\">",
"      Wolfe RA, Port FK, Hawthorne VM, Guire KE. A comparison of survival among dialytic therapies of choice: in-center hemodialysis versus continuous ambulatory peritoneal dialysis at home. Am J Kidney Dis 1990; 15:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10614/abstract/32\">",
"      Held PJ, Port FK, Turenne MN, et al. Continuous ambulatory peritoneal dialysis and hemodialysis: comparison of patient mortality with adjustment for comorbid conditions. Kidney Int 1994; 45:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10614/abstract/33\">",
"      Bloembergen WE, Port FK, Mauger EA, Wolfe RA. A comparison of mortality between patients treated with hemodialysis and peritoneal dialysis. J Am Soc Nephrol 1995; 6:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10614/abstract/34\">",
"      Vonesh EF, Snyder JJ, Foley RN, Collins AJ. The differential impact of risk factors on mortality in hemodialysis and peritoneal dialysis. Kidney Int 2004; 66:2389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10614/abstract/35\">",
"      Zimmerman SW, Sollinger H, Wakeen M, et al. Renal replacement therapy in diabetic nephropathy. Adv Ren Replace Ther 1994; 1:66.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1853 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-201.65.114.212-1237D62C13-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_23_10614=[""].join("\n");
var outline_f10_23_10614=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATIENT SURVIVAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIALYSIS VERSUS RENAL TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      HEMODIALYSIS VERSUS PERITONEAL DIALYSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Survival",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      INSULIN THERAPY IN PERITONEAL DIALYSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIALYSIS DOSE AND ACCESS ISSUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/58/1962?source=related_link\">",
"      Adequacy of peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/16/23816?source=related_link\">",
"      Arteriovenous fistulas and grafts for chronic hemodialysis access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15399?source=related_link\">",
"      Assessment of nutritional status in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/43/18102?source=related_link\">",
"      Carbohydrate and insulin metabolism in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/32/31240?source=related_link\">",
"      Hemodynamic instability during hemodialysis: Overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19144?source=related_link\">",
"      Home hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6378?source=related_link\">",
"      Kt/V and the adequacy of hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7865?source=related_link\">",
"      Management of hyperglycemia in diabetics with end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/24/3465?source=related_link\">",
"      Outcomes associated with nocturnal hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/63/30714?source=related_link\">",
"      Overview of diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17992?source=related_link\">",
"      Patient survival after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37082?source=related_link\">",
"      Patient survival and maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/39/36472?source=related_link\">",
"      Renal transplantation in diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/56/8072?source=related_link\">",
"      Withdrawal from and withholding of dialysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_23_10615="Leiomyosarcoma B";
var content_f10_23_10615=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F53942&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F53942&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Poorly differentiated uterine leiomyosarcoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William Mann, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_23_10615=[""].join("\n");
var outline_f10_23_10615=null;
var title_f10_23_10616="Overview of causes of and risk factors for fetal growth restriction";
var content_f10_23_10616=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of causes of and risk factors for fetal growth restriction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/23/10616/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/23/10616/contributors\">",
"     Michael Y Divon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/23/10616/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/23/10616/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/23/10616/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/23/10616/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/23/10616/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal growth restriction (FGR, also called intrauterine growth restriction [IUGR]) is the term used to designate a fetus that has not reached its growth potential because of genetic or environmental factors. It may be caused by fetal, placental, or maternal factors, with significant overlap among these entities. This term should not be used to describe a constitutionally small, but otherwise healthy fetus. Determining the underlying cause of poor fetal growth is not always possible, but is important for estimating the potential risk of recurrence.",
"   </p>",
"   <p>",
"    Etiologies of FGR will be reviewed here. The diagnosis and management of FGR are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22906?source=see_link\">",
"     \"Diagnosis of fetal growth restriction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23994?source=see_link\">",
"     \"Fetal growth restriction: Evaluation and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FETAL FACTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Population-based intergenerational studies of birth weight have found that genetic factors contribute 30 to 50 percent of the variation in birth weight, with the remainder due to environmental factors [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10616/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Maternal genes influence birth weight more than paternal genes, but both have an effect. Specific allelic variants associated with birth weight include mutations in GCK and HNF1beta, which have been associated with low birth weight, and mutations in HNF4 alpha, which have been associated with high birth weight [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10616/abstract/5\">",
"     5",
"    </a>",
"    ]. Variants in ADCY5 and loci near CCNL1 also appear to lower birth weight [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10616/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The susceptibility to FGR is also heritable; in epidemiologic studies, women who were SGA themselves at birth have a two-fold increase in risk of FGR in their offspring [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10616/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Women who give birth to a growth restricted fetus are at high risk of recurrence, and the risk increases with increasing numbers of FGR deliveries.",
"   </p>",
"   <p>",
"    Karyotypic abnormalities account for up to 20 percent of all FGR [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10616/abstract/9-13\">",
"     9-13",
"    </a>",
"    ]. The presence of a chromosomal abnormality often results in restriction of fetal growth early in pregnancy; as many as one-quarter of fetuses with early onset FGR have chromosomal abnormalities. Most cases are symmetric, but asymmetric early FGR also occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10616/abstract/14\">",
"     14",
"    </a>",
"    ]. One mechanism may be a reduced number of small muscular arteries in the tertiary stem villi of affected fetuses [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10616/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genetic abnormalities associated with FGR include (",
"    <a class=\"graphic graphic_table graphicRef72782 \" href=\"UTD.htm?32/54/33643\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10616/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aneuploidy (eg, trisomy 18 or 13, Turner 45 X, triploidy)",
"     </li>",
"     <li>",
"      Partial deletions, duplications, mutations (eg, Cri du chat syndrome 5q, Wolf-Hirschhorn syndrome 4q, mutations in the gene for insulin-like growth factor [",
"      <a class=\"abstract\" href=\"UTD.htm?10/23/10616/abstract/17-19\">",
"       17-19",
"      </a>",
"      ])",
"     </li>",
"     <li>",
"      Ring chromosomes",
"     </li>",
"     <li>",
"      Uniparental disomy (eg, for chromosomes 6, 7, 14, or 16)",
"     </li>",
"     <li>",
"      Confined placental mosaicism",
"     </li>",
"     <li>",
"      Genomic imprinting",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Congenital anomalies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major or multiple congenital anomalies are associated with failure to maintain normal fetal growth, but account for only 1 to 2 percent of all FGR in fetuses without identifiable genetic defects [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10616/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. The combination of structural and chromosomal abnormalities and FGR, however, is common. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23994?source=see_link&amp;anchor=H2#H2\">",
"     \"Fetal growth restriction: Evaluation and management\", section on 'Initial diagnostic evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Multiple gestation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal growth in multiple gestations has a direct relationship to the number of fetuses present; the type of placentation also plays a role (monochorionic versus dichorionic). Growth is similar to that of singletons until the third trimester and then slows. The lower weight of fetuses from multiple gestations is thought to be due to an inability of the environment to meet the nutritional needs of multiple fetuses, as well as pregnancy complications more common in multiple gestation (eg, maternal undernutrition, preeclampsia, twin-twin transfusion, congenital anomalies). Placental and umbilical cord anomalies potentially associated with underperfusion (eg, velamentous cord insertion) are also more common in multiple gestations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40682?source=see_link&amp;anchor=H17#H17\">",
"     \"Twin pregnancy: Prenatal issues\", section on 'Evaluation of fetal growth'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections that develop early in pregnancy have the greatest effect on subsequent growth, but account for less than 5 percent of all cases of FGR. Viruses and parasites (eg, rubella, toxoplasmosis, cytomegalovirus, varicella-zoster, malaria, syphilis, herpes) may gain access to the fetus transplacentally or across the intact fetal membranes and impair fetal growth by a variety of mechanisms (eg, cell death, vascular insufficiency). Although uncommon, CMV is the most frequent viral etiology of FGR in developed countries [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10616/abstract/22\">",
"     22",
"    </a>",
"    ]. There is less evidence implicating bacterial infection as an etiology for FGR, although maternal infection with listeria, tuberculosis, chlamydia, and mycoplasma has been reported to increase the risk to FGR. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/63/4089?source=see_link\">",
"     \"Placental infections\"",
"    </a>",
"    .) (Also see topic reviews on specific infections).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PLACENTAL FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many cases of FGR, particularly recurrent cases, are the result of ischemic placental disease. This term refers to a disease process of the placenta that clinically manifests as preeclampsia, FGR, abruption, or a combination of these disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10616/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. All of these disorders may be associated with preterm birth or fetal loss and represent late manifestations of abnormal placental development dating from the earliest stages of pregnancy.",
"   </p>",
"   <p>",
"    Abnormal vascular connections in the placenta can cause FGR and growth discordance associated with multifetal pregnancies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40682?source=see_link&amp;anchor=H17#H17\">",
"     \"Twin pregnancy: Prenatal issues\", section on 'Evaluation of fetal growth'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28039?source=see_link\">",
"     \"Pathogenesis and diagnosis of twin-twin transfusion syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Gross and histological lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any mismatch between fetal nutritional or respiratory demands and placental supply can result in impaired fetal growth. Studies in sheep and in humans suggest there is significant excess placental functional capacity. In sheep models, fetal growth is affected when one-half of the placenta is removed [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10616/abstract/25\">",
"     25",
"    </a>",
"    ]. The human fetus may be more sensitive to a reduction in placental mass: placental weight is 24 percent smaller in growth restricted fetuses than in normally grown fetuses when adjustments are made for gestational age [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10616/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, placental functional capacity cannot be accurately assessed from placental weight or dimensions alone. Abnormal development, narrowing or obstruction of placental vessels, and physical separation at the maternal interface all impair placental function. The types, distributions, and sizes of parenchymal and vascular lesions also play a role; moreover, some maternal disorders (eg, severe maternal malnutrition or alcohol abuse) can affect fetal nutrition without causing a recognizable histopathological lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10616/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Identifiable placental histological abnormalities associated with fetal undernutrition include abnormalities of the uteroplacental vasculature (maldevelopment, obstruction, disruption), chronic abruption, chronic infectious and idiopathic inflammatory lesions (eg, infection related villitis, chronic villitis of unknown etiology), infarction, distal villous hypoplasia, massive perivillous fibrin deposition (ie, maternal floor infarction), and thrombosis in the uteroplacental, intervillous",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fetoplacental vasculature [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10616/abstract/27\">",
"     27",
"    </a>",
"    ]. Diffuse chronic villitis of unknown etiology appears to be the most common placental finding in otherwise idiopathic FGR [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10616/abstract/22,27,28\">",
"     22,27,28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/46/27370?source=see_link\">",
"     \"Histopathology of placental disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gross placental structural anomalies possibly associated with FGR include single umbilical artery, velamentous umbilical cord insertion, marginal cord insertion, bilobate placenta, circumvallate placenta, and placental hemangioma. If an association between these entities and FGR exists, it is at most mild. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40840?source=see_link\">",
"     \"Gross examination of the placenta\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Confined placental mosaicism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Confined placental mosaicism (CPM) refers to chromosomal mosaicism (usually involving a trisomy) found in the placenta, but not in the fetus. It occurs significantly more often in the placentas associated with FGR than in controls of normal weight. Approximately 10 percent of placentas associated with idiopathic FGR have been reported to have CPM [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10616/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]; the rate of CPM in controls undergoing CVS is about 1 percent. The extent of FGR depends upon the chromosomes involved, the proportion of mosaic cells, and the presence of uniparental disomy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10616/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Placentas with CPM have a high ratio of placental infarcts and decidual vasculopathy, and one-third of placentas with these findings and FGR have CPM [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10616/abstract/29\">",
"     29",
"    </a>",
"    ]. Limited data suggest that long-term development of children from these pregnancies is normal [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10616/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28169?source=see_link&amp;anchor=H19#H19\">",
"     \"Chorionic villus sampling: Risks, complications, and techniques\", section on 'Confined placental mosaicism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MATERNAL FACTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Disorders resulting in reduced uteroplacental blood flow",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uteroplacental blood flow may be diminished by faulty development, acquired obstruction, or disruption of the uteroplacental vasculature. Maternal medical disorders (eg, hypertension, renal insufficiency, diabetes, collagen vascular disease, systemic lupus erythematosus, antiphospholipid syndrome) and obstetrical complications (eg, preeclampsia) associated with vasculopathy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reduced maternal blood volume or blood pressure diminish uteroplacental perfusion and result in FGR [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10616/abstract/33\">",
"     33",
"    </a>",
"    ]. Preeclampsia, in particular, is characterized by primary failure of trophoblast invasion of the spiral arteries leading to failure of dilatation of these vessels, acute atherosis, occlusion, and infarction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34777?source=see_link\">",
"     \"Pathogenesis of preeclampsia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Delivery of a very SGA infant has been associated with an increased risk of maternal hospitalization or death from cardiovascular disease later in life (hazard ratio 1.38 and 3.40 for term and preterm SGA), after accounting for socioeconomic factors, smoking, and pregnancy-related complications [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10616/abstract/34\">",
"     34",
"    </a>",
"    ]. This suggests that maternal cardiovascular factors can affect uteroplacental perfusion and fetal growth even before maternal disease becomes clinically overt.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Low prepregnancy weight and poor weight gain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal weight at birth, prepregnancy weight, and weight gain during pregnancy are generally responsible for about 10 percent of the variance in fetal weight [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10616/abstract/35\">",
"     35",
"    </a>",
"    ]. However, severe maternal starvation during pregnancy can have a major impact on fetal growth. As an example, the Dutch population suffered severe famine during the winter of 1944 to 1945; mean maternal caloric intake fell to 450 to 750 kcal a day. As one result of this deprivation, average infant birth weight during this period decreased by 250 grams. Similarly, in Leningrad during the World War II German siege, which resulted in a longer and more profound starvation period (down to 300 kcal of mostly carbohydrates and no protein), average birth weight fell by more than 500 grams [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10616/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Modest degrees of nutritional deficiency also have an effect on birth weight. Women who are underweight at the start of pregnancy or have poor weight gain during pregnancy are at higher risk of delivering an infant weighing less than 2500 grams. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19304?source=see_link\">",
"     \"Weight gain and loss in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/44/28362?source=see_link\">",
"     \"Nutrition in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Malabsorption of nutrients in pregnant women with celiac disease has also been associated with intrauterine growth restriction [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10616/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Hypoxemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic maternal hypoxemia due to pulmonary disease, cyanotic heart disease, or severe anemia is associated with diminished fetal growth. As an example, a study of 96 pregnancies in women with cyanotic congenital heart disease reported that the mean birth weight of full term infants was only 2575 grams, which is significantly lower than the mean birth weight of 3500 grams in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10616/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Residing at high altitude also results in a chronic hypoxemic state and lower birth weight. A direct relationship between increasing altitude and lower birth weight has been demonstrated in studies performed in Denver and Leadville, Colorado (altitude 1600 and 3100 m, respectively), Tibet (altitude 3658 m), and Peru [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10616/abstract/39-42\">",
"     39-42",
"    </a>",
"    ]. Birth weight data from 15 areas in Peru located anywhere from sea level to 4575 meters showed birth weight declines an average of 65 grams for every additional 500 meters in altitude above 2000 meters [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10616/abstract/41\">",
"     41",
"    </a>",
"    ]. Pregnancy among inhabitants of Cerro de Pasco, Peru (altitude 4370 m) was associated with 31 percent lower maternal cardiac output and 11 percent lower birth weight than observed in pregnant women residing at sea level (mean birth weight 2935 and 3290 grams, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10616/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The fetus can compensate for hypoxemia in a number of ways, including redistribution of circulation to vital organs and deferment of growth, decreased gross body movements, and increasing tissue oxygen extraction. The exact level and duration of fetal hypoxemia that exceed these compensatory mechanisms are not defined in humans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Hematological and immunologic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematological disorders, such as sickle cell disease, may cause thrombosis of the intervillous space. Autoimmune and alloimmune disorders (eg, antiphospholipid syndrome) may cause chronic villitis, as well as vasculopathy. Fetal undernutrition and hypoxia are possible sequelae. The role of inherited thrombophilias as a cause of FGR is controversial; available data are inconsistent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/5/26714?source=see_link\">",
"     \"Inherited thrombophilias in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/2/41000?source=see_link\">",
"     \"Obstetrical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Substance use and cigarette smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal use of cigarettes, alcohol, and illicit drugs can cause FGR either by a direct cytotoxic effect or indirectly from related variables, such as inadequate nutrition. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/12/6346?source=see_link\">",
"     \"Overview of illicit drug use in pregnant women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41575?source=see_link\">",
"     \"Alcohol intake and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Smoking during the third trimester appears to have the greatest impact on birth weight; women who quit smoking by the third trimester have birth weights similar to those of nonsmokers [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10616/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/53/27482?source=see_link\">",
"     \"Smoking and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Numerous studies have attempted to determine the relationship between exposure of pregnant women to environmental tobacco smoke (ETS) and infant birth weight. Results have been discordant, although most show an increased risk of low birth weight in women with ETS [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10616/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. These studies are limited by the difficulty in accurately quantitating maternal exposure and adjusting for the multiple factors which affect birth weight. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22505?source=see_link\">",
"     \"Secondhand smoke exposure: Effects in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Toxins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxic exposures, including various medications such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , anticonvulsants, antineoplastic agents, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    antagonists, can produce FGR with specific dysmorphic features [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10616/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. It is not clear whether FGR in hypertensive women is solely a result of the underlying condition or, in part, a side effect of antihypertensive medications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22633?source=see_link\">",
"     \"Risks associated with epilepsy and pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=see_link\">",
"     \"Management of hypertension in pregnant and postpartum women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Caffeine consumption may have a small detrimental effect on fetal growth; there is no clear threshold effect. This topic is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/35/20026?source=see_link&amp;anchor=H19#H19\">",
"     \"The effects of caffeine on reproductive outcomes in women\", section on 'Fetal growth restriction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fetal exposure to therapeutic, but not diagnostic, doses of radiation can cause permanent restriction of growth. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=see_link\">",
"     \"Diagnostic imaging procedures during pregnancy\"",
"    </a>",
"    .) Prepregnancy radiation therapy to the pelvis can result in anatomic changes in the pelvic vasculature that may lead to reduced fetoplacental perfusion and growth restriction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7977?source=see_link\">",
"     \"Overview of fertility and pregnancy in cancer survivors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Assisted reproductive technologies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Singleton pregnancies conceived via assisted reproductive technologies have a higher prevalence of both low birth weight and SGA infants compared with naturally conceived pregnancies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/6/2154?source=see_link\">",
"     \"Pregnancy outcome after assisted reproductive technology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Uterine malformations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine malformations may affect uteroplacental perfusion and result in FGR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;FGR is more common among pregnancies at the extremes of reproductive life [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10616/abstract/48-51\">",
"     48-51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A short interpregnancy interval has been associated with low birth weight and FGR, and this may be mediated through a relative depletion in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10616/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/63/13302?source=see_link\">",
"     \"Interpregnancy interval and pregnancy outcome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chronic maternal stress may also be a factor, and is an active area of investigation. Chronic stress is associated with elevated corticotropin-releasing hormone (CRH) levels, which, in turn, may be associated with impaired fetal growth and preterm birth [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10616/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32393?source=see_link&amp;anchor=H4#H4\">",
"     \"Pathogenesis of spontaneous preterm birth\", section on 'Corticotropin-releasing hormone'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Identification of maternal single-nucleotide polymorphisms associated with development of FGR is an area of active investigations [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10616/abstract/55-57\">",
"     55-57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fetal growth restriction (FGR) may be caused by fetal, placental, or maternal factors, often with contributions from multiple, overlapping factors. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Karyotypic abnormalities account for up to 20 percent of all FGR. These abnormalities are most common among growth restricted fetuses with congenital anomalies. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Genetic factors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Congenital anomalies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A history of FGR in the mother herself or in her offspring is a risk factor for recurrence in future pregnancies. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Genetic factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A variety of gross and histological placental abnormalities may cause FGR. Abnormal development, narrowing or obstruction of placental vessels, and physical separation at the maternal interface all impair placental function. Diffuse chronic villitis of unknown etiology appears to be the most common histological placental finding in otherwise idiopathic FGR. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Placental factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Maternal medical disorders may cause FGR as a result of diminished uteroplacental blood flow from faulty development, acquired obstruction, or disruption of the uteroplacental vasculature. Examples of these disorders include hypertension, renal insufficiency, diabetes, collagen vascular disease, systemic lupus erythematosus, antiphospholipid syndrome, and preeclampsia. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Maternal factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/1\">",
"      PENROSE LS. Data on the genetics of birth weight. Ann Eugen 1952; 16:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/2\">",
"      Svensson AC, Pawitan Y, Cnattingius S, et al. Familial aggregation of small-for-gestational-age births: the importance of fetal genetic effects. Am J Obstet Gynecol 2006; 194:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/3\">",
"      Clausson B, Lichtenstein P, Cnattingius S. Genetic influence on birthweight and gestational length determined by studies in offspring of twins. BJOG 2000; 107:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/4\">",
"      Lunde A, Melve KK, Gjessing HK, et al. Genetic and environmental influences on birth weight, birth length, head circumference, and gestational age by use of population-based parent-offspring data. Am J Epidemiol 2007; 165:734.",
"     </a>",
"    </li>",
"    <li>",
"     www.iom.edu/CMS/3788/48191/68004/68230.aspx. (Accessed May 29, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/6\">",
"      Freathy RM, Mook-Kanamori DO, Sovio U, et al. Variants in ADCY5 and near CCNL1 are associated with fetal growth and birth weight. Nat Genet 2010; 42:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/7\">",
"      Klebanoff MA, Meirik O, Berendes HW. Second-generation consequences of small-for-dates birth. Pediatrics 1989; 84:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/8\">",
"      Selling KE, Carstensen J, Finnstr&ouml;m O, Sydsj&ouml; G. Intergenerational effects of preterm birth and reduced intrauterine growth: a population-based study of Swedish mother-offspring pairs. BJOG 2006; 113:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/9\">",
"      Neerhof MG. Causes of intrauterine growth restriction. Clin Perinatol 1995; 22:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/10\">",
"      Lin CC, Santolaya-Forgas J. Current concepts of fetal growth restriction: part I. Causes, classification, and pathophysiology. Obstet Gynecol 1998; 92:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/11\">",
"      Spiro RP, Christian SL, Ledbetter DH, et al. Intrauterine growth retardation associated with maternal uniparental disomy for chromosome 6 unmasked by congenital adrenal hyperplasia. Pediatr Res 1999; 46:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/12\">",
"      Eggermann T, Curtis M, Zerres K, Hughes HE. Maternal uniparental disomy 16 and genetic counseling: new case and survey of published cases. Genet Couns 2004; 15:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/13\">",
"      Kotzot D. Maternal uniparental disomy 14 dissection of the phenotype with respect to rare autosomal recessively inherited traits, trisomy mosaicism, and genomic imprinting. Ann Genet 2004; 47:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/14\">",
"      Snijders RJ, Sherrod C, Gosden CM, Nicolaides KH. Fetal growth retardation: associated malformations and chromosomal abnormalities. Am J Obstet Gynecol 1993; 168:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/15\">",
"      Rochelson B, Kaplan C, Guzman E, et al. A quantitative analysis of placental vasculature in the third-trimester fetus with autosomal trisomy. Obstet Gynecol 1990; 75:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/16\">",
"      Gross SJ. Intrauterine growth restriction: a genetic perspective. Clin Obstet Gynecol 1997; 40:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/17\">",
"      Abuzzahab MJ, Schneider A, Goddard A, et al. IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation. N Engl J Med 2003; 349:2211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/18\">",
"      Accili D, Nakae J, Kim JJ, et al. Targeted gene mutations define the roles of insulin and IGF-I receptors in mouse embryonic development. J Pediatr Endocrinol Metab 1999; 12:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/19\">",
"      Walenkamp MJ, Wit JM. Single gene mutations causing SGA. Best Pract Res Clin Endocrinol Metab 2008; 22:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/20\">",
"      Hendrix N, Berghella V. Non-placental causes of intrauterine growth restriction. Semin Perinatol 2008; 32:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/21\">",
"      Khoury MJ, Erickson JD, Cordero JF, McCarthy BJ. Congenital malformations and intrauterine growth retardation: a population study. Pediatrics 1988; 82:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/22\">",
"      Redline RW. Villitis of unknown etiology: noninfectious chronic villitis in the placenta. Hum Pathol 2007; 38:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/23\">",
"      Ananth CV, Peltier MR, Chavez MR, et al. Recurrence of ischemic placental disease. Obstet Gynecol 2007; 110:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/24\">",
"      Ananth CV, Vintzileos AM. Maternal-fetal conditions necessitating a medical intervention resulting in preterm birth. Am J Obstet Gynecol 2006; 195:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/25\">",
"      Salafia CM. Placental pathology of fetal growth restriction. Clin Obstet Gynecol 1997; 40:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/26\">",
"      Heinonen S, Taipale P, Saarikoski S. Weights of placentae from small-for-gestational age infants revisited. Placenta 2001; 22:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/27\">",
"      Redline RW. Placental pathology: a systematic approach with clinical correlations. Placenta 2008; 29 Suppl A:S86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/28\">",
"      Boog G. Chronic villitis of unknown etiology. Eur J Obstet Gynecol Reprod Biol 2008; 136:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/29\">",
"      Wilkins-Haug L, Quade B, Morton CC. Confined placental mosaicism as a risk factor among newborns with fetal growth restriction. Prenat Diagn 2006; 26:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/30\">",
"      Robinson WP, Pe&ntilde;aherrera MS, Jiang R, et al. Assessing the role of placental trisomy in preeclampsia and intrauterine growth restriction. Prenat Diagn 2010; 30:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/31\">",
"      Robinson WP, Barrett IJ, Bernard L, et al. Meiotic origin of trisomy in confined placental mosaicism is correlated with presence of fetal uniparental disomy, high levels of trisomy in trophoblast, and increased risk of fetal intrauterine growth restriction. Am J Hum Genet 1997; 60:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/32\">",
"      Amor DJ, Neo WT, Waters E, et al. Health and developmental outcome of children following prenatal diagnosis of confined placental mosaicism. Prenat Diagn 2006; 26:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/33\">",
"      von Dadelszen P, Ornstein MP, Bull SB, et al. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis. Lancet 2000; 355:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/34\">",
"      Bonamy AK, Parikh NI, Cnattingius S, et al. Birth Characteristics and Subsequent Risks of Maternal Cardiovascular Disease. Circulation 2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/35\">",
"      Berghella V. Prevention of recurrent fetal growth restriction. Obstet Gynecol 2007; 110:904.",
"     </a>",
"    </li>",
"    <li>",
"     Nathanielsz, PW. The Dutch hunger winter. In, Life in the womb: the origin of health and disease. Ithaca, NY, Promethean press, 1999 p. 33.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/37\">",
"      N&oslash;rg&aring;rd B, Fonager K, S&oslash;rensen HT, Olsen J. Birth outcomes of women with celiac disease: a nationwide historical cohort study. Am J Gastroenterol 1999; 94:2435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/38\">",
"      Presbitero P, Somerville J, Stone S, et al. Pregnancy in cyanotic congenital heart disease. Outcome of mother and fetus. Circulation 1994; 89:2673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/39\">",
"      Moore LG, Young D, McCullough RE, et al. Tibetan protection from intrauterine growth restriction (IUGR) and reproductive loss at high altitude. Am J Hum Biol 2001; 13:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/40\">",
"      Galan HL, Rigano S, Radaelli T, et al. Reduction of subcutaneous mass, but not lean mass, in normal fetuses in Denver, Colorado. Am J Obstet Gynecol 2001; 185:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/41\">",
"      Mortola JP, Frappell PB, Aguero L, Armstrong K. Birth weight and altitude: a study in Peruvian communities. J Pediatr 2000; 136:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/42\">",
"      Kametas NA, McAuliffe F, Krampl E, et al. Maternal cardiac function during pregnancy at high altitude. BJOG 2004; 111:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/43\">",
"      Lieberman E, Gremy I, Lang JM, Cohen AP. Low birthweight at term and the timing of fetal exposure to maternal smoking. Am J Public Health 1994; 84:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/44\">",
"      Goel P, Radotra A, Singh I, et al. Effects of passive smoking on outcome in pregnancy. J Postgrad Med 2004; 50:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/45\">",
"      Kharrazi M, DeLorenze GN, Kaufman FL, et al. Environmental tobacco smoke and pregnancy outcome. Epidemiology 2004; 15:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/46\">",
"      Bernstein PS, Divon MY. Etiologies of fetal growth restriction. Clin Obstet Gynecol 1997; 40:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/47\">",
"      Wen SW, Zhou J, Yang Q, et al. Maternal exposure to folic acid antagonists and placenta-mediated adverse pregnancy outcomes. CMAJ 2008; 179:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/48\">",
"      Strobino DM, Ensminger ME, Kim YJ, Nanda J. Mechanisms for maternal age differences in birth weight. Am J Epidemiol 1995; 142:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/49\">",
"      Lee KS, Ferguson RM, Corpuz M, Gartner LM. Maternal age and incidence of low birth weight at term: a population study. Am J Obstet Gynecol 1988; 158:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/50\">",
"      Aldous MB, Edmonson MB. Maternal age at first childbirth and risk of low birth weight and preterm delivery in Washington State. JAMA 1993; 270:2574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/51\">",
"      Vorherr H. Factors influencing fetal growth. Am J Obstet Gynecol 1982; 142:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/52\">",
"      van Eijsden M, Smits LJ, van der Wal MF, Bonsel GJ. Association between short interpregnancy intervals and term birth weight: the role of folate depletion. Am J Clin Nutr 2008; 88:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/53\">",
"      Wadhwa PD, Garite TJ, Porto M, et al. Placental corticotropin-releasing hormone (CRH), spontaneous preterm birth, and fetal growth restriction: a prospective investigation. Am J Obstet Gynecol 2004; 191:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/54\">",
"      Goland RS, Jozak S, Warren WB, et al. Elevated levels of umbilical cord plasma corticotropin-releasing hormone in growth-retarded fetuses. J Clin Endocrinol Metab 1993; 77:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/55\">",
"      Robinson R, Hsu CD, Chesebro AL, et al. A single-nucleotide polymorphism (-670) of the maternal Fas gene is associated with intrauterine growth restriction. Am J Obstet Gynecol 2009; 201:620.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/56\">",
"      Zhang XQ, Varner M, Dizon-Townson D, et al. A molecular variant of angiotensinogen is associated with idiopathic intrauterine growth restriction. Obstet Gynecol 2003; 101:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10616/abstract/57\">",
"      Sata F, Yamada H, Suzuki K, et al. Functional maternal catechol-O-methyltransferase polymorphism and fetal growth restriction. Pharmacogenet Genomics 2006; 16:775.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6824 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-906C751B57-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_23_10616=[""].join("\n");
var outline_f10_23_10616=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FETAL FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Genetic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Congenital anomalies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Multiple gestation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PLACENTAL FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Gross and histological lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Confined placental mosaicism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MATERNAL FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Disorders resulting in reduced uteroplacental blood flow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Low prepregnancy weight and poor weight gain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Hypoxemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Hematological and immunologic disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Substance use and cigarette smoking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Toxins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Assisted reproductive technologies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Uterine malformations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6824\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6824|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/54/33643\" title=\"table 1\">",
"      Genetic causes of FGR",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41575?source=related_link\">",
"      Alcohol intake and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28169?source=related_link\">",
"      Chorionic villus sampling: Risks, complications, and techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22906?source=related_link\">",
"      Diagnosis of fetal growth restriction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=related_link\">",
"      Diagnostic imaging procedures during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23994?source=related_link\">",
"      Fetal growth restriction: Evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40840?source=related_link\">",
"      Gross examination of the placenta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/46/27370?source=related_link\">",
"      Histopathology of placental disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/5/26714?source=related_link\">",
"      Inherited thrombophilias in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/63/13302?source=related_link\">",
"      Interpregnancy interval and pregnancy outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=related_link\">",
"      Management of hypertension in pregnant and postpartum women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/44/28362?source=related_link\">",
"      Nutrition in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/2/41000?source=related_link\">",
"      Obstetrical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7977?source=related_link\">",
"      Overview of fertility and pregnancy in cancer survivors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/12/6346?source=related_link\">",
"      Overview of illicit drug use in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28039?source=related_link\">",
"      Pathogenesis and diagnosis of twin-twin transfusion syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34777?source=related_link\">",
"      Pathogenesis of preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32393?source=related_link\">",
"      Pathogenesis of spontaneous preterm birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/63/4089?source=related_link\">",
"      Placental infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/6/2154?source=related_link\">",
"      Pregnancy outcome after assisted reproductive technology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22633?source=related_link\">",
"      Risks associated with epilepsy and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22505?source=related_link\">",
"      Secondhand smoke exposure: Effects in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/53/27482?source=related_link\">",
"      Smoking and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/35/20026?source=related_link\">",
"      The effects of caffeine on reproductive outcomes in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40682?source=related_link\">",
"      Twin pregnancy: Prenatal issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19304?source=related_link\">",
"      Weight gain and loss in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_23_10617="Primary care management of medically unexplained symptoms";
var content_f10_23_10617=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Primary care management of medically unexplained symptoms",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/23/10617/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/23/10617/contributors\">",
"     Robert C Smith, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/23/10617/contributors\">",
"     Francesca C Dwamena, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/23/10617/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/23/10617/contributors\">",
"     Thomas L Schwenk, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/23/10617/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/23/10617/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/23/10617/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medically unexplained symptoms (MUS) are those physical symptoms having little or no basis in underlying organic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/1\">",
"     1",
"    </a>",
"    ]. When organic disease exists, the symptoms are inconsistent with or out of proportion to the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/2\">",
"     2",
"    </a>",
"    ]. People with MUS are not necessarily abnormal; many people exhibit MUS but seldom seek care [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/3\">",
"     3",
"    </a>",
"    ]. MUS become a problem when they lead to frequent healthcare-seeking for feared but nonexistent physical illness [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients seeking medical care, the prevalence of MUS of any type is in the range of 50 percent, varying from 25 to 75 percent, with pain being the most common symptom [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/5\">",
"     5",
"    </a>",
"    ]. Only 16 percent of patients presenting to a hospital internal medicine clinic with new common physical symptoms (chest pain, fatigue, dizziness, headache, edema, back pain, dyspnea, insomnia, abdominal pain, numbness, impotence, weight loss, cough, and constipation) were found to have an organic disease basis for their symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/6\">",
"     6",
"    </a>",
"    ]. MUS are thus common in medical clinics. For the 80 percent of patients with mild symptoms, assessment by history and physical examination should suffice. Treatment is simple reassurance, symptomatic medications, and a good provider-patient relationship; laboratory tests should be avoided in most of these patients with short-term, often stress-related physical symptoms that clear in a week or two [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More troublesome are the remaining 20 percent of MUS patients whose symptoms are chronic and more severe, and may result in physical as well as psychological disability. If not already performed, these patients need definitive study",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    consultation to exclude an underlying organic disease. Studies should not be repeated in search of organic disease with previous non-contributory evaluations [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/5\">",
"     5",
"    </a>",
"    ]. Of note also is that most chronic MUS patients have comorbid organic diseases such as diabetes and hypertension. When studies have failed to demonstrate an organic basis for the patient&rsquo;s symptoms, diagnostic evaluation ends and treatment begins, as outlined here.",
"   </p>",
"   <p>",
"    The term \"medically unexplained symptoms\" is useful, over and above somatization, because it represents a broader concept, includes the full spectrum of severity, and is consistent with the presence of concurrent organic and psychiatric illness causing these symptoms. Nevertheless, most published research is based upon DSM criteria developed in psychiatry. The literature, therefore, represents findings in the very severe MUS patients. More recently, the less severe syndrome, Multi-Somatoform Disorder (MSD) has been defined and is providing a wider research base to understand MUS, especially in the context of primary care [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. In the process of revising DSM-IV, use of a negative criterion, &ldquo;unexplained&rdquo; symptoms, has been questioned as the basis for making a diagnosis, but no better approach using positive psychological or physical symptom criteria has yet been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/10\">",
"     10",
"    </a>",
"    ]. The term MUS has been especially useful in primary care because most disabled, high-utilizing MUS patients are not otherwise covered by DSM-IV Somatoform categories [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MUS can present in multiple forms, and many specialties have diagnostic categories for patients with a predominant system involved, including irritable bowel syndrome (gastroenterology), non-cardiac chest pain (cardiology), and fibromyalgia (rheumatology) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/12\">",
"     12",
"    </a>",
"    ]. In addition, the majority of mental health patients in primary care settings present with chronic MUS, two-thirds presenting solely with chronic unexplained physical symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/13\">",
"     13",
"    </a>",
"    ]. We view MUS as part of a spectrum with both physical and psychological components; conditions along this spectrum should be identified by three components: severity, duration, and comorbidities [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic summarizes a plan for managing a broad spectrum of chronic, high-utilizing patients with MUS in a primary care setting. The psychiatric diagnoses and psychiatric management of somatization and related disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5450?source=see_link\">",
"     \"Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are relatively few studies to help clinicians manage medically unexplained symptoms (MUS). Nearly all randomized, controlled trials for chronic MUS patients have tested treatments provided by mental health specialists, mostly outside primary care settings [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/14\">",
"     14",
"    </a>",
"    ]. A literature review of 34 randomized controlled trials for the treatment of somatoform disorders found that few of these studies were performed in primary care and those showed mixed results [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatments that have been found effective in mental health and other settings have been summarized in literature reviews [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. Studies of multidisciplinary somatization treatment programs (eg, chronic pain) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/18-20\">",
"     18-20",
"    </a>",
"    ] and consultation-liaison psychiatry programs [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/21\">",
"     21",
"    </a>",
"    ] have shown that cognitive-behavioral techniques (CBT) improve short-term outcomes in MUS patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/22\">",
"     22",
"    </a>",
"    ]. CBT techniques have also been demonstrated to be effective when employed in a primary care setting [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CBT for MUS has not proven effective over the long term, however, when provided in a specialty setting (such as a counseling environment or pain clinic), most likely because of the time-limited exposure (typically six to eight weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/24\">",
"     24",
"    </a>",
"    ]. Many MUS patients revert to their baseline state after discontinuing specialty care [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/25\">",
"     25",
"    </a>",
"    ]. However, only 50 percent of MUS patients have persistent symptoms over a five-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even if effective long-term treatment were available through specialty referral, about 50 percent of patients refuse referral [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/24,27\">",
"     24,27",
"    </a>",
"    ]. In contrast, MUS patients were more willing to have psychosocial treatment (in addition to usual care) administered by their primary care clinician [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Collaborative care integrates multiple domains, including social services, physical therapy, pain clinic, specialty medical referral, and psychological referral [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. These activities can be coordinated by the clinician or by a case manager who works closely with the clinician, and they are used only as needed on an individualized basis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many reports emphasize the centrality of the provider-patient relationship (PPR) and lament almost universally poor relationships of providers and their MUS patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/32\">",
"     32",
"    </a>",
"    ]. Although the importance of communication and the PPR have been recognized [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/33\">",
"     33",
"    </a>",
"    ], few studies have explicitly addressed the PPR [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF CHRONIC MEDICALLY UNEXPLAINED SYMPTOMS (MUS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;We describe a management plan that is designed for primary care and other medical providers, is patient-centered, and has adapted and integrated successful treatment elements from specialty care (eg, CBT, proper use of antidepressants and management of prescription narcotic misuse) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/16\">",
"     16",
"    </a>",
"    ]. The patient-centered component was initially studied in a randomized, controlled trial and was shown to effectively prepare clinicians to establish a positive provider-patient relationship (PPR) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/3/8249?source=see_link\">",
"     \"Patient-centered interviewing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These principles of management apply both to patients with MUS and those with chronic, often disabling organic disease conditions, such as diabetic neuropathy, cancer, and sickle cell disease. In these conditions, the organic disease is treated concurrent with management of its psychological effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Provider-patient relationship",
"    </span>",
"    &nbsp;&mdash;&nbsp;A primary objective of treatment is to elicit and respond to patient emotions, such as",
"    <span class=\"nowrap\">",
"     anxiety/depression,",
"    </span>",
"    anger, and sadness, that are commonly experienced by MUS patients. After identifying the emotion (\"How did that make you feel?\") the provider expresses empathy by",
"    <strong>",
"     N",
"    </strong>",
"    aming the emotion,",
"    <strong>",
"     U",
"    </strong>",
"    nderstanding it,",
"    <strong>",
"     R",
"    </strong>",
"    especting it, and",
"    <strong>",
"     S",
"    </strong>",
"    upporting it; ie, one \"NURSs\" the emotion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. These specific empathy skills are an important tool in improving relationships and satisfaction. Studies have found that primary care patients accept psychosocial evaluation, and that test-ordering is not as important to patients as perceived by the clinician [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/3/8249?source=see_link\">",
"     \"Patient-centered interviewing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, caretakers improve their relationships by:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Showing positive regard, trust, and caring.",
"     </li>",
"     <li>",
"      Tailoring care to the patient's personality style [",
"      <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/36\">",
"       36",
"      </a>",
"      ]. As an example, one reassures the histrionic patient about bodily integrity and appearance and de-emphasizes cognitive material [",
"      <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/36\">",
"       36",
"      </a>",
"      ]. For the obsessive MUS patient, providers focus upon cognitive data, encouraging the patient's control, and putting less emphasis on the emotions [",
"      <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Encouraging patients to be responsible, negotiating expectations and limitations, and being open to compromise [",
"      <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Recognizing and working on one's own negative reactions to the frequently disliked MUS patient [",
"      <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/2,40\">",
"       2,40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Cognitive-behavioral treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intent of cognitive behavioral therapy (CBT) is to alter unhealthy thinking patterns and associated behaviors. CBT is most often provided by trained therapists, as a specified course of treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29751?source=see_link&amp;anchor=H432862147#H432862147\">",
"     \"Overview of psychotherapies\", section on 'Cognitive and behavioral therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Framework for patient management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several components of formal CBT can be incorporated into routine follow-up medical visits with patients.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Setting goals &mdash; Identify achievable long-term goals [",
"      <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/18\">",
"       18",
"      </a>",
"      ]; eg, decreased symptoms, improved functioning and well being, improved",
"      <span class=\"nowrap\">",
"       work/school",
"      </span>",
"      record, and improved interpersonal relationships [",
"      <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/2,16\">",
"       2,16",
"      </a>",
"      ]. Short-term goals should be limited to no more than two to three activities for the next visit, often labeled \"homework.\"",
"     </li>",
"     <li>",
"      Achieving better understanding &mdash; Determine the patient's explanatory model: what the patient believes the problem is, the treatment he or she expects, what he or she thinks is causing the illness [",
"      <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/16\">",
"       16",
"      </a>",
"      ]. This is done to establish baseline understanding because CBT is designed to foster correction of the patient's frequent misunderstanding of the illness and the abnormal illness behaviors that ensue [",
"      <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/18\">",
"       18",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Some MUS patients believe that every symptom means some type of disease exists, that they should seek care, and that some test",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      treatment is needed. They usually are worried about the causes of their symptoms and have definite expectations for care [",
"      <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/4\">",
"       4",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Understanding these expectations enhances the PPR and provides guidance for treatment. Explanations should not involve blaming the patient [",
"      <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/41\">",
"       41",
"      </a>",
"      ]. Differences in doctors' and patients' expectations contribute to the poor PPR [",
"      <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cognitive reorientation &mdash; In cognitive reorientation, sometimes called reattribution, the provider works closely with the patient to establish new understandings of symptoms. Cognitive reorientation cannot occur in isolation because patients seek support for their ideas and their own explanatory model of what they believe is occurring [",
"      <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/28,43\">",
"       28,43",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Effective re-orientation must integrate the patient perspective with the clinician's understanding of the patient's condition, and is facilitated greatly by negotiating a strong provider-patient relationship over time [",
"      <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/28\">",
"       28",
"      </a>",
"      ]. The provider establishes the following, often new understanding [",
"      <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/16\">",
"       16",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      That ominous conditions have not been found, especially the ones the patient is concerned about; eg, multiple sclerosis, cancer, AIDS, heart disease (\"The good news is&hellip;\").",
"     </li>",
"     <li>",
"      That surgery, further testing, and additional consultation are not required (\"More good news is&hellip;\"). We also reassure the patient that we will maintain close clinical observation for organic diseases [",
"      <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/18,24\">",
"       18,24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      That the problem is \"real\" and somatic; we avoid implying or stating that it is \"all in your head\" (\"No, this is real and in your body, you're not making it up\").",
"     </li>",
"     <li>",
"      What the diagnosis is; we explain the mechanism and confidently reassure the patient that we know the diagnosis, have experience with it, and that it is a common problem [",
"      <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/18,24\">",
"       18,24",
"      </a>",
"      ]. The clinician provides a benign somatic diagnosis and its mechanism [",
"      <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/24,44\">",
"       24,44",
"      </a>",
"      ]. Chronic muscle strain is a good explanation for many pain syndromes, \"altered brain chemicals\" can help to describe depression, and the use of popular names such as irritable bowel syndrome or fibromyalgia also works well.",
"     </li>",
"     <li>",
"      That stress, anxiety, and depression are important components in the illness [",
"      <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/45\">",
"       45",
"      </a>",
"      ], but that the patient is not crazy or a \"psych case\" (\"No you're not a psych case, anyone with this much pain would be depressed, I know I would.\").",
"     </li>",
"     <li>",
"      That opioids, sleeping pills, and tranquilizers often do more harm than good, especially when the many other dimensions of the patient's problem are not addressed [",
"      <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      That cure is unlikely [",
"      <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/47\">",
"       47",
"      </a>",
"      ]. Nevertheless, the clinician should convey hope that the treatment recommended can help the patient live a better and more productive life [",
"      <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/18,24\">",
"       18,24",
"      </a>",
"      ] (\"I'd cure the pain if I could, but we may have to be content to just gradually take it out of the center of your life\").",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obtaining a commitment &mdash; Obtain a commitment to treatment after giving an overview of the treatment options. For example, the clinician might recommend antidepressants, tapering of controlled substances, exercise, and regular visits. An explicit commitment to work on the treatment program must follow because it involves the patient in his or her own program and encourages the patient's responsibility for his or her own health (\"I need to know if you're up for this and willing to do the hard work you and I will need to do.\") [",
"      <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Negotiating a specific treatment plan &mdash; Treat underlying psychiatric conditions (ie, depression or panic disorder) that are often present, address use of controlled substances, and agree on a schedule for visits and treatment goals.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Treating underlying psychiatric conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;One study of patients with MUS found that 45 percent of patients had an undetected psychiatric disorder, usually involving mood or anxiety [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/48\">",
"     48",
"    </a>",
"    ]. A study of patients with chronic pain symptoms found that the number of pain symptoms was correlated with the severity of depression [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/49\">",
"     49",
"    </a>",
"    ]. Conversely, about two-thirds of patients with mental health problems who are first seen for evaluation in primary care present with unexplained medical symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with MUS have dysthymia or major depression [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/50\">",
"     50",
"    </a>",
"    ], and some just have neurovegetative manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/51\">",
"     51",
"    </a>",
"    ]. Patients with major depression should be treated according to validated guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/52-57\">",
"     52-57",
"    </a>",
"    ]; treatment with either pharmacotherapy or psychotherapy is superior to usual care for patients with major depression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data on the use of antidepressant therapy in patients with MUS are incomplete but suggest that treatment is successful [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/15\">",
"     15",
"    </a>",
"    ]. Antidepressant medication may be helpful, even in patients who do not meet criteria for major depression. A systematic review of randomized trials found that the number of people with MUS needed to treat with antidepressant to achieve symptom response in one person was four; effectiveness was independent of antidepressant action [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Findings from the STAR*D trial, a multicenter randomized trial of stepped care for patients with depression, indicate improved long-term outcome for patients who are treated to achieve full remission, and the use of a combination of antidepressants, or antidepressants plus cognitive behavioral therapy, to achieve remission [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/55,56,59\">",
"     55,56,59",
"    </a>",
"    ]. Nonresponders and partial responders should be reassessed for accuracy of diagnosis and compliance six to eight weeks after treatment with full dose antidepressant therapy. Attention should focus on unrecognized medical illness, interference from other medications, and covert substance abuse as possible causes of poor response.",
"   </p>",
"   <p>",
"    For partial response, antidepressants can be increased in dose, changed to another agent, or combined with an agent from another drug class (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    added to an SSRI) with continued close follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/60-62\">",
"     60-62",
"    </a>",
"    ]. Referral to a mental health professional should occur if there is not improvement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=see_link\">",
"     \"Treatment of resistant depression in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Panic disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many chronic MUS patients have panic disorder and other types of",
"    <strong>",
"     anxiety",
"    </strong>",
"    , often in combination with depression [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/63\">",
"     63",
"    </a>",
"    ]. Clinicians prescribe SSRIs, but they should limit sedatives because of their addictive potential. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7305?source=see_link\">",
"     \"Pharmacotherapy for panic disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Tapering and discontinuing addicting medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Controlled substances may contribute to depression and, therefore, the patient may unwittingly aggravate the",
"    <span class=\"nowrap\">",
"     depression/pain",
"    </span>",
"    problem by using them. In response to the frequent \"It's the only thing that helps,\" the clinician indicates that the medications will not be withdrawn abruptly. Rather, only after another pain medication, an antidepressant, is begun will the controlled substances be slowly reduced. The clinician indicates that the antidepressant is a better pain medication for the patient's situation than sedatives or opioids, and that it is not addicting [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Maintaining a good relationship requires using emotion-handling skills frequently during what can be difficult interactions over the need to decrease and discontinue addicting medications [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/24\">",
"     24",
"    </a>",
"    ]. Long-term opiates should be instituted only if the multiple dimensions of treatment discussed above are ineffective [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/64-66\">",
"     64-66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest the following outpatient detoxification plan for patients with opioid abuse related to management of MUS. If it is not effective, referral to pain or addiction medicine specialists is indicated, and may result in inpatient detoxification. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29514?source=see_link\">",
"     \"Treatment of opioid abuse and dependence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1191?source=see_link\">",
"     \"Opioid detoxification during treatment for addiction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/33/27160?source=see_link\">",
"     \"Prescription drug abuse and addiction: Prevention, identification, and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A program of gradual tapering should usually be negotiated, typically with the intent of complete discontinuation. The clinician may have to compromise around speed of reduction and, occasionally, complete discontinuation may not be possible.",
"   </p>",
"   <p>",
"    Key points are summarized below.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Baseline",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Ascertain the average daily dose at present.",
"     </li>",
"     <li>",
"      Negotiate how much the patient thinks he or she needs on more severe days.",
"     </li>",
"     <li>",
"      Prescribe this amount on a fixed schedule rather than the usual as-needed (prn) basis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Taper",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Negotiate a reduction schedule; suggest a decrease in one tablet daily each week; eg, one tablet four times daily for the next week, then one tablet three times daily the following week, etc. But be prepared to accept up to monthly reductions in dose.",
"     </li>",
"     <li>",
"      When more than one addicting medication is involved, determine the patient's initial preference for tapering or if he or she prefers simultaneous reduction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Discontinue",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Simply stop the drug after the dose is down to one-half to one tablet daily; most patients achieve this by two to four months, and many in one month.",
"     </li>",
"     <li>",
"      A few patients cannot completely stop. It is appropriate to maintain them at the lowest possible dose as long as they have made some reductions [",
"      <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Process",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Give just enough medication to last until the next visit, initially every one to two weeks.",
"     </li>",
"     <li>",
"      Provide only one \"grace period\" refill if patients report losing their medication.",
"     </li>",
"     <li>",
"      Urine toxicology screening and review of pharmacy reports (where available) for use of opioids and other substances can be useful [",
"      <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Problematic patients benefit from written contracts, but most do not fall into this category and are easy to work with.",
"     </li>",
"     <li>",
"      For pain and other symptoms, use non-addicting, symptomatic medications; eg, an anticholinergic drug for irritable bowel syndrome or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      for fibromyalgia. Lower doses of SSRIs or other antidepressants also are useful for pain management, independent of an antidepressant effect [",
"      <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/68\">",
"       68",
"      </a>",
"      ]. Because many patients are depressed, however, they will be taking full doses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Exercise and lifestyle",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with back pain, fatigue, or fibromyalgia who are advised activity, rather than rest, have been shown to have better outcomes in randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/69\">",
"     69",
"    </a>",
"    ]. To develop more healthy behaviors and to achieve symptom relief, simple relaxation exercises [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/70\">",
"     70",
"    </a>",
"    ] can be taught in addition to simple physical therapy procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/47\">",
"     47",
"    </a>",
"    ]. Usual prescriptions are for 10 to 30 minutes once or twice daily. These procedures are taught to patients by the primary clinician (or other members of the care team who have close patient contact) and integrated into the remainder of the program.",
"   </p>",
"   <p>",
"    These patients are often severely de-conditioned; physical exercise programs are demonstrated, discussed, and individualized rather than just giving the patient a print-out or costly referral [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/47\">",
"     47",
"    </a>",
"    ]. The more healthy behaviors the provider and patient agree upon, the more effective the treatment. Dietary counseling, especially about weight, is often necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Diary",
"    </span>",
"    &nbsp;&mdash;&nbsp;If patients persist in worrying about physical symptoms, ask them to keep diaries of their symptoms and of the activities, thoughts, and emotions that accompany them. Providers then help patients better understand the symptoms and their meanings.",
"   </p>",
"   <p>",
"    Diary-keeping may become a focus of treatment in a few patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/18\">",
"     18",
"    </a>",
"    ], cognitively reorienting them to realize that the fear they experience with every symptom is not realistic and does not mean a serious disease is present or that a test is required. Most MUS patients do not require diaries because the initial reorienting work (see above) usually suffices, particularly when emphasized frequently.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Family involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The provider asks patients to have a significant-other person accompany them for one or more visits. Because the patient's basic illness behaviors must change, the best allies often do not support the patient's present efforts and are not understanding of failure to improve [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/71\">",
"     71",
"    </a>",
"    ]. A very supportive spouse often facilitates the very illness behaviors the patient needs to change, and they may require work themselves in this regard before the patient can improve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Managing comorbid illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of comorbid disease problems, new and preexisting, is handled in the usual fashion except that the MUS care plan must be integrated with it.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Psychological problems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians should encourage MUS patients to discuss personal material at each visit, and provide friendly support and common-sense advice for problems, much as one might do with a friend. This degree of \"counseling\" suffices for providers without mental health training.",
"   </p>",
"   <p>",
"    During the initial weeks to months of stability and improvement, the treatment plan leads many patients to quit talking about symptoms and to focus upon their personal lives so that we often hear about difficulties with a job, their living situation, or a spouse. One uses emotion-handling skills and encourages a patient's own responsibility. For example, they might say, \"So, that's been a hard time for you. What's the game plan? Do you know the next step?\" Referral for counseling can be very effective in providing the support and insight necessary for further improvement. On the other hand, many patients do not want counseling, and the provider should accept and support this.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Medical complaints",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical investigation, referral, and hospitalization occur only with objective evidence of disease. During office visits, it is important to determine that there is no change in symptoms suggesting an organic disease and, on the other hand, to recognize that every complaint does not need investigation.",
"   </p>",
"   <p>",
"    Referral for special or refractory problems is not uncommon; eg, counseling, osteopathic manipulative therapy, psychiatry for medication recommendations. Clinicians should negotiate that patients neither see other providers nor visit the emergency department without discussing it beforehand. Similarly, they should negotiate that patients will not get medications refilled from prior sources, that they will use only one pharmacy, and that they will pick up their medications in person [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/2,46\">",
"     2,46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Priorities and pace of care",
"    </span>",
"    &nbsp;&mdash;&nbsp;The specific order and initial emphasis of the above treatment plan varies according to patient needs; eg, exercise might receive more initial emphasis in a de-conditioned patient, while the focus for a depressed patient is upon antidepressants. Treatment elements are negotiated, not unilaterally prescribed. Providers are careful not to overload patients and to match the introduction of new aspects of treatment with the patient's capacities, eventually trying to touch each point in the plan above. The provider also encourages patients to identify and formulate pertinent questions as a way to encourage responsibility, involvement, and assertiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The specifics of treatment are negotiated on a time-contingent schedule; eg, visits, medications, and exercise are regularly scheduled. We also use treatments that have worked before in the individual patient, and avoid those that have not where possible.",
"   </p>",
"   <p>",
"    It is necessary to warn patients to adhere to the negotiated agreement (eg, exercise, addicting medication) regardless of whether they are feeling well or feeling exceptionally poorly. Any change in treatment schedule is negotiated at the next visit. These types of CBT work require repetition over time and remain prominent throughout treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/18,20,22\">",
"     18,20,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These already high-utilizing patients require regular, frequent visits, particularly at the outset when most need to be seen every one to two weeks. As stability occurs and progress begins, the visit intervals are progressively lengthened as long as the patient remains stable [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/2,21\">",
"     2,21",
"    </a>",
"    ]. Usual intervals with stable patients are 4 to 12 weeks. With crises, more frequent visits may again be needed. Some patients benefit from three to five minute phone calls midway between visits or, sometimes, instead of visits. For both periodic visits and for telephone calls, a nurse or case manager can be a useful co-manager with the primary care provider. While intake visits may take longer than usual (with complex histories), regular follow-up visits are the usual 10 to 20 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/2,21\">",
"     2,21",
"    </a>",
"    ]. This method can be continued indefinitely in managing MUS patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 12 month study of implementation of the treatment approach described above, utilizing nurse practitioners specially trained in management of MUS patients, and a multimodal program (including cognitive behavioral, pharmacological, exercise, and physical therapy, and comorbid disease management interventions) was conducted in a staff model HMO [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/16,73\">",
"     16,73",
"    </a>",
"    ]. Patients (n = 200) were randomly assigned to the treatment program or usual care; significantly more patients in the treatment group showed symptom improvement as measured by the Mental Component Summary of the SF-36 (48 versus 34 percent, RR 1.47; 95% CI 1.05-2.07) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/73\">",
"     73",
"    </a>",
"    ]. This program was also effective in a small trial involving primary care physicians who had undergone 16 to 20 hours of training [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The more severe and the more refractory the patient, the more likely one will need mental health consultation. The following are guidelines for referral:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Suicidal or homicidal thoughts",
"     </li>",
"     <li>",
"      Psychosis",
"     </li>",
"     <li>",
"      Failure of depression or anxiety to respond to treatment",
"     </li>",
"     <li>",
"      Worsening of (or the development of) dysfunctional behaviors",
"     </li>",
"     <li>",
"      The patient requests referral",
"     </li>",
"     <li>",
"      Failure of patient to become engaged in the treatment",
"     </li>",
"     <li>",
"      When primary care treatment has been successful in identifying the need and desire for counseling",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     psychiatric/psychological",
"    </span>",
"    consultant requires advance information, particularly to know that significant organic disease has not been found or is not causing the symptoms, lest the consultant inadvertently recommend additional diagnostic investigation or otherwise convey concern about organic disease possibilities [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/2\">",
"     2",
"    </a>",
"    ]. Joint management with a psychological or psychiatric consultant can be very helpful in the more severe patients. Consultation requires advance planning, discussion, and often negotiation with the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10617/abstract/2\">",
"     2",
"    </a>",
"    ]. It is particularly important that the primary care clinician indicate that he or she will remain actively involved and in charge of the patient's care, and that the patient will not be abandoned.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although the diagnosis of medically unexplained symptoms (MUS) depends on excluding specific medical conditions as a cause of symptoms, most often this exclusion is based on taking an appropriate history, performing a physical examination, and reviewing previous records. Extensive and repeat testing can lead to significant expense and potential morbidity; targeted studies should be based on history and physical findings suggesting possible underlying disease.",
"     </li>",
"     <li>",
"      Most patients with chronic medically unexplained symptoms can be effectively managed in primary care with a multimodal treatment program. Components of this program include attention to the patient-provider relationship, cognitive-behavioral therapy, pharmacologic measures, exercise, relaxation, family involvement, and management of comorbid medical illness.",
"     </li>",
"     <li>",
"      At the beginning of treatment, the provider-patient relationship is often the most challenging. Patients may test the provider, who should demonstrate commitment and emotional balance. Taking care to establish a respectful, caring relationship, in concert with the multimodal program, can lead to improved health outcomes.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/1\">",
"      Lipowski ZJ. Somatization: the concept and its clinical application. Am J Psychiatry 1988; 145:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/2\">",
"      Smith RC. Somatization disorder: defining its role in clinical medicine. J Gen Intern Med 1991; 6:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/3\">",
"      Verbrugge LM, Ascione FJ. Exploring the iceberg. Common symptoms and how people care for them. Med Care 1987; 25:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/4\">",
"      Kravitz RL. Measuring patients' expectations and requests. Ann Intern Med 2001; 134:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/5\">",
"      Smith RC, Dwamena FC. Classification and diagnosis of patients with medically unexplained symptoms. J Gen Intern Med 2007; 22:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/6\">",
"      Kroenke K, Mangelsdorff AD. Common symptoms in ambulatory care: incidence, evaluation, therapy, and outcome. Am J Med 1989; 86:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/7\">",
"      Fava GA, Porcelli P. Multisomatoform disorder. Arch Gen Psychiatry 1998; 55:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/8\">",
"      Kroenke K, Spitzer RL, deGruy FV 3rd, et al. Multisomatoform disorder. An alternative to undifferentiated somatoform disorder for the somatizing patient in primary care. Arch Gen Psychiatry 1997; 54:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/9\">",
"      Kroenke K, Spitzer RL, Williams JB. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med 2002; 64:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/10\">",
"      Sykes R. Somatoform disorder and the DSM-V Workgroup's interim proposals: two central issues. Psychosomatics 2012; 53:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/11\">",
"      Smith RC, Gardiner JC, Lyles JS, et al. Exploration of DSM-IV criteria in primary care patients with medically unexplained symptoms. Psychosom Med 2005; 67:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/12\">",
"      Hatcher S, Arroll B. Assessment and management of medically unexplained symptoms. BMJ 2008; 336:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/13\">",
"      Kroenke K. The Interface Between Physical and Psychological Symptoms. Primary Care Companion J Clin Psychiatry 2003; 5:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/14\">",
"      Sharpe M, Carson A. \"Unexplained\" somatic symptoms, functional syndromes, and somatization: do we need a paradigm shift? Ann Intern Med 2001; 134:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/15\">",
"      Kroenke K. Efficacy of treatment for somatoform disorders: a review of randomized controlled trials. Psychosom Med 2007; 69:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/16\">",
"      Smith RC, Lein C, Collins C, et al. Treating patients with medically unexplained symptoms in primary care. J Gen Intern Med 2003; 18:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/17\">",
"      Sumathipala A. What is the evidence for the efficacy of treatments for somatoform disorders? A critical review of previous intervention studies. Psychosom Med 2007; 69:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/18\">",
"      Sharpe M, Peveler R, Mayou R. The psychological treatment of patients with functional somatic symptoms: a practical guide. J Psychosom Res 1992; 36:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/19\">",
"      Kashner TM, Rost K, Cohen B, et al. Enhancing the health of somatization disorder patients. Effectiveness of short-term group therapy. Psychosomatics 1995; 36:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/20\">",
"      Klimes I, Mayou RA, Pearce MJ, et al. Psychological treatment for atypical non-cardiac chest pain: a controlled evaluation. Psychol Med 1990; 20:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/21\">",
"      Katon W, Von Korff M, Lin E, et al. Collaborative management to achieve treatment guidelines. Impact on depression in primary care. JAMA 1995; 273:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/22\">",
"      Sharpe M, Hawton K, Simkin S, et al. Cognitive behaviour therapy for the chronic fatigue syndrome: a randomized controlled trial. BMJ 1996; 312:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/23\">",
"      Escobar JI, Gara MA, Diaz-Martinez AM, et al. Effectiveness of a time-limited cognitive behavior therapy type intervention among primary care patients with medically unexplained symptoms. Ann Fam Med 2007; 5:328.",
"     </a>",
"    </li>",
"    <li>",
"     Bass CM. Assessment and management of patients with functional somatic symptoms. In: Somatization: physical symptoms and psychological illness, Bass CM (Ed), Blackwell, Oxford 1990. p.40.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/25\">",
"      Whiting P, Bagnall AM, Sowden AJ, et al. Interventions for the treatment and management of chronic fatigue syndrome: a systematic review. JAMA 2001; 286:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/26\">",
"      Jackson JL, Passamonti M. The outcomes among patients presenting in primary care with a physical symptom at 5 years. J Gen Intern Med 2005; 20:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/27\">",
"      Regier DA, Boyd JH, Burke JD Jr, et al. One-month prevalence of mental disorders in the United States. Based on five Epidemiologic Catchment Area sites. Arch Gen Psychiatry 1988; 45:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/28\">",
"      Peters S, Rogers A, Salmon P, et al. What do patients choose to tell their doctors? Qualitative analysis of potential barriers to reattributing medically unexplained symptoms. J Gen Intern Med 2009; 24:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/29\">",
"      Speckens AE, van Hemert AM, Bolk JH, et al. The acceptability of psychological treatment in patients with medically unexplained physical symptoms. J Psychosom Res 1995; 39:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/30\">",
"      Katon W, Von Korff M, Lin E, et al. Stepped collaborative care for primary care patients with persistent symptoms of depression: a randomized trial. Arch Gen Psychiatry 1999; 56:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/31\">",
"      Von Korff M, Gruman J, Schaefer J, et al. Collaborative management of chronic illness. Ann Intern Med 1997; 127:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/32\">",
"      Barsky AJ. Clinical practice. The patient with hypochondriasis. N Engl J Med 2001; 345:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/33\">",
"      Fink P, Rosendal M, Toft T. Assessment and treatment of functional disorders in general practice: the extended reattribution and management model--an advanced educational program for nonpsychiatric doctors. Psychosomatics 2002; 43:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/34\">",
"      Smith RC, Lyles JS, Mettler J, et al. The effectiveness of intensive training for residents in interviewing. A randomized, controlled study. Ann Intern Med 1998; 128:118.",
"     </a>",
"    </li>",
"    <li>",
"     Smith RC. Videotape of Evidence-Based Interviewing: 1) Patient-Centered Interviewing and 2) Doctor-Centered Interviewing. Produced by Michigan State University Broadcasting Services, Eric Schultz, Producer. Available at: www.msuvmall.msu.edu/imc (Accessed on March 07, 2005).",
"    </li>",
"    <li>",
"     Smith RC. Patient-Centered Interviewing: An Evidence-Based Method, 2nd ed, Lippincott Williams and Wilkins, Philadelphia 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/37\">",
"      Salmon P, Ring A, Humphris GM, et al. Primary care consultations about medically unexplained symptoms: how do patients indicate what they want? J Gen Intern Med 2009; 24:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/38\">",
"      Salmon P, Wissow L, Carroll J, et al. Doctors' attachment style and their inclination to propose somatic interventions for medically unexplained symptoms. Gen Hosp Psychiatry 2008; 30:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/39\">",
"      Quill TE. Partnerships in patient care: a contractual approach. Ann Intern Med 1983; 98:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/40\">",
"      Smith RC, Dwamena FC, Fortin AH 6th. Teaching personal awareness. J Gen Intern Med 2005; 20:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/41\">",
"      Salmon P, Peters S, Stanley I. Patients' perceptions of medical explanations for somatisation disorders: qualitative analysis. BMJ 1999; 318:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/42\">",
"      Hahn SR. Physical symptoms and physician-experienced difficulty in the physician-patient relationship. Ann Intern Med 2001; 134:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/43\">",
"      Jackson JL, George S, Hinchey S. Medically unexplained physical symptoms. J Gen Intern Med 2009; 24:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/44\">",
"      Bass C, Benjamin S. The management of chronic somatisation. Br J Psychiatry 1993; 162:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/45\">",
"      Kellner R. Psychotherapeutic strategies in hypochondriasis: a clinical study. Am J Psychother 1982; 36:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/46\">",
"      Ballantyne JC, Mao J. Opioid therapy for chronic pain. N Engl J Med 2003; 349:1943.",
"     </a>",
"    </li>",
"    <li>",
"     Lee VC, Rowlingson JC. Chronic Pain Management. In: Quality of Life Assessments in Clinical Trials, Spilker B (Ed), Raven Press, New York 1990.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/48\">",
"      Crimlisk HL, Bhatia K, Cope H, et al. Slater revisited: 6 year follow up study of patients with medically unexplained motor symptoms. BMJ 1998; 316:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/49\">",
"      Vaccarino AL, Sills TL, Evans KR, Kalali AH. Multiple pain complaints in patients with major depressive disorder. Psychosom Med 2009; 71:159.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. and Statistical Manual of Mental Disorders -- DSM-IV-TR, American Psychiatric Association, Washington, DC 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/51\">",
"      Katon W, Lin E, Von Korff M, et al. Somatization: a spectrum of severity. Am J Psychiatry 1991; 148:34.",
"     </a>",
"    </li>",
"    <li>",
"     Depression Guideline Panel. Depression in Primary Care, Volume 1, Detection and Diagnosis. Agency for Health Care Policy and Research; US Department of Health and Human Services, Rockville, MD 1993.",
"    </li>",
"    <li>",
"     Depression Guideline Panel. Depression in Primary Care, Volume 2, Treatment of Major Depression. Agency for Health Care Policy and Research; US Department of Health and Human Services, Rockville, MD 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/54\">",
"      Schulberg HC, Block MR, Madonia MJ, et al. Treating major depression in primary care practice. Eight-month clinical outcomes. Arch Gen Psychiatry 1996; 53:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/55\">",
"      Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163:1905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/56\">",
"      Menza M. STAR*D: the results begin to roll in. Am J Psychiatry 2006; 163:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/57\">",
"      Nelson JC. The STAR*D study: a four-course meal that leaves us wanting more. Am J Psychiatry 2006; 163:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/58\">",
"      O'Malley PG, Jackson JL, Santoro J, et al. Antidepressant therapy for unexplained symptoms and symptom syndromes. J Fam Pract 1999; 48:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/59\">",
"      Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/60\">",
"      Delgado PL. Approaches to the enhancement of patient adherence to antidepressant medication treatment. J Clin Psychiatry 2000; 61 Suppl 2:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/61\">",
"      Hirschfeld RM, Montgomery SA, Aguglia E, et al. Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry 2002; 63:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/62\">",
"      Looper KJ, Kirmayer LJ. Hypochondriacal concerns in a community population. Psychol Med 2001; 31:577.",
"     </a>",
"    </li>",
"    <li>",
"     Katon W. Panic Disorder in the Medical Setting. DHHS Publication no. (ADM)89-1629, National Institute of Mental Health; US Department of Health and Human Services, Washington, DC 1989.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/64\">",
"      The use of opioids for the treatment of chronic pain. A consensus statement from the American Academy of Pain Medicine and the American Pain Society. Clin J Pain 1997; 13:6.",
"     </a>",
"    </li>",
"    <li>",
"     Chronic Pain Working Group. The Management of Opioid Therapy for Chronic Pain. VA Office of Quality and Performance and Quality Management; Directorate United States Army MEDCOM, Washington, DC 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/66\">",
"      Ballantyne JC, LaForge KS. Opioid dependence and addiction during opioid treatment of chronic pain. Pain 2007; 129:235.",
"     </a>",
"    </li>",
"    <li>",
"     Department of Community Health. Michigan Automated Prescription System (MAPS): State of Michigan. Department of Community Health, MI 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/68\">",
"      Fishbain DA, Cutler RB, Rosomoff HL, Rosomoff RS. Do antidepressants have an analgesic effect in psychogenic pain and somatoform pain disorder? A meta-analysis. Psychosom Med 1998; 60:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/69\">",
"      Henningsen P, Zipfel S, Herzog W. Management of functional somatic syndromes. Lancet 2007; 369:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/70\">",
"      Keefer L, Blanchard EB. The effects of relaxation response meditation on the symptoms of irritable bowel syndrome: results of a controlled treatment study. Behav Res Ther 2001; 39:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/71\">",
"      Benjamin S, Mawer J, Lennon S. The knowledge and beliefs of family care givers about chronic pain patients. J Psychosom Res 1992; 36:211.",
"     </a>",
"    </li>",
"    <li>",
"     Kaplan SH, Greenfield S, Ware JE. Impact of the doctor-patient relationship on the outcomes of chronic disease. In: Communicating with Medical Patients, Stewart M, Roter D (Eds), Sage Publications, London 1989. p.228.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/73\">",
"      Smith RC, Lyles JS, Gardiner JC, et al. Primary care clinicians treat patients with medically unexplained symptoms: a randomized controlled trial. J Gen Intern Med 2006; 21:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10617/abstract/74\">",
"      Smith RC, Gardiner JC, Luo Z, et al. Primary care physicians treat somatization. J Gen Intern Med 2009; 24:829.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6954 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-4327E6E395-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_23_10617=[""].join("\n");
var outline_f10_23_10617=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MANAGEMENT OF CHRONIC MEDICALLY UNEXPLAINED SYMPTOMS (MUS)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Provider-patient relationship",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Cognitive-behavioral treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Framework for patient management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Treating underlying psychiatric conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Depression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Panic disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Tapering and discontinuing addicting medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Exercise and lifestyle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Diary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Family involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Managing comorbid illness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Psychological problems",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Medical complaints",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Priorities and pace of care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1191?source=related_link\">",
"      Opioid detoxification during treatment for addiction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29751?source=related_link\">",
"      Overview of psychotherapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/3/8249?source=related_link\">",
"      Patient-centered interviewing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7305?source=related_link\">",
"      Pharmacotherapy for panic disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/33/27160?source=related_link\">",
"      Prescription drug abuse and addiction: Prevention, identification, and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5450?source=related_link\">",
"      Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29514?source=related_link\">",
"      Treatment of opioid abuse and dependence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=related_link\">",
"      Treatment of resistant depression in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_23_10618="Staging and prognostic studies in multiple myeloma";
var content_f10_23_10618=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Staging and prognostic studies in multiple myeloma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/23/10618/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/23/10618/contributors\">",
"     S Vincent Rajkumar, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/23/10618/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/23/10618/contributors\">",
"     Robert A Kyle, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/23/10618/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/23/10618/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/23/10618/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma cell myeloma is characterized by the neoplastic proliferation of a single clone of plasma cells producing a monoclonal immunoglobulin and can present as a single lesion (solitary plasmacytoma) or multiple lesions (multiple myeloma). This clone of plasma cells proliferates in the bone marrow and often results in extensive skeletal destruction with osteolytic lesions, osteopenia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fractures.",
"   </p>",
"   <p>",
"    Multiple myeloma (MM) is a heterogeneous disease with some patients progressing rapidly despite treatment, and others not requiring therapy for a number of years. The prognosis of patients with myeloma, as in most other cancers, is dependent on four key factors: tumor burden (staging), patient factors, disease biology and aggressiveness (eg, cytogenetic abnormalities, proliferative rate), and response to therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/1\">",
"     1",
"    </a>",
"    ]. This topic review will discuss the staging and prognostic studies used in multiple myeloma.",
"   </p>",
"   <p>",
"    The pathogenesis, clinical manifestations, diagnosis, and the different modalities used for therapy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27977?source=see_link\">",
"     \"Pathobiology of multiple myeloma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=see_link\">",
"     \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=see_link\">",
"     \"Determination of initial therapy in patients with multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the diagnosis of myeloma is made, patients undergo an initial evaluation to determine the disease stage (ie, the tumor burden). Two main staging systems exist: the International staging system (ISS) and the Durie-Salmon staging system. Of these, the ISS has become the preferred staging system because of its simplicity and lack of subjectivity. These staging systems are predominantly used to stratify patients enrolled in clinical trials and allow clinicians to better interpret and compare such trials. Other prognostic studies, such as bone marrow cytogenetics and studies of chromosomal translocations are more frequently used to determine the preferred treatment approach. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Prognostic studies'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=see_link&amp;anchor=H5#H5\">",
"     \"Determination of initial therapy in patients with multiple myeloma\", section on 'Risk stratification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1827881563\">",
"    <span class=\"h2\">",
"     International staging system (ISS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;An International Staging System (ISS) was developed based on 10,750 previously untreated patients with myeloma from over 17 institutions worldwide. It incorporates data on the levels of serum beta-2 microglobulin (B2M) and serum albumin to divide disease burden into three stages with prognostic significance [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage I &mdash; B2M &lt;3.5",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      and serum albumin &ge;3.5",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"     </li>",
"     <li>",
"      Stage II &mdash; neither stage I nor stage III",
"     </li>",
"     <li>",
"      Stage III &mdash; B2M &ge;5.5",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Median overall survival for patients with ISS stages I, II, and III were 62, 44, and 29 months, respectively.",
"   </p>",
"   <p>",
"    The ISS should be used only in patients with symptomatic, overt myeloma; it should not be used in patients with smoldering myeloma or monoclonal gammopathy of undetermined significance (MGUS) since its value in such populations is not known. Unlike the Durie-Salmon staging system, the ISS is not a reliable indicator of tumor burden; both albumin and B2M that form the basis of the ISS are also affected by patient factors, such as renal failure and comorbidities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Durie-Salmon staging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Durie-Salmon clinical staging system incorporates several factors correlating with tumor cell mass. Using this method, stage is determined based upon a subjective measure of tumor cell density in the bone marrow along with measures of end organ damage (renal insufficiency, anemia, hypercalcemia, lytic bone lesions) and immunoglobulin burden (",
"    <a class=\"graphic graphic_table graphicRef56890 \" href=\"UTD.htm?11/18/11564\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/3\">",
"     3",
"    </a>",
"    ]. While it is a standardized system for the staging of multiple myeloma, the Durie-Salmon staging system has a number of shortcomings relating to its ability to predict prognosis and survival. As an example, this system incorporates the observer-dependent quantitation of lytic lesions on skeletal survey. Including subjective measures decreases its precision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PROGNOSTIC STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient and tumor specific factors that best predict the survival of patients with myeloma include those incorporated into the staging systems described above and certain cytogenetic studies. Support for the prognostic values of these tests is presented here. The complete pretreatment evaluation of patients with myeloma is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=see_link&amp;anchor=H26#H26\">",
"     \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\", section on 'Evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=see_link&amp;anchor=H5#H5\">",
"     \"Determination of initial therapy in patients with multiple myeloma\", section on 'Risk stratification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most of the data regarding prognostic studies in myeloma patients come from evaluations at the time of diagnosis. It is unclear how many of these factors may affect outcomes in previously treated patients. In addition, it is not clear how the prognostic value of these factors will change with the emergence of new therapies. Prognostic studies have numerous benefits in both the clinical and research setting. As examples, they [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Provide the patient and physician with a better understanding of the aggressiveness of disease and chance of survival",
"     </li>",
"     <li>",
"      Lead to a better understanding of the patient population studied in a particular trial",
"     </li>",
"     <li>",
"      Allow for a gross comparison between patient populations in different trials",
"     </li>",
"     <li>",
"      May help guide therapy selection &mdash; eg, initial therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      -based regimen in patients with t(4;14) translocation",
"     </li>",
"     <li>",
"      Identify new targets for therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1902470566\">",
"    <span class=\"h2\">",
"     Patient factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical outcome for patients with myeloma depends upon a complex interaction between biologic features of the plasma cell clone and patient specific factors such as age, performance status, and comorbidities. Patients with comorbidities that limit their ability to withstand treatment will have a poor outcome even if they have a myeloma with features commonly associated with a better prognosis. While much of the research evaluating prognosis in myeloma has focused on the biologic properties of the malignant clone, large case series have identified numerous prognostic factors in patients with myeloma, some of which are patient dependent factors.",
"   </p>",
"   <p>",
"    As an example, univariate analysis of a series of 1027 patients with multiple myeloma seen at the Mayo Clinic between 1985 and 1998, uncovered the following significant adverse prognostic risk factors for survival (relative risks in parentheses) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Performance status 3 or 4 (",
"      <a class=\"graphic graphic_table graphicRef72901 \" href=\"UTD.htm?9/15/9467\">",
"       table 2",
"      </a>",
"      ) (1.9)",
"     </li>",
"     <li>",
"      Serum albumin &lt;3",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (1.7)",
"     </li>",
"     <li>",
"      Serum creatinine &ge;2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.5)",
"     </li>",
"     <li>",
"      Platelet count",
"      <span class=\"nowrap\">",
"       &lt;150,000/microL",
"      </span>",
"      (1.5)",
"     </li>",
"     <li>",
"      Age &ge;70 years (1.5)",
"     </li>",
"     <li>",
"      Beta-2-microglobulin &gt;4",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      (1.5)",
"     </li>",
"     <li>",
"      Plasma cell labeling index &ge;1 percent (1.5)",
"     </li>",
"     <li>",
"      Serum calcium &ge;11",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.3)",
"     </li>",
"     <li>",
"      Hemoglobin &lt;10",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (1.3)",
"     </li>",
"     <li>",
"      Bone marrow plasma cell percentage &ge;50 percent (1.2)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another analysis of 10,549 patients reported that patients older than 50 years had significantly shorter survival when treated with either chemotherapy alone or high-dose therapy followed by transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/6\">",
"     6",
"    </a>",
"    ]. While younger patients tended to present with more favorable features, age at diagnosis itself was an independent predictor of overall survival. A subsequent analysis of the same patient cohort with a median follow-up time of 3.25 years reported mean overall survival times of 6.3, 6.4, 5.3, 4.3, 3.4, and 2.5 years for those patients &lt;40, 40 to 49, 50 to 59, 60 to 69, 70 to 79, and &ge;80 years at the time of diagnosis, respectively, indicating that although younger patients have better survival, the number of years of life lost was greater [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cytogenetic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytogenetic abnormalities are powerful prognostic factors in myeloma. A combination of conventional cytogenetics and interphase fluorescence in situ hybridization (FISH) is currently used to stratify tumors into high and standard risk disease. Such stratification can help guide therapy. We recommend at least one, but preferably both, of the following tests be performed to assess risk in newly diagnosed patients (",
"    <a class=\"graphic graphic_table graphicRef78344 \" href=\"UTD.htm?24/32/25099\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      FISH for detection of t(11;14), t(6;14), t(4;14), t(14;16), t(14;20), del17p13, and trisomies of odd numbered chromosomes",
"     </li>",
"     <li>",
"      Conventional cytogenetics (karyotyping) for detection of del 13, monosomy 13, or hypodiploidy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with t(14;16), t(14;20), or del17p13 by FISH account for approximately 15 percent of MM and are considered to have high risk MM [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. These patients have a median survival of approximately two to three years despite standard treatment. Studies indicate that the presence of trisomies in patients with high risk cytogenetics may ameliorate some of the adverse prognostic effect of high risk cytogenetic abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/12\">",
"     12",
"    </a>",
"    ]. Patients with t(4;14) by FISH or deletion",
"    <span class=\"nowrap\">",
"     13/hypodiploidy",
"    </span>",
"    by conventional cytogenetics were previously considered to have high risk disease, but with appropriate therapy (early use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    -containing regimens and stem cell transplantation) have an outcome approaching that of standard risk myeloma. These patients are therefore now considered as having intermediate risk MM. All other patients with MM who lack any of the high or intermediate risk cytogenetic abnormalities are considered to have standard risk MM. An expanded genetic testing panel is suggested for patients enrolled in clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=see_link&amp;anchor=H5#H5\">",
"     \"Determination of initial therapy in patients with multiple myeloma\", section on 'Risk stratification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1827882473\">",
"    <span class=\"h3\">",
"     Conventional cytogenetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conventional cytogenetic studies are difficult in multiple myeloma because of the low proliferative activity of plasma cells. Such studies show abnormal karyotypes in only 20 to 30 percent of patients. Typically, cytogenetic abnormalities are characterized by complex karyotypes with frequent numerical and structural aberrations, such as a 13q14 deletion (",
"    <a class=\"graphic graphic_figure graphicRef64638 \" href=\"UTD.htm?16/3/16446\">",
"     figure 1",
"    </a>",
"    ). Cytogenetic abnormalities may be more common (68 percent) and complex in patients with plasma cell leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/13\">",
"     13",
"    </a>",
"    ]. Patients with tumors that demonstrate deletion 13 including monosomy of chromosome 13,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypodiploidy on conventional cytogenetics have a particularly adverse prognosis when treated with regimens that do not incorporate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    and transplantation (",
"    <a class=\"graphic graphic_table graphicRef78344 \" href=\"UTD.htm?24/32/25099\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    As an example, a retrospective analysis of 290 patients with newly diagnosed symptomatic myeloma treated with novel agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    ) reported that patients with high risk cytogenetics (ie, deletion 13, monosomy of chromosome 13,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypodiploidy) had significantly shorter median overall survival (29 versus 69 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies that have examined these specific cytogenetic changes in MM include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ploidy &mdash; Hyperdiploidy refers to the gain of numerous chromosomes (trisomies) in the clonal cell population. The term non-hyperdiploid refers to cases with hypodiploidy, pseudodiploidy, and near tetraploidy. In a multivariate analysis of 208 patients with multiple myeloma, a non-hyperdiploid karyotype was the most significant factor adversely affecting overall survival [",
"      <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/15\">",
"       15",
"      </a>",
"      ]. When compared with patients with a hyperdiploid myeloma, patients with non-hyperdiploid myeloma had significantly shorter median overall survival (13 versus 34 months). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27977?source=see_link&amp;anchor=H8#H8\">",
"       \"Pathobiology of multiple myeloma\", section on 'Hyperdiploidy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Del 13 or monosomy 13 &mdash; Numerous studies have demonstrated poor outcomes associated with myeloma cases with monosomy 13 or in which partial deletions of chromosome 13 are detected [",
"      <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/16-23\">",
"       16-23",
"      </a>",
"      ]. Since chromosome 13 deletion does not prognosticate among patients with hyperdiploid [",
"      <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/24\">",
"       24",
"      </a>",
"      ] or non-hyperdiploid [",
"      <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/25\">",
"       25",
"      </a>",
"      ] myeloma, it has been suggested that chromosome 13 deletion acts as a surrogate for the non-hyperdiploid MM with which it is associated [",
"      <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While patients with monosomy",
"    <span class=\"nowrap\">",
"     13/deletion",
"    </span>",
"    13 or hypodiploidy by conventional cytogenetics were previously considered to have high risk disease, these patients are now considered to have intermediate risk myeloma because patients with these findings have outcomes approaching that of standard risk myeloma when therapy incorporates the early use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    -containing regimens and hematopoietic cell transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=see_link&amp;anchor=H5#H5\">",
"     \"Determination of initial therapy in patients with multiple myeloma\", section on 'Risk stratification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Fluorescent in situ hybridization (FISH)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytogenetic abnormalities detected in bone marrow plasma cells by conventional karyotyping are present in only 20 to 30 percent of patients, due to a low number of metaphases in such specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/5\">",
"     5",
"    </a>",
"    ]. However, cytogenetic abnormalities are almost universal if more sensitive molecular genetic techniques, such as interphase fluorescent in situ hybridization (FISH), are used [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/4,26,27\">",
"     4,26,27",
"    </a>",
"    ]. The preferred FISH techniques for the evaluation of MM are either interphase FISH in purified plasma cells or light chain-restricted plasma cell cytoplasmic immunoglobulin enhanced FISH [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/4\">",
"     4",
"    </a>",
"    ]. These selective tests are required in order to maintain sensitivity in the context of hemodilution of the bone marrow aspirate sample.",
"   </p>",
"   <p>",
"    Using FISH, multiple myeloma can be molecularly classified into unique cytogenetic entities (",
"    <a class=\"graphic graphic_table graphicRef83079 \" href=\"UTD.htm?27/47/28412\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/4,12\">",
"     4,12",
"    </a>",
"    ]. Some cytogenetic subtypes, such as t(11;14) and t(6;14) and trisomies of odd numbered chromosomes, are considered to indicate standard-risk myeloma. By contrast, the detection of t(4;14), t(14;16), t(14;20),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    del17p13 are associated with poor prognosis in myeloma when treated with standard therapy (",
"    <a class=\"graphic graphic_table graphicRef78344 \" href=\"UTD.htm?24/32/25099\">",
"     table 3",
"    </a>",
"    ). The poor prognosis of these high risk factors may be abrogated by the presence of at least one trisomy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/12\">",
"     12",
"    </a>",
"    ]. In addition, the poor outcomes seen in patients with t(4;14) by FISH are at least partially overcome by therapy that incorporates the early use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    -containing regimens and hematopoietic cell transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28536?source=see_link&amp;anchor=H15538638#H15538638\">",
"     \"Cytogenetic and molecular genetic diagnostic tools\", section on 'Interphase FISH'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prognostic value of these chromosomal translocations and deletions detected by FISH analysis has been shown in numerous studies. For example, one study evaluated 351 patients treated with conventional melphalan-based chemotherapy in an ECOG clinical trial [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/28\">",
"     28",
"    </a>",
"    ]. The study found that patients with myeloma can be stratified into three groups with differing prognosis, as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Poor prognosis (median survival 25 months): t(4;14)(p16;q32), t(14;16)(q32;q23), and del17p13",
"     </li>",
"     <li>",
"      Intermediate prognosis (median survival 42 months): del13q14",
"     </li>",
"     <li>",
"      Good prognosis (median survival 50 months): all others, including patients with trisomies of odd numbered chromosomes with the exception of 1 and 13",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings on FISH retained their prognostic value in a subsequent ECOG clinical trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/29\">",
"     29",
"    </a>",
"    ]. Similarly, a retrospective analysis of 290 patients with newly diagnosed symptomatic myeloma treated with novel agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    , lenalidomide,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    ) reported that patients with FISH studies demonstrating t(4;14), t(14;16),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    del17p13 had significantly shorter median overall survival (30 months versus not reached with a median follow-up of 29 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/14\">",
"     14",
"    </a>",
"    ]. In another study, inferior overall survival was seen among patients with these abnormalities treated with bortezomib-based induction therapy followed by bortezomib maintenance [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/30\">",
"     30",
"    </a>",
"    ]. Additional details concerning these abnormalities and their prognostic significance are listed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1902473776\">",
"    <span class=\"h4\">",
"     Specific IgH translocations and prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common chromosomal translocations in MM involve 14q32, the site of the immunoglobulin heavy chain (IgH) locus, and are referred to as \"primary IgH translocations&rdquo;. These include: t(11;14)(q13;q32), t(4;14)(p16.3;q32.3) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/31\">",
"     31",
"    </a>",
"    ], t(6;14)(p25;q32), t(8;14)(q24;q32), and t(14;16)(q32.3;q23).",
"   </p>",
"   <p>",
"    The most common of these translocations is t(11;14)(q13;q32), which results in the up-regulation of cyclin D1 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/32\">",
"     32",
"    </a>",
"    ]. While t(11;14) does not appear to have adverse prognostic value, it does define a subgroup of myeloma with a particular clinicopathologic phenotype. The incidence of t(11;14) ranges from 10 to 31 percent in patients with IgG, IgA, IgD, and light chain myeloma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]; it is increased in patients with non-secretory myeloma (83 percent), as well as in IgM (7 of 8) and IgE (2 of 2) myeloma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Patients with MM and t(11;14) are more likely to have lower levels of serum monoclonal proteins and lymphoplasmacytic or small mature plasma cell morphology, CD20 expression, and lambda light chains [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/32,35-37\">",
"     32,35-37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27977?source=see_link&amp;anchor=H7#H7\">",
"     \"Pathobiology of multiple myeloma\", section on 'Immunoglobulin heavy chain translocations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several other recurring primary translocations have been identified, including t(4;14)(p16.3;q32.3) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/31\">",
"     31",
"    </a>",
"    ], t(6;14)(p25;q32) and t(14;16)(q32.3;q23). The t(4;14) and t(14;20) translocations are associated with poor prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/28,38\">",
"     28,38",
"    </a>",
"    ]. Of note, while t(4;14) is associated with chemotherapy-sensitive disease, it was previously associated with a high rate of relapse, even in those undergoing high-dose chemotherapy followed by autologous hematopoietic cell transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. Subsequent studies indicate that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    can overcome the adverse prognostic effect of the t(4;14) translocation, and hence this abnormality is now considered to indicate intermediate risk myeloma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An initial series that included 15 patients with t(14;16) reported that this translocation was associated with a poor outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/28\">",
"     28",
"    </a>",
"    ]. A subsequent retrospective analysis of 1003 patients with newly diagnosed myeloma that identified 32 patients with t(14;16) reported similar survival rates for these patients when compared with the group as a whole [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/43\">",
"     43",
"    </a>",
"    ]. Despite this report, t(14;16) is still considered a marker of high risk disease based on the results of total therapy 3 in which patients with t(14;16) and t(14;20) had inferior survival despite early incorporation of all active anti-myeloma agents and double autologous transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1902473819\">",
"    <span class=\"h4\">",
"     Del(17p) and prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deletions of 17p, including 17p13, the p53 locus, are found in 10 percent of MM patients, and are associated with a shorter survival after both conventional chemotherapy and hematopoietic cell transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/28,38,45-48\">",
"     28,38,45-48",
"    </a>",
"    ]. This deletion is highly associated with a low rate of complete response, rapid disease progression, advanced disease stages, plasma cell leukemia, and central nervous system multiple myeloma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. As an example, a study of 59 patients with previously untreated myeloma reported that those patients with a p53 gene deletion (present in 33 percent) had a significantly shorter median survival (14 versus 39 months from the time of diagnosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27977?source=see_link&amp;anchor=H15#H15\">",
"     \"Pathobiology of multiple myeloma\", section on 'Deletion of 17p13'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H615967\">",
"    <span class=\"h4\">",
"     Trisomies and prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperdiploidy is a well recognized predictor of favorable outcomes in multiple myeloma. Hyperdiploidy occurs in myeloma typically due to trisomies of odd numbered chromosomes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/15\">",
"     15",
"    </a>",
"    ]. In one retrospective study of 484 patients with newly diagnosed symptomatic myeloma, a",
"    <strong>",
"    </strong>",
"    trisomy was present in approximately 60 percent of all patients and 40 percent of patients with high risk myeloma as defined by FISH showing t(4;14), t(14;16), t(14;20), or loss of p53 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/12\">",
"     12",
"    </a>",
"    ]. The overall survival for patients with trisomy in the setting of high risk myeloma was similar to that of patients with standard risk myeloma defined by FISH. In comparison, patients with high risk myeloma without trisomy had significantly shorter survival. (See",
"    <a class=\"local\" href=\"#H1827882473\">",
"     'Conventional cytogenetics'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1902474814\">",
"    <span class=\"h3\">",
"     Other cytogenetic lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other cytogenetic lesions have been suggested as prognostic factors that require further clarification. Further confirmation is needed to assess how this information is to be applied clinically, relative to other known prognostic markers such as t(4;14), t(14;16), and del(17p13). These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abnormalities in both the short and long arms of chromosome 1 have been associated with shorter survival in many, but not all, studies [",
"      <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/53-56\">",
"       53-56",
"      </a>",
"      ]. In general, 1q gain (four or more copies) and 1p deletion, and 1q21 aberrations are associated with both disease progression and poor prognosis [",
"      <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one study, there was an attempt made to identify the subset of myeloma patients associated with excellent (better than expected) outcome [",
"      <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/57\">",
"       57",
"      </a>",
"      ]. They found that the 20 percent of myeloma patients without t(4;14), del(17p), and 1q gain and with a beta-2-microglobulin &lt;5.5",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      had an estimated survival at eight years of 75 percent.",
"     </li>",
"     <li>",
"      Initial studies have suggested that 12p deletions are associated with short event-free and overall survival rates [",
"      <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1827881794\">",
"    <span class=\"h2\">",
"     Beta-2 microglobulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum beta-2 microglobulin level is one of the prognostic factors incorporated into the International staging system. The serum beta-2 microglobulin level is elevated (ie, &gt;2.7",
"    <span class=\"nowrap\">",
"     mg/L)",
"    </span>",
"    in 75 percent of patients at the time of diagnosis. Patients with high values have inferior survival [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1827881563\">",
"     'International staging system (ISS)'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The prognostic value of serum beta-2 microglobulin level in myeloma is probably due to two factors:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      High levels are associated with greater tumor burden.",
"     </li>",
"     <li>",
"      High levels are also associated with renal failure, which carries an unfavorable prognosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1827881801\">",
"    <span class=\"h2\">",
"     Bone marrow plasma cell immunophenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;The malignant plasma cells in multiple myeloma generally express cytoplasmic immunoglobulin, CD38, CD56 (neural cell adhesion molecule), and CD138 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/59\">",
"     59",
"    </a>",
"    ]. About 15 to 20 percent of patients will have cells that express CD20; such patients are likely to have t(11;14) along with lymphoplasmacytic or small mature plasma cell morphology. Absence of CD56 expression is often seen in plasma cell leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16039?source=see_link&amp;anchor=H10#H10\">",
"     \"Plasma cell leukemia\", section on 'Prognosis'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H1902473776\">",
"     'Specific IgH translocations and prognosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients with plasma cells in the bone marrow that demonstrate an immunophenotype resembling normal, reactive plasma cells may have a better prognosis when compared with patients whose bone marrow contains plasma cells with an immunophenotype more typical of myeloma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. As an example, a prospective series of 685 patients with newly diagnosed MM uniformly treated on protocol found that patients who expressed CD19 or CD28 or lacked CD117 had significantly shorter progression-free and overall survival [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/62\">",
"     62",
"    </a>",
"    ]. The clinical use of bone marrow plasma cell immunophenotyping studies to help determine prognosis needs further clarification. Normal plasma cells typically express CD19. Therefore, the statement that CD19 is associated with a poor prognosis contradicts the statement that an immunophenotype resembling normal plasma cells has a better prognosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Monoclonal protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical course of myeloma may be determined in part by the type of monoclonal protein produced:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with light chain or IgD myeloma have a higher incidence of renal failure and associated amyloidosis, a smaller serum M component, and a higher rate of light chain excretion than those with IgG or IgA myeloma [",
"      <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/63,64\">",
"       63,64",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/31/1530?source=see_link\">",
"       \"An overview of amyloidosis\"",
"      </a>",
"      .) IgD myelomas typically have a lambda light chain.",
"     </li>",
"     <li>",
"      Patients with a cryoglobulin (type I cryoglobulinemia) may develop renal disease, or may have problems with hyperviscosity or other symptoms related to the presence of a cold-insoluble protein. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27400?source=see_link&amp;anchor=H13#H13\">",
"       \"Types of renal disease in multiple myeloma\", section on 'Other causes of ARF'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22522?source=see_link&amp;anchor=H12#H12\">",
"       \"Overview of cryoglobulins and cryoglobulinemia\", section on 'Type I CG'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      It is not clear whether the survival of patients with light chain myeloma is adversely affected. In three large reviews, light chain myeloma was reported to be not associated with a difference in prognosis [",
"      <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/5\">",
"       5",
"      </a>",
"      ], or a significant reduction in survival [",
"      <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/2\">",
"       2",
"      </a>",
"      ]. A significant reduction in survival occurs only if light chain myeloma is accompanied by renal impairment at presentation [",
"      <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Circulating plasma cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monoclonal plasma cells can be detected using a slide-based immunofluorescence assay in the peripheral blood of 100 percent of patients with plasma cell leukemia, 80 percent of those with active multiple myeloma, and in more than 90 percent of those with relapsed or refractory myeloma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16039?source=see_link\">",
"     \"Plasma cell leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=see_link&amp;anchor=H17#H17\">",
"     \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\", section on 'Peripheral smear'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Using a two-color immunoassay technique (ELISPOT), monoclonal plasma cells were detected at a concentration of 0.36, 0.85, and 9.3 percent of peripheral blood mononuclear cells in patients with stage",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    MM, stage III MM, and plasma cell leukemia, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/66\">",
"     66",
"    </a>",
"    ]. The number of these cells was also significantly correlated with the serum level of beta-2 microglobulin, suggesting the use of this technique for estimating tumor burden [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Circulating myeloma cells can also be detected via flow cytometry by gating on",
"    <span class=\"nowrap\">",
"     CD38+/CD45-",
"    </span>",
"    cells [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/67\">",
"     67",
"    </a>",
"    ]. When present at the time of hematopoietic cell transplantation, they serve as a surrogate for high-risk disease, especially when found in combination with abnormal cytogenetics.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prognostic value of determining the number of circulating plasma cells (PCs) by flow cytometry of",
"      <span class=\"nowrap\">",
"       CD38+/CD45-",
"      </span>",
"      cells was evaluated in 302 patients with previously untreated multiple myeloma [",
"      <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/68\">",
"       68",
"      </a>",
"      ]. Patients with &le;10 versus those with &gt;10 circulating PCs per 50,000 mononuclear cells had significantly longer median survivals (59 versus 37 months, respectively). On multivariate analysis, the prognostic value of circulating PCs was independent of the two components of the ISS (ie, serum levels of beta-2 microglobulin and albumin). (See",
"      <a class=\"local\" href=\"#H1827881563\">",
"       'International staging system (ISS)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A risk stratification model with a prognostic value exceeding that of the ISS alone incorporated the following three adverse risk factors:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Beta-2 microglobulin &gt;3.5",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"     </li>",
"     <li>",
"      Albumin &lt;3.5",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"     </li>",
"     <li>",
"      Circulating PCs &gt;10 per 50,000 mononuclear cells",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with no (low risk), one (low-intermediate risk), two (high-intermediate risk), or three (high risk) of these adverse factors had median survivals of &gt;79, 48, 32, and 13 months, respectively. This assay, which will require development and validation in other centers, may be especially valuable for identifying a subset of patients with a particularly poor prognosis prior to chemotherapy or hematopoietic cell transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of circulating myeloma cells and abnormal cytogenetics also has been shown to stratify patients at increased risk of progression following autologous HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/67\">",
"     67",
"    </a>",
"    ]. In a Mayo Clinic study of 246 subjects undergoing autologous HCT, those with neither, one, or both of these adverse prognostic factors had median times to progression of 22, 15, and 6 months, respectively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=see_link\">",
"     \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In comparison to overt myeloma or plasma cell leukemia, most patients with MGUS or SMM have few or no circulating monoclonal plasma cells that can be detected using the assays described above. The presence of circulating plasma cells in a patient with apparent MGUS or SMM may suggest early disease progression and the need for careful follow up.",
"   </p>",
"   <p>",
"    The presence of circulating plasma cells in patients with SMM is a risk factor for progression. In one series of 57 patients with smoldering myeloma, for example, 16 showed signs of progression within 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/69\">",
"     69",
"    </a>",
"    ]. Almost two-thirds of these patients had increased plasma cells of the same isotype in the peripheral blood compared with only 10 percent of those who remained stable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Serum free light chain ratio",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum",
"    <span class=\"nowrap\">",
"     kappa/lambda",
"    </span>",
"    free light chain (FLC) assay is a sensitive method for the detection of excess free light chains and an abnormal",
"    <span class=\"nowrap\">",
"     kappa/lambda",
"    </span>",
"    FLC ratio is used as a surrogate marker for clonal expansion. The presence of an abnormal (monoclonal)",
"    <span class=\"nowrap\">",
"     kappa/lambda",
"    </span>",
"    FLC ratio in the serum is associated with a significantly higher risk of disease progression in patients with monoclonal gammopathy of undetermined significance (MGUS), solitary plasmacytoma, or smoldering myeloma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/60/4041?source=see_link&amp;anchor=H22391048#H22391048\">",
"     \"Clinical course and management of monoclonal gammopathy of undetermined significance\", section on 'Risk stratification'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=see_link&amp;anchor=H2212928#H2212928\">",
"     \"Recognition of monoclonal proteins\", section on 'Serum free light chains'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The FLC ratio may have prognostic value in patients with newly diagnosed symptomatic myeloma when used in conjunction with the International staging system (ISS). As an example, one study evaluated the serum FLC ratio measurement that was available from 790 out of 1027 patients with newly diagnosed myeloma seen at a large referral center [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/70\">",
"     70",
"    </a>",
"    ]. Patients with abnormal FLC ratio (&lt;0.03 or &gt;32) had a significantly shorter median survival when compared with patients with a FLC ratio between 0.03 and 32 (30 versus 39 months, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H737440\">",
"    <span class=\"h2\">",
"     Plasma cell labeling index",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bone marrow plasma cell labeling index (PCLI) is a slide-based measure of the percentage of plasma cells in the S phase of the cell cycle that is available at some centers as a research tool [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/71-73\">",
"     71-73",
"    </a>",
"    ]. An elevated value (ie, &ge;1 percent) in a patient with apparent MGUS or SMM may suggest early disease progression and the need for careful follow up. A normal value is less helpful in differentiating MM from MGUS, since it is seen in 35 percent of patients with overt MM requiring therapy. An elevated value in patients with apparently stable, plateau phase MM is an adverse parameter that may predict a short time to disease progression and death [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An increased PCLI (&ge;1 percent) is associated with adverse prognosis in myeloma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/75\">",
"     75",
"    </a>",
"    ], and a reduction following treatment may predict improved survival [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the above studies, the use of PCLI is limited by lack of widespread availability. Assays to measure the proliferative rate of plasma cells using sensitive flow cytometric methods are in development.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Experimental studies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Gene expression profiling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gene expression profiling has been utilized to aid in the discrimination between plasma cells from normal subjects and those with monoclonal gammopathy of undetermined significance (MGUS), myeloma, AL amyloidosis, and extramedullary plasmacytomas [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/55,77-83\">",
"     55,77-83",
"    </a>",
"    ], as well as to identify patients with high-risk myeloma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/84-89\">",
"     84-89",
"    </a>",
"    ]. Currently the 70-gene gene expression profiling signature developed by the Myeloma Institute for Research and Therapy at Little Rock, Arkansas, appears to be one of the best models for identifying patients with high-risk disease, but the test is not yet commercially available [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. This technology, as well as comparative genomic hybridization, tumor-associated antigens, and multiparameter flow cytometry may ultimately have utility for diagnostic, therapeutic, and prognostic purposes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/90-97\">",
"     90-97",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39674?source=see_link\">",
"     \"Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27977?source=see_link\">",
"     \"Pathobiology of multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Bone marrow microvessel density",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of bone marrow microvessel density as a measure of angiogenesis may be of prognostic value. In one study, median survivals for patients with low-, intermediate-, or high-grade bone marrow angiogenesis were 77, 30, and 14 months, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?10/23/10618/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A discussion of the role of imaging studies in patients with multiple myeloma and effect on prognosis is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=see_link&amp;anchor=H22#H22\">",
"     \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\", section on 'Radiographic studies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?12/16/12547?source=see_link\">",
"       \"Patient information: Multiple myeloma symptoms, diagnosis, and staging (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1827883253\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multiple myeloma (MM) is a heterogeneous disease with some patients progressing rapidly despite treatment and others remaining stable without therapy for a number of years. Distinction between these groups is important so that treatment can be initiated in appropriate patients and postponed in those who do not need it.",
"     </li>",
"     <li>",
"      Once the diagnosis of MM is made, patients are typically staged using the International staging system (ISS), which incorporates data on the levels of serum beta-2 microglobulin (B2M) and serum albumin to divide disease burden into three stages with prognostic significance. (See",
"      <a class=\"local\" href=\"#H1827881563\">",
"       'International staging system (ISS)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical outcome for patients with myeloma depends upon a complex interaction between biologic features of the plasma cell clone and patient specific factors such as age, performance status, and comorbidities. (See",
"      <a class=\"local\" href=\"#H1902470566\">",
"       'Patient factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A combination of conventional cytogenetics and interphase fluorescence in situ hybridization (FISH) can be used to stratify tumors into high and standard risk disease. Such stratification may help guide therapy. We recommend at least one, but preferably both, of the following tests be performed to assess risk in newly diagnosed patients (",
"      <a class=\"graphic graphic_table graphicRef78344 \" href=\"UTD.htm?24/32/25099\">",
"       table 3",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      FISH for detection of t(11;14), t(6;14), t(4;14), t(14;16), t(14;20), del17p13, and trisomies of odd numbered chromosomes. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Fluorescent in situ hybridization (FISH)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Conventional cytogenetics (karyotyping) for detection of deletions of chromosome 13 or hypodiploidy. (See",
"      <a class=\"local\" href=\"#H1827882473\">",
"       'Conventional cytogenetics'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The detection of trisomies by FISH is a predictor of good prognosis. (See",
"      <a class=\"local\" href=\"#H615967\">",
"       'Trisomies and prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with t(14;16), t(14;20), or del17p13 by FISH account for approximately 15 percent of MM and are considered to have high risk MM. These patients have a median survival of approximately two to three years despite standard treatment. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Fluorescent in situ hybridization (FISH)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with t(4;14) by FISH or deletion",
"      <span class=\"nowrap\">",
"       13/hypodiploidy",
"      </span>",
"      by conventional cytogenetics are considered to have intermediate risk MM.",
"     </li>",
"     <li>",
"      All other patients with MM who lack any of the high or intermediate risk cytogenetic abnormalities are considered to have standard risk MM. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Cytogenetic abnormalities'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=see_link&amp;anchor=H5#H5\">",
"       \"Determination of initial therapy in patients with multiple myeloma\", section on 'Risk stratification'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/1\">",
"      Russell SJ, Rajkumar SV. Multiple myeloma and the road to personalised medicine. Lancet Oncol 2011; 12:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/2\">",
"      Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23:3412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/3\">",
"      Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/4\">",
"      Fonseca R, Bergsagel PL, Drach J, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009; 23:2210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/5\">",
"      Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/6\">",
"      Ludwig H, Durie BG, Bolejack V, et al. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. Blood 2008; 111:4039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/7\">",
"      Ludwig H, Bolejack V, Crowley J, et al. Survival and years of life lost in different age cohorts of patients with multiple myeloma. J Clin Oncol 2010; 28:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/8\">",
"      Dispenzieri A, Rajkumar SV, Gertz MA, et al. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc 2007; 82:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/9\">",
"      Stewart AK, Bergsagel PL, Greipp PR, et al. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia 2007; 21:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/10\">",
"      Rajkumar SV. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol 2012; 87:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/11\">",
"      Rajkumar SV. Treatment of multiple myeloma. Nat Rev Clin Oncol 2011; 8:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/12\">",
"      Kumar S, Fonseca R, Ketterling RP, et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood 2012; 119:2100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/13\">",
"      Avet-Loiseau H, Daviet A, Brigaudeau C, et al. Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du My&eacute;lome and the Groupe Fran&ccedil;ais de Cytog&eacute;n&eacute;tique H&eacute;matologique. Blood 2001; 97:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/14\">",
"      Kapoor P, Fonseca R, Rajkumar SV, et al. Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie. Mayo Clin Proc 2010; 85:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/15\">",
"      Smadja NV, Bastard C, Brigaudeau C, et al. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 2001; 98:2229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/16\">",
"      Zojer N, K&ouml;nigsberg R, Ackermann J, et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 2000; 95:1925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/17\">",
"      Shaughnessy J, Tian E, Sawyer J, et al. High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood 2000; 96:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/18\">",
"      Shaughnessy J Jr, Tian E, Sawyer J, et al. Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II. Br J Haematol 2003; 120:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/19\">",
"      Shaughnessy J, Jacobson J, Sawyer J, et al. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression. Blood 2003; 101:3849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/20\">",
"      Tricot G, Barlogie B, Jagannath S, et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 1995; 86:4250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/21\">",
"      Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/22\">",
"      Tricot G, Sawyer JR, Jagannath S, et al. Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J Clin Oncol 1997; 15:2659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/23\">",
"      Facon T, Avet-Loiseau H, Guillerm G, et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001; 97:1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/24\">",
"      Chng WJ, Santana-D&aacute;vila R, Van Wier SA, et al. Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations. Leukemia 2006; 20:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/25\">",
"      Chiecchio L, Protheroe RK, Ibrahim AH, et al. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia 2006; 20:1610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/26\">",
"      Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002; 2:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/27\">",
"      Nowakowski GS, Dewald GW, Hoyer JD, et al. Interphase fluorescence in situ hybridization with an IGH probe is important in the evaluation of patients with a clinical diagnosis of chronic lymphocytic leukaemia. Br J Haematol 2005; 130:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/28\">",
"      Fonseca R, Blood E, Rue M, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003; 101:4569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/29\">",
"      Jacobus SJ, Kumar S, Uno H, et al. Impact of high-risk classification by FISH: an eastern cooperative oncology group (ECOG) study E4A03. Br J Haematol 2011; 155:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/30\">",
"      Mateos MV, Guti&eacute;rrez NC, Mart&iacute;n-Ramos ML, et al. Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance. Blood 2011; 118:4547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/31\">",
"      Keats JJ, Reiman T, Maxwell CA, et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 2003; 101:1520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/32\">",
"      Fonseca R, Blood EA, Oken MM, et al. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood 2002; 99:3735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/33\">",
"      Avet-Loiseau H, Garand R, Lod&eacute; L, et al. Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. Blood 2003; 101:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/34\">",
"      Feyler S, O'Connor SJ, Rawstron AC, et al. IgM myeloma: a rare entity characterized by a CD20-CD56-CD117- immunophenotype and the t(11;14). Br J Haematol 2008; 140:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/35\">",
"      Hoyer JD, Hanson CA, Fonseca R, et al. The (11;14)(q13;q32) translocation in multiple myeloma. A morphologic and immunohistochemical study. Am J Clin Pathol 2000; 113:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/36\">",
"      Robillard N, Avet-Loiseau H, Garand R, et al. CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. Blood 2003; 102:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/37\">",
"      Garand R, Avet-Loiseau H, Accard F, et al. t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma. Leukemia 2003; 17:2032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/38\">",
"      Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du My&eacute;lome. Blood 2007; 109:3489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/39\">",
"      Jaksic W, Trudel S, Chang H, et al. Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance. J Clin Oncol 2005; 23:7069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/40\">",
"      Chang H, Sloan S, Li D, et al. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br J Haematol 2004; 125:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/41\">",
"      Gertz MA, Lacy MQ, Dispenzieri A, et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 2005; 106:2837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/42\">",
"      San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/43\">",
"      Avet-Loiseau H, Malard F, Campion L, et al. Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor? Blood 2011; 117:2009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/44\">",
"      Nair B, van Rhee F, Shaughnessy JD Jr, et al. Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood 2010; 115:4168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/45\">",
"      Drach J, Kaufmann H, Urbauer E, et al. The biology of multiple myeloma. J Cancer Res Clin Oncol 2000; 126:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/46\">",
"      Chang H, Yeung J, Qi C, Xu W. Aberrant nuclear p53 protein expression detected by immunohistochemistry is associated with hemizygous P53 deletion and poor survival for multiple myeloma. Br J Haematol 2007; 138:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/47\">",
"      Xiong W, Wu X, Starnes S, et al. An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood 2008; 112:4235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/48\">",
"      Reece D, Song KW, Fu T, et al. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood 2009; 114:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/49\">",
"      Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004; 64:1546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/50\">",
"      Chang H, Sloan S, Li D, Keith Stewart A. Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions. Br J Haematol 2004; 127:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/51\">",
"      Schilling G, Hansen T, Shimoni A, et al. Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma. Leukemia 2008; 22:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/52\">",
"      Drach J, Ackermann J, Fritz E, et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood 1998; 92:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/53\">",
"      Hanamura I, Stewart JP, Huang Y, et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 2006; 108:1724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/54\">",
"      Debes-Marun CS, Dewald GW, Bryant S, et al. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia 2003; 17:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/55\">",
"      Shaughnessy JD Jr, Zhan F, Burington BE, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007; 109:2276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/56\">",
"      Avet-Loiseau H, Li C, Magrangeas F, et al. Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol 2009; 27:4585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/57\">",
"      Avet-Loiseau H, Attal M, Campion L, et al. Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. J Clin Oncol 2012; 30:1949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/58\">",
"      Rossi D, Fangazio M, De Paoli L, et al. Beta-2-microglobulin is an independent predictor of progression in asymptomatic multiple myeloma. Cancer 2010; 116:2188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/59\">",
"      Rawstron AC, Davies FE, DasGupta R, et al. Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood 2002; 100:3095.",
"     </a>",
"    </li>",
"    <li>",
"     Grogan TM, Van Camp B, Kyle RA. Plasma cell neoplasms. In: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, Jaffe ES, Harris NL, Stein H, Vardinman JW (Eds), IARC Press, Lyon 2001. p.142.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/61\">",
"      Paiva B, Vidriales MB, Mateo G, et al. The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients. Blood 2009; 114:4369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/62\">",
"      Mateo G, Montalb&aacute;n MA, Vidriales MB, et al. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol 2008; 26:2737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/63\">",
"      Blad&eacute; J, Lust JA, Kyle RA. Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases. J Clin Oncol 1994; 12:2398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/64\">",
"      Kim MK, Suh C, Lee DH, et al. Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients. Ann Oncol 2011; 22:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/65\">",
"      Drayson M, Begum G, Basu S, et al. Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials. Blood 2006; 108:2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/66\">",
"      Cordoba F, Lavabre-Bertrand T, Salhi SL, et al. Spontaneous monoclonal immunoglobulin-secreting peripheral blood mononuclear cells as a marker of disease severity in multiple myeloma. Br J Haematol 2000; 108:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/67\">",
"      Dingli D, Nowakowski GS, Dispenzieri A, et al. Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system. Blood 2006; 107:3384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/68\">",
"      Nowakowski GS, Witzig TE, Dingli D, et al. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood 2005; 106:2276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/69\">",
"      Witzig TE, Gertz MA, Lust JA, et al. Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma. Blood 1996; 88:1780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/70\">",
"      Snozek CL, Katzmann JA, Kyle RA, et al. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia 2008; 22:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/71\">",
"      Greipp PR, Witzig TE, Gonchoroff NJ, et al. Immunofluorescence labeling indices in myeloma and related monoclonal gammopathies. Mayo Clin Proc 1987; 62:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/72\">",
"      Gonchoroff NJ, Greipp PR, Kyle RA, Katzmann JA. A monoclonal antibody reactive with 5-bromo-2-deoxyuridine that does not require DNA denaturation. Cytometry 1985; 6:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/73\">",
"      Lokhorst HM, Boom SE, Bast BJ, Ballieux RE. Determination of the plasma cell labelling index with bromodeoxyuridine in a double fluorescence technique. Br J Haematol 1986; 64:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/74\">",
"      Steensma DP, Gertz MA, Greipp PR, et al. A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death. Blood 2001; 97:2522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/75\">",
"      Greipp PR, Lust JA, O'Fallon WM, et al. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 1993; 81:3382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/76\">",
"      Larsen JT, Chee CE, Lust JA, et al. Reduction in plasma cell proliferation after initial therapy in newly diagnosed multiple myeloma measures treatment response and predicts improved survival. Blood 2011; 118:2702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/77\">",
"      Tarte K, Zhan F, De Vos J, et al. Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation. Blood 2003; 102:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/78\">",
"      Claudio JO, Masih-Khan E, Tang H, et al. A molecular compendium of genes expressed in multiple myeloma. Blood 2002; 100:2175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/79\">",
"      Zhan F, Tian E, Bumm K, et al. Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development. Blood 2003; 101:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/80\">",
"      Magrangeas F, Nasser V, Avet-Loiseau H, et al. Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease. Blood 2003; 101:4998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/81\">",
"      Hedvat CV, Comenzo RL, Teruya-Feldstein J, et al. Insights into extramedullary tumour cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma. Br J Haematol 2003; 122:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/82\">",
"      Davies FE, Dring AM, Li C, et al. Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood 2003; 102:4504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/83\">",
"      Abraham RS, Ballman KV, Dispenzieri A, et al. Functional gene expression analysis of clonal plasma cells identifies a unique molecular profile for light chain amyloidosis. Blood 2005; 105:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/84\">",
"      Dring AM, Davies FE, Fenton JA, et al. A global expression-based analysis of the consequences of the t(4;14) translocation in myeloma. Clin Cancer Res 2004; 10:5692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/85\">",
"      Decaux O, Lod&eacute; L, Magrangeas F, et al. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du My&eacute;lome. J Clin Oncol 2008; 26:4798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/86\">",
"      Zhou Y, Barlogie B, Shaughnessy JD Jr. The molecular characterization and clinical management of multiple myeloma in the post-genome era. Leukemia 2009; 23:1941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/87\">",
"      Haessler J, Shaughnessy JD Jr, Zhan F, et al. Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. Clin Cancer Res 2007; 13:7073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/88\">",
"      Broyl A, Hose D, Lokhorst H, et al. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood 2010; 116:2543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/89\">",
"      Kumar SK, Uno H, Jacobus SJ, et al. Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood 2011; 118:4359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/90\">",
"      Pellat-Deceunynck C. Tumour-associated antigens in multiple myeloma. Br J Haematol 2003; 120:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/91\">",
"      Guti&eacute;rrez NC, Garc&iacute;a JL, Hern&aacute;ndez JM, et al. Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma. Blood 2004; 104:2661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/92\">",
"      Moreaux J, Cremer FW, Reme T, et al. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood 2005; 106:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/93\">",
"      Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood 2006; 108:2020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/94\">",
"      Zhan F, Barlogie B, Arzoumanian V, et al. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood 2007; 109:1692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/95\">",
"      P&eacute;rez-Persona E, Vidriales MB, Mateo G, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 2007; 110:2586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/96\">",
"      Nair B, Shaughnessy JD Jr, Zhou Y, et al. Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival. Blood 2009; 113:6572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/97\">",
"      Anguiano A, Tuchman SA, Acharya C, et al. Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma. J Clin Oncol 2009; 27:4197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/23/10618/abstract/98\">",
"      Kumar S, Fonseca R, Dispenzieri A, et al. Bone marrow angiogenesis in multiple myeloma: effect of therapy. Br J Haematol 2002; 119:665.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6658 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-8D13A6BE0D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_23_10618=[""].join("\n");
var outline_f10_23_10618=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1827883253\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1827881563\">",
"      International staging system (ISS)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Durie-Salmon staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PROGNOSTIC STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1902470566\">",
"      Patient factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cytogenetic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1827882473\">",
"      - Conventional cytogenetics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Fluorescent in situ hybridization (FISH)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1902473776\">",
"      Specific IgH translocations and prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1902473819\">",
"      Del(17p) and prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H615967\">",
"      Trisomies and prognosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1902474814\">",
"      - Other cytogenetic lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1827881794\">",
"      Beta-2 microglobulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1827881801\">",
"      Bone marrow plasma cell immunophenotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Monoclonal protein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Circulating plasma cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Serum free light chain ratio",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H737440\">",
"      Plasma cell labeling index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Experimental studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Gene expression profiling",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Bone marrow microvessel density",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1827883253\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/6658\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6658|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/3/16446\" title=\"figure 1\">",
"      Chromosome 13 in myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6658|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/18/11564\" title=\"table 1\">",
"      Durie Salmon staging system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/15/9467\" title=\"table 2\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/32/25099\" title=\"table 3\">",
"      Risk stratification of myeloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/47/28412\" title=\"table 4\">",
"      FISH classification MM",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/31/1530?source=related_link\">",
"      An overview of amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/60/4041?source=related_link\">",
"      Clinical course and management of monoclonal gammopathy of undetermined significance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=related_link\">",
"      Clinical features, laboratory manifestations, and diagnosis of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28536?source=related_link\">",
"      Cytogenetic and molecular genetic diagnostic tools",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=related_link\">",
"      Determination of initial therapy in patients with multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22522?source=related_link\">",
"      Overview of cryoglobulins and cryoglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39674?source=related_link\">",
"      Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27977?source=related_link\">",
"      Pathobiology of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/16/12547?source=related_link\">",
"      Patient information: Multiple myeloma symptoms, diagnosis, and staging (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16039?source=related_link\">",
"      Plasma cell leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=related_link\">",
"      Recognition of monoclonal proteins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27400?source=related_link\">",
"      Types of renal disease in multiple myeloma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_23_10619="Rai staging system CLL";
var content_f10_23_10619=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F56284&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F56284&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Modified Rai clinical staging system for chronic lymphocytic leukemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Risk",
"       </td>",
"       <td class=\"subtitle1\">",
"        Stage",
"       </td>",
"       <td class=\"subtitle1\">",
"        Description",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        Lymphocytosis in blood or bone marrow",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Intermediate",
"       </td>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        Lymphocytosis + enlarged lymph nodes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        II",
"       </td>",
"       <td>",
"        Lymphocytosis + enlarged liver or spleen with or",
"without lymphadenopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        High",
"       </td>",
"       <td>",
"        III",
"       </td>",
"       <td>",
"        Lymphocytosis + anemia (Hgb &lt;11 g/dL)",
"with&nbsp;or without enlarged liver, spleen, or lymph lnodes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        Lymphocytosis + thrombocytopenia (platelet count",
"&lt;100,000/&micro;L) with or without anemia or enlarged liver,",
"spleen, or lymph nodes",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_23_10619=[""].join("\n");
var outline_f10_23_10619=null;
var title_f10_23_10620="2011 US soft lens market";
var content_f10_23_10620=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F67029&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F67029&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    2011 United States soft lens market",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        By lens material",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Silicone hydrogel",
"       </td>",
"       <td>",
"        67",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Soft hydrogel",
"       </td>",
"       <td>",
"        24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        RGP",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hybrid",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        By lens type",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Soft spherical",
"       </td>",
"       <td>",
"        54",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Soft toric",
"       </td>",
"       <td>",
"        23",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Soft multifocal",
"       </td>",
"       <td>",
"        11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        RGP spherical",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        RGP multifocal",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        By disposal schedule",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Daily",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Weekly",
"       </td>",
"       <td>",
"        &lt;1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Two weeks",
"       </td>",
"       <td>",
"        33",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        One month",
"       </td>",
"       <td>",
"        46",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Three months",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Annual",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     RGP: rigid gas permeable.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Nichols JJ, et al. Contact Lenses 2011. Contact Lens Spectrum 2012. Available at: file://www.clspectrum.com/articleviewer.aspx?articleID=106550.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_23_10620=[""].join("\n");
var outline_f10_23_10620=null;
var title_f10_23_10621="Thiazides and cardiac arrest";
var content_f10_23_10621=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F68346&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F68346&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dose-dependence of thiazides and cardiac arrest",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 440px; height: 252px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The odds ratio for primary cardiac arrest in hypertensive subjects treated with different daily doses of hydrochlorothiazide (HCTZ) with or without concurrent administration of a potassium-sparing diuretic (Ksp). When compared to 25 mg of hydrochlorothiazide per day, the risk of cardiac arrest increased progressively at higher thiazide doses, but was reduced by a potassium-sparing diuretic.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Siscovick DS, Raghunathan TE, Psaty BM, et al. N Engl J Med 1994; 330:1852.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_23_10621=[""].join("\n");
var outline_f10_23_10621=null;
var title_f10_23_10622="Contents: Spinal disease and back pain";
var content_f10_23_10622=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Spinal disease and back pain",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Spinal disease and back pain",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Ankylosing spondylitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/23/35194\">",
"           Assessment and treatment of ankylosing spondylitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/9/151\">",
"           Clinical manifestations of ankylosing spondylitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/51/12090\">",
"           Pathogenesis of spondyloarthritis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Low back pain",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/10/18601\">",
"           Approach to the diagnosis and evaluation of low back pain in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/7/14458\">",
"           Clinical manifestations and treatment of osteoporotic thoracolumbar vertebral compression fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/21/12633\">",
"           Diagnostic testing for low back pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/43/6841\">",
"           Exercise-based therapy for low back pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/28/1480\">",
"           Lumbar spinal stenosis: Pathophysiology, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/15/22776\">",
"           Lumbar spinal stenosis: Treatment and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/34/42535\">",
"           Occupational low back pain: Evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/47/14072\">",
"           Occupational low back pain: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/16/41222\">",
"           Spinal manipulation in the treatment of musculoskeletal pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/52/39753\">",
"           Subacute and chronic low back pain: Nonsurgical interventional treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/24/19850\">",
"           Subacute and chronic low back pain: Pharmacologic and noninterventional treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/5/34905\">",
"           Subacute and chronic low back pain: Surgical treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/21/13658\">",
"           Treatment of acute low back pain",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neck pain",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/18/27944\">",
"           Cervical spondylotic myelopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/19/36152\">",
"           Clinical features and diagnosis of cervical radiculopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/24/1418\">",
"           Evaluation of the patient with neck pain and cervical spine disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/47/17144\">",
"           Treatment of cervical radiculopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/36/23113\">",
"           Treatment of neck pain",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/6/35940\">",
"           Coccydynia (coccygodynia)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/16/41222\">",
"           Spinal manipulation in the treatment of musculoskeletal pain",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-E6B75DFCC4-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f10_23_10622=[""].join("\n");
var outline_f10_23_10622=null;
var title_f10_23_10623="Digital tourniquet";
var content_f10_23_10623=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F71108&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F71108&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Digital tourniquet",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 266px; height: 331px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A digital tourniquet provides hemostasis and a bloodless field for repair of a fingertip injury. A Penrose drain that is secured with a hemostat may also be used.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard A Saladino, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_23_10623=[""].join("\n");
var outline_f10_23_10623=null;
